Investigating BET proteins as a therapeutic target in keloid scarring by Bell, Rachel Emma
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 
















Investigating BET proteins as a 
therapeutic target in keloid scarring. 
 
 








A thesis presented for the degree of Doctor of Philosophy 
 
Centre for Inflammation Biology and Cancer Immunology, 







Keloid scars form due to an over-exuberant, fibrotic wound response in the skin of predisposed 
individuals. There is currently no clear genetic link identified, and limited treatment options 
available. Epigenetic changes in fibrosis, and specifically in keloids, are beginning to be 
identified and this offers potential targets for treatment. 
This project explored the bromodomain and extraterminal (BET) family of proteins: Brd2, Brd3 
and Brd4, which function as epigenetic regulators through their binding to acetylated lysine 
residues, predominantly on histone proteins. We hypothesised that they would be a target of 
therapeutic value given that their inhibition has shown anti-proliferative and anti-inflammatory 
properties in other cell types. 
We identified an overexpression of Brd2 in keloid tissue compared to normal controls, 
including a possible expression of a differential Brd2 isoform. We then used a small molecule 
bromodomain inhibitor, I-BET151 (GSK), to investigate the effect of BET protein inhibition in 
primary dermal fibroblast cultures from normal skin (NDFs) and keloid scars (KDFs). We 
confirmed previous literature findings, in other disease models, that BET inhibition decreased 
proliferation, as well as the expression of the inflammatory cytokine interleukin-6 (IL-6). 
In addition, we identified some more novel effects of BET inhibition, including a decrease in 
fibroblast contraction in a collagen gel model and decreases in proteolytic activity in fibroblast 
cultures, as well as a more complex ex vivo tissue model. Interestingly, we also observed 
profound differences between NDFs and KDFs in their signalling downstream of IL-6 in serum 
free environments. In particular, a strong induction of pAkt was observed in KDFs after 30 
minutes of cytokine stimulation, which was not seen in NDFs, and BET inhibition abrogated 
this.  
In conclusion, BET inhibition appears to offer therapeutic value in keloid scars by targeting a 
number of disease-associated cell behaviours, including aberrant signalling responses, which 
may influence the fibrotic response. Some of these effects may be of relevance in other disease 
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Chapter 1: Introduction 
 
1.1.   Mammalian skin 
 1.1.1.  Anatomy and function of the skin 
 
The skin is a vital integumentary organ protecting the underlying tissue from a range of 
environmental insults. The skin is derived early in development where a simple ectoderm 
epithelium overlies mesenchyme. In humans, after several months of foetal development this 
layer becomes stratified, and pigmented by neural crest derived melanoblasts, and functional 
appendages can develop (Fuchs, 2007). Fully developed skin from different anatomical 
locations varies in its composition. Variability in dermal and epidermal thickness, hair follicle 
and sebaceous gland content allows regional specialisation of skin dependent on function. For 
example, the glabrous skin covering the palms of hands and soles of feet is relatively thick in 
structure, absent of hair follicles and sebaceous glands but has an increased amount of 
mechanoreceptors (Johansson and Vallbo, 1983; McGrath, Eady and Pope, 2004).  
Adult human skin consists of a keratinised, stratified epithelial layer, with an underlying 
basement membrane, sitting above a relatively thick dermal layer (Figure 1.1). The zip-like 
interface between the epidermal rete ridges and dermal papillae gives the skin tensile strength 
and a robust barrier capacity. Below the dermis is the hypodermal layer containing mostly 
adipocytes. The hypodermis is conventionally described as cushioning, insulation and a 
functional energy reserve (Freinkel and Woodley, 2001). However, more recent research has 
shown its importance as an endocrine organ, releasing a range of factors which may be of 
particular significance during wound repair (Schmidt and Horsley, 2013; Musi and Guardado-
Mendoza, 2014).  
In addition to the aforementioned functions, the skin is also important for vitamin D production, 
protection from ultraviolet (UV) radiation and temperature regulation. Irregularities in cell types 
or proteins in the epidermis can lead to barrier defect phenotypes from the relatively mild such 
as atopic dermatitis (Agrawal and Woodfolk, 2014) to the severe such as epidermolysis bullosa 




















Figure 1.1 - Normal skin histology showing microstructure and tissue architecture. 
Formalin fixed, paraffin embedded normal skin section stained with haemotoxylin and eosin 
(H&E). Epidermis (E) is undulating with characteristical rete ridges. The dermis in two 
sections, the upper papillary (PD) and lower reticular dermis (RD) with typical loose, waved, 





 1.1.2.  Development of the skin 
 
 
Mammalian skin is derived from two main compartments to form the top epithelial layer and the 
underlying dermis. The epithelial layer of the skin is known as the epidermis. The epidermis is 
derived from the same developmental niche as the nervous system, the neuroectoderm, early in 
mammalian development (Fuchs, 2007). From this preliminary single layered structure, cells 
proliferate and differentiate in response to environmental cues including Wnt and BMP 
signalling in order to progress to an epidermal fate (Figure 1.2) (Fuchs, 2007). It is interesting to 
note that these fate determining differentiation events seem to be cell specific (Fuchs, 2007) and 
may be due to intrinsic differences in these precursor cells which are not yet elucidated. Briefly, 
cells in this primitive layer that do not respond to Wnt signalling become the integral epidermal 
cells, whereas those that do respond to Wnt, and other signals including those from the 
underlying dermis, become appendages eventually resulting in hair follicle development (Figure 
1.2) (Fuchs, 2007). This demonstrates the necessity of functional signalling between the dermal 
and epidermal compartment.  
 
Figure 1.2: Schematic adapted from Fuchs, 2007 demonstrating the importance of 
signalling in epidermal development. Embryonic epidermal cells are derived from the 
ectodermal progenitor cells that are responsive to Wnt and BMP signalling, these progenitor 
cells further specialise to become stratified epidermis, when responsive to BMP and Notch 





Again, Wnt and β-catenin signalling is thought to be important in the development of the 
dermis, but much less is known about the cellular and molecular basis of dermal development. 
However, it is known that depending on the anatomical location, the dermis is derived from 
different locations, which may give rise to distinct functional characteristics later in mature skin. 
The ventral and flank dermis is derived from the lateral plate mesoderm, the head skin is 
derived from the neural crest ectoderm and the dorsal dermis is derived from the somatic 
dermatome (Olivera-Martinez, Thélu and Dhouailly, 2004). The transition from the somatic 
dermatome to dorsal dermis happens between gestation days 2 and 7 in chick (Olivera-Martinez, 
Thélu and Dhouailly, 2004), but still the molecular mechanisms for this transition are not well 
understood.  
The skin continues to mature throughout gestation, with complete epidermal maturation by 34 
weeks in humans (Oranges, Dini and Romanelli, 2015). Neonates tend to have a thinner 
epidermal layer with a weakened barrier function compared to adult skin, which continues to 




 1.1.3.  The epidermis 
 
The epidermis tends to be between 12.7µm and 16.6µm thick depending on anatomical location 
(Sandby-Møller, Poulsen and Wulf, 2003) and its structural bulk is made predominantly of 
keratinocytes. Stratified layers of keratinocytes are found in adult skin in five main layers, from 
the inner to outermost being: basal, spinous, granular, upper granular and cornified (Candi, 
Schmidt and Melino, 2005)  The upper cornified layer of the epidermis, known as the stratum 
corneum, is formed by terminal differentiated, dead keratinocytes as well as various structural 
proteins, including involucrin and profillagrin, which give the skin further strength, resistance 
and control of water permeability (Candi, Schmidt and Melino, 2005) A small percentage of 
keratinocytes, resident in the basal layer of the epithelium retain multi-potency into adulthood 
and are integral in the maintenance of skin homeostasis but also the response to injury 
(Fernandes, Toma and Miller, 2008; Fuchs, 2008; Jones and Wagers, 2008).  This population of 
cells is often described as a stem cell niche and has been heavily studied in the fields of 
developmental biology and oncology but also has a key role to play in wound healing as a pool 
for replacing lost cells (Watt, 1998).  
Melanocytes are another important cell type in the epidermis, derived from the neural crest as 
melanoblasts which migrate, proliferate and differentiate to form mature melanocytes (Lin and 
Fisher, 2007). Melanocytes typically reside in the basal layer of the epidermis in close 
proximity to the dermis or the hair follicle bulbs. These cells are responsible for producing the 
pigment melanin, in granules known as melanosomes, which is important for UV protection as 
well as giving colour to skin and hair (Lin and Fisher, 2007). It is important to note that colour 
is determined by the number and size of melanosomes, rather than the number of melanocytes 
which is similar between individuals (Lin and Fisher, 2007).  Mechanosensory cells called 
Merkel cells are also found in the epidermis and are important for the perception of touch and 
pressure (Maksimovic et al., 2014). Debate has arisen as to the origin of these cells, but the 
most recent evidence suggests they are epidermally derived rather than derived from neural 
crest (Van Keymeulen et al., 2009) 
A range of immune cells are also present in the epidermis including specialised gamma delta T 
cells (known as dendritic epidermal T cells in mice, DETCs) and Langerhans cells (McGrath, 
Eady and Pope, 2004). Langerhans are abundant immune cells in the epidermis with a 
mesenchymal origin, making up 3 to 8% of epidermal cells (Katz, Tamaki and Sachs, 1979). As 
well as being a first line of defence in skin immunity (Merad, Ginhoux and Collin, 2008), these 
cells are highly important in skin immune homeostasis with the ability to both induce activation 
of regulatory T cells and effector memory T cells (Seneschal et al., 2012). DETCs also 
contribute to the skin immune response (McGrath, Eady and Pope, 2004), as well as being early 
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and rapid responders to cutaneous injury by helping to drive the proliferative response of 
keratinocytes (Havran and Jameson, 2011).  
 
 1.1.4.  The dermis and integral role of dermal fibroblasts 
 
The dermal layer of the skin is a collagenous matrix of two stratifying layers, the reticular and 
the papillary dermis (Figure 1.1). The dermis is populated mainly by fibroblasts but also 
contains small populations of resident immune cells including a range of T cells subsets, 
dendritic cells and mast cells (Nestle et al., 2009). The dermis holds blood vessels and a number 
of appendage structures including sebaceous glands and hair follicles (McGrath, Eady and Pope, 
2004). Like the epidermis, there is also a dermal stem cell niche in the form of specialised 
dermal fibroblasts residing at the dermal papilla of hair follicles. These cells are thought to be 
important in the anagen phase of the hair cycle (Driskell et al., 2013). 
Fibroblasts are resident in many connective tissues including the dermis of the skin and are the 
main cell type of interest in this project. Fibroblasts were first described over 150 years ago and 
are characterised by their elongated, spindle-like appearance (Virchow, 1859). Despite existing 
as a stable non-proliferative population in vivo, dermal fibroblasts  become highly proliferative 
in culture (Sorrell and Caplan, 2004). A vital role of all fibroblasts is to produce the 
extracellular matrix (ECM) that is vital for tissue structure, flexibility and integrity (Tracy, 
Minasian and Caterson, 2016). In the skin, fibroblasts tend to produce collagens I and III, 
however shortly after wounding they can efficiently produce immature ECM including fibrin 
and fibronectin to fill the wound bed (Tracy, Minasian and Caterson, 2016). 
Dermal fibroblasts have been a strong focus in regenerative medicine due to their highly plastic 
and reprogrammable phenotype (Takahashi et al., 2007; Nakagawa et al., 2008). Fibroblasts are 
also capable of differentiation to myofibroblasts within the wound bed induced by signals 
including transforming growth factor beta 1 (TGF-β1) (Hinz, 2007). This plasticity will be 
further discussed in the context of wound repair later.  It has also become clear in recent 
research that fibroblasts in the dermis are not a homogenous population but a collection of sub-
populations that may have distinct functions in homeostasis and in the response to wounding 
(Driskell et al., 2013). It has been identified in mouse dorsal skin that it is predominantly En1 
positive, reticular dermal fibroblasts that contribute towards the fibrotic response seen in scar 





1.2.   Normal wound healing in the skin 
 1.2.1.  An overview of the wound healing process 
 
There are several major challenges to overcome after cutaneous wounding (Figure 1.3). 
Immediately after wounding, the critical problem is the physical gap and damage to the tissue, 
causing bleeding and a barrier breach for opportunistic pathogens. There is an immediate 
intervening reaction in the recruitment of the innate immune response and the formation of a 
blood clot, driven by a variety of cytokine and growth factor pathways (Martin, 1997). The 
activation of platelets shortly after wounding allows the formation of a haemostatic plug which 
is reinforced by the production of fibrin (Golebiewska and Poole, 2015). This fibrin clot gives a 
structure on which to re-build the epidermis from the wound edges. The rapid recruitment of 
neutrophils to the wound allows for clearing of invading pathogens and debris, as well as 
triggering  downstream signalling that can promote other wound healing processes (Theilgaard-
Monch et al., 2004). Neutrophils are relatively short-lived in this environment and are 
phagocytosed by tissue resident macrophages, or monocyte derived macrophages from the 
circulation (Eming, Krieg and Davidson, 2007).  
Meanwhile, the successive activation of keratinocytes to become migratory and proliferative, 
followed by the re-building of the dermal layer by fibroblast proliferation, ECM production and 
contracture, brings the wound edges together and reconstitutes the wound bed (Shaw and 
Martin, 2016).  
The initial ECM tends to be rapidly produced and haphazardly arranged to create strength and 
protection, so this basic post-wound structure must be remodelled to regain normal skin 
function. Re-vascularisation by angiogenesis as well as the re-building of various appendages 
including sebaceous glands and hair follicles must occur. In many cases, especially in more 
extreme wounds, this remodelling is not entirely successful and will result in a scar with a loss 
of function (Xue and Jackson, 2015).  
The plasticity of cells during repair is crucial at all stages for successful wound healing (Shaw 
and Martin, 2016). It is well-appreciated in the literature that wound repair is a tightly controlled 
and cross-regulating process, including vital paracrine signalling events between cell 
populations. Misregulation at any stage can therefore cause major issues in the repair process 
including failure to heal, the formation of aberrant scars, and development of cancer (Arnold et 
al., 2015; Ge et al., 2017). 
For example, wound edge keratinocytes must be able to become migratory to ‘fill the gap’ in the 
epidermis, and fibroblasts must be able to become ‘activated’ to produce matrix, whilst being 
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able to return to a homeostatic phenotype following wound resolution. The cues for these 
differentiation events are not entirely characterised. It is thought in early stages of wound repair 
that the production of growth factors and cytokines may play a key role in initiating and driving 
these changes (Ploeger et al., 2013), but the ‘off switches’ for many wound repair activities are 




Figure 1.3 - Schematic showing the main stages of cutaneous wound healing. There are four 
main stages to cutaneous wound repair; although they are depicted as a consecutive, linear 
process these processes occur in tandem with overlapping phases of inflammation and 




 1.2.2.  Proliferation, migration and contraction in wound 
healing 
 
Proliferation, migration and contraction of cells are all important processes that can occur 
concurrently in wound repair, and errors in these processes can cause disease. Firstly, 
proliferation of cells in wound repair is essential to replace cells that are lost during wounding; 
in the skin this tends to be mainly fibroblasts, and keratinocytes which also differentiate to 
reform the stratified epithelium that has been damaged (Bielefeld, Amini-Nik and Alman, 
2013). Proliferation of fibroblasts in the skin is thought to be partially driven by β-catenin, 
thought to be independent of Wnt signalling (Bielefeld et al., 2011). Interestingly TGF-β1, 
which is known as another strong inducer of fibroblast proliferation, has an anti-proliferative 
effect on keratinocytes (Pietenpol et al., 1990). Proliferation can also be driven through cell-cell 
interactions, such as Langerhans cells and keratinocytes (Morhenn, 1988) and through paracrine 
signalling between keratinocytes and fibroblasts (Werner, Krieg and Smola, 2007). 
Migration of cells, especially wound edge keratinocytes is vital for successful re-epithelisation 
(Shaw and Martin, 2016).  Cells often collectively migrate in a sheet in a fashion reminiscent to 
embryonic morphogenesis (Jiang et al., 2013) and the advancing cells also deposit immature 
matrix in order to form a substrate for this movement (Shaw and Martin, 2016). 
Fibroblast contraction is also important in order to pull the wound edges together and is driven 
by TGF-β1 and mechanical tension in the environment (Hinz et al., 2001). There is a subset of 
dermal fibroblasts that can differentiate into specialised, highly-contractile myofibroblasts 
which are characterised as being alpha-smooth muscle actin (ɑ-SMA) positive (Hinz, 2007). 
However, there is also strong evidence that there are important contractile ɑ-SMA negative 
fibroblasts, as shown in ɑ-SMA-null mice which still elicit significant contraction upon 




 1.2.3.  Inflammation in wound healing 
 
Inflammation is highly influential in wound repair; as well as neutrophils and macrophages, 
other inflammatory cells including adaptive immune cells such as T cell subsets also influx to 
the wound and may regulate processes including matrix remodelling (Havran and Jameson, 
2011). The importance of some other immune cells, such as mast cells, is less clear (Willenborg 
et al., 2014). 
Several studies have attempted to unravel the importance of inflammation in wound repair using 
immune-deficient models such as the PU.1 null mouse. PU.1 is the master transcription factor 
for the myeloid lineage, therefore PU.1 null mice lack a range of immune cells including 
macrophages, dendritic cells and T cells (Martin et al., 2003). Despite typically dying shortly 
post-birth from opportunistic infections, they have been shown to generate scar-free wounds 
upon injury (Martin et al., 2003). This study supports the idea that there is a necessity of 
balance in the immune response after wounding, preventing pathogen invasion yet avoiding 
excessive scar formation through typical inflammation-driven responses.  
Based on this evidence, it is logical to suggest that application of anti-inflammatory or 
immunosuppressive compounds could be used beneficially to promote scar-free healing, 
especially through modulation of macrophage activity. Macrophages can be polarised along a 
spectrum of pro-inflammatory (M1) to anti-inflammatory (M2), and there is a great deal of 
debate as to the functional importance of these cells to wound repair (Eming, Krieg and 
Davidson, 2007). It has recently been shown that M2-like macrophages can indirectly contribute 
to scarring through the production of insoluble scar-type cross-linked collagen by fibroblasts 
through IL-4 signalling (Knipper et al., 2015). It has been demonstrated that the relevance of 
macrophages varies temporally, with the depletion of macrophages early in repair showing 




 1.2.4.  Matrix remodelling in wound healing and a role for MMPs 
 
After the initial filling of the connective tissue gap with immature matrix, ECM is remodelled 
over time, driven chiefly through protease activity, to return the tissue as close to the original 
state as possible (Lu et al., 2011). A fine balance must be struck in regards to protease levels as 
an increase in proteolytic activity may cause damage to local tissue or non-healing wounds such 
as seen in diabetic foot ulcers (Mast and Schultz, 1996; McCarty and Percival, 2013), whereas a 
lack of proteolytic activity may result in excessive ECM deposition leading to unresolved scar 
tissue (Ghosh and Vaughan, 2012). 
There are many proteases that have roles in the remodelling of ECM including adamlysins 
(ADAM), cathepsins, hyaluronidases, heparanases, cysteine proteases and plasminogens 
(Roycik, Fang and Sang, 2009). However, the most well characterised of these proteases are the 
matrix metalloproteinases (MMPs) (Roycik, Fang and Sang, 2009; Rohani and Parks, 2015). A 
range of cells in the skin can contribute to MMP production (Table 1.1). MMPs are best 
recognised for their ability to remodel matrix (Rohani and Parks, 2015). MMPs can cleave a 
range of substrates in tissue, many of which may not yet be defined but include those that are 
typically found in repaired skin matrix such as collagen I, III and fibronectin (Yates, Hebda and 
Wells, 2012). 
MMPs can also cleave a range of other proteins including growth factors and cell surface 
receptors, causing a plethora of downstream cellular consequences (Figure 1.4). Cleaved 
bioactive peptides, known as matrikines, generated from degradation of ECM proteins are also 
capable of regulating cellular processes by receptor engagement. For example, proline-glycine-
proline fragments have been shown to trigger chemotaxis of neutrophils (Wells, Gaggar and 
Blalock, 2015). Also, the regulation of growth factor activation, such as TGF-β1, epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF) and platelet derived growth 
factor (PDGF) by MMPs is further evidence for their importance and the need for regulation of 
their activity (Sternlicht and Werb, 2009) and may explain why MMP1 is able to mobilise the 
migration of wound edge keratinocytes in the early stage of wound repair (Martin, 1997; Rohani 
and Parks, 2015).  
It has indeed been shown that MMPs are elevated in both benign (Denys et al., 2004) and 
malignant tumours (Kessenbrock, Plaks and Werb, 2010) driving growth, and metastasis in the 
case of cancer. For example, it is known that MMPs 2, 9 and 14 are important for driving 
angiogenesis in the tumour microenvironment (Kessenbrock, Plaks and Werb, 2010) 
particularly through the release and activation of VEGF (Bergers et al., 2000). Moreover, it is 







Table 1.1 - Summary of likely sources of MMP in skin/scar tissue. 
 Enzyme type Potential sources in the skin 
MMP-1  Collagenase Fibroblasts, keratinocytes, melanocytes* 
MMP-2 Gelatinase Fibroblasts, keratinocytes 
MMP-3 Stromelysin Fibroblasts, keratinocytes, melanocytes* 
MMP-7 Matrilysin Sweat gland epithelium, fibroblasts 
MMP-8 Collagenase Mostly neutrophils, fibroblasts 
MMP-9 Gelatinase Neutrophils, fibroblasts, keratinocytes, eosinophils, 
melanocytes* 
MMP-10 Stromelysin Fibroblasts, keratinocytes 
MMP-11 Stromelysin Fibroblasts, melanocytes* 
MMP-12 Elastase Macrophages, fibroblasts 





Fibroblasts, keratinocytes, macrophages 
*= melanocytes in melanoma (healthy melanocytes do not make MMP-11), chondrocyte 






















Figure 1.4 - Schematic summarising non-structural changes induced by MMPs that may 











1.3.   Scarring and fibrosis 
 
 1.3.1.  Spectrum of wound repair success, from 
regeneration to scarring 
 
The perfect response to a wound would be the complete regeneration to a normal resting state. 
In early stages of foetal development there is an inherent ability to regenerate after a wounding 
event leading to scar-free healing (Leung, Crombleholme and Keswani, 2012). Indeed, in some 
organisms, such as the planarian flatworm or those in the Caudata order, this ability is retained 
into adulthood (Tanaka and Reddien, 2011). These organisms are therefore intensively studied 
as models of regeneration and can provide useful information in the context of wound healing. 
Axolotyl, a salamander species, is able to regenerate entire limbs following amputation, 
requiring the accurate development of multiple tissue types (Tanaka and Reddien, 2011). This 
process clearly requires tight regulation in order to retain regenerative ability upon wounding 
whilst not spontaneously growing unnecessary tissue. The regulation of these processes are 
heavily studied by the regenerative medicine field in the hope that this will allow the 
development of tools to regenerate tissue and organs in humans (Roy and Gatien, 2008; Seifert 
et al., 2012). 
Importantly, even within mammals there is differential ability to regenerate between different 
organs. The liver is extraordinarily regenerative upon injury, with the ability to regrow after two 
thirds of its mass is removed. However, the central nervous system is renowned for being very 
poor in repairing wounds, with intense research focus on improving the prognosis of those with 
spinal cord injuries who typically suffer from excessive scarring and loss of normal organ 
function resulting in paralysis (Fitch and Silver, 2012). The skin is also less successful in 
healing wounds, especially large and full thickness wounds like burns which tend to result in 
hypertrophic scars (van den Broek et al., 2014). 
Scar tissue is characteristically fibrotic and is associated with some loss of architecture and 
function in the tissue (Xue and Jackson, 2015). For example, in the skin there is an altered 
structure and content of matrix, with the loss of normal flexibility and elasticity, there is also a 
failure to redevelop functional appendages including hair follicles and sebaceous glands (Bayat, 
McGrouther and Ferguson, 2003). The reason for the generation of scars is not well understood 
but it is proposed that it is an evolutionary by-product of a rapid wound repair process that is 
prioritised to protect from a pathogenic environment (Allen and Wynn, 2011).  It has also been 
suggested that scar tissue formation can be a protective mechanism against further insults to that 
area (Gauglitz et al., 2011). 
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 1.3.2.  Common mechanisms in scarring and fibrosis 
 
Fibrosis can occur as a result of injury, or other causes of inflammation, including infection 
(Wynn, 2013). Fibroblasts are the driving cell type in this pathology as they are responsible for 
the production of matrix (Kendall, Feghali-Bostwick and Rauch, 2014). Persistent activation of 
myofibroblasts can also drive fibrosis and can be promoted by paracrine signals from immune 
cells, autocrine signals from other myofibroblasts or even through interaction of pathogens via 
fibroblast toll-like receptors (TLRs) (Wynn, Yugandhar and Clark, 2013). Increasingly, 
epigenetic mechanisms are being linked to fibrosis, including influences on myofibroblast 
activation (Mann and Mann, 2013). 
Chronic inflammation often correlates with fibrosis with a presumed causal relationship both 
through innate and adaptive arms of immunity (Wynn, Yugandhar and Clark, 2013). Persistence 
of innate immune cells, such as neutrophils and then macrophages, can cause tissue damage. 
High neutrophil counts have been associated with severity of disease in idiopathic pulmonary 
fibrosis (IPF) (Obayashi et al., 1997) and the release of extracellular chromatin structures by 
neutrophils, called neutrophil extracellular traps, causes the myofibroblast differentiation of 
lung fibroblasts (Chrysanthopoulou et al., 2014). Depletion of neutrophils in an infection driven 
pulmonary fibrosis model ameliorated the disease (Puerta-Arias et al., 2016). 
There is even stronger evidence for the influence of both pro-inflammatory “M1” and pro-
fibrotic “M2” skewed macrophages on fibrosis (Wynn and Vannella, 2016). It appears that both 
subtypes can drive fibrosis, either through the production of TGF-β1, as noted in IPF (Murray et 
al., 2011) or indirectly through the activation of Th2 responses and IL-13 secretion (Kaviratne 
et al., 2004) (Figure 1.5). Depletion of macrophages in fibrosis models have shown their 
importance in both pulmonary and liver fibrosis with a decrease in disease severity (Duffield et 
al., 2005; Gibbons et al., 2011).  
Coagulation has also been linked to fibroses in liver and lung, with the neutralisation of 
coagulation factors II, V, VII, IX and XI preventing fibrosis in animal models (Scotton et al., 
2009; Mercer and Chambers, 2013). It also appears that dysregulation of vasculature can 
influence fibrosis. Interestingly, it has been noted in systemic sclerosis (SSc) that a loss of 
normal vasculature often occurs prior to the onset of fibrosis (Varga and Abraham, 2007), 
whereas in many fibrotic eye conditions, there is uncontrolled proliferation of unstable blood 
vessels that then leak inflammatory products, further fuelling fibrosis (Friedlander, 2007) and an 
increased angiogenic stage has been seen in hypertrophic versus normal skin that may promote 
scar growth (Van Der Veer et al., 2011). 
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Figure 1.5 - Schematic demonstrating macrophage influence on fibrosis from (Wynn and 
Vannella, 2016) where the red macrophage represents “M1” and the green macrophage 
represents “M2” 
 
Adaptive immunity can also influence fibrosis through the actions of polarised CD4 T cells 
(Wynn, 2004). Helper T cells can generate two alternative responses: Th1, which is 
characterised as an interferon type, phagocyte dependent inflammation; or Th2, which is 
characterised as an IL-4 driven response that is phagocyte independent (Romagnani, 2000). It 
appears that the balance of Th1 and Th2 responses is critical, with a more Th2 heavy response 
tending to exacerbate fibrosis (Wynn, 2004; Allen and Wynn, 2011). This was first 
demonstrated in an IL-12 based vaccination against schistosome mediated fibrosis which 
successfully primed a Th1 heavy response to attenuate fibrosis (Wynn et al., 1995).  
B cells have also been implicated in fibrosis, although this is more controversial and has only 
been shown convincingly in liver fibrosis models so far (Novobrantseva et al., 2005) with 




 1.3.3.  Role of growth factors and cytokines in scarring and 
fibrosis  
 
Since fibrosis is driven by the pathological behaviour of fibroblasts, it is important to 
understand factors that are capable of activating fibroblasts and influencing their behaviour 
(Wynn, Yugandhar and Clark, 2013). There are a number of growth factors and cytokines, 
especially interleukins, reported in the literature to be associated with fibrosis  (Borthwick, 
Wynn and Fisher, 2013; Wynn, Yugandhar and Clark, 2013), the most prevalent of which will 
be described in the following sub-sections. The inclusion of the following growth factors and 
cytokines is by no means inclusive of every factor that may be involved in fibrosis, or 
specifically keloid pathology, but represent some of the most well characterised and reported. 
 
 1.3.3.1.  TGF-β 
 
Transforming growth factor beta (TGF-β) is one particularly well characterised factor that is 
implicated in the fibroses of many organs (Meng, Nikolic-Paterson and Lan, 2016). The family 
member TGF-β1 has been shown to be an important driver of inflammation during cutaneous 
wound healing (Wang et al. 2006) and indeed mice lacking SMAD3, a key mediator of TGF-β 
signalling,  have accelerated wound healing associated with a decrease in inflammation during 
repair (Ashcroft et al., 1999). However, TGF-β1 is frequently reported as ‘out-of-control’ in the 
formation of abnormal, excessive scars (Beanes et al., 2003) and could also play a role in 
driving a pro-fibrotic M2 macrophage response that can further exacerbate fibrosis (Wynn and 
Vannella, 2016). A landmark study in 1995 demonstrated the TGF-β1 and TGF-β2 isoforms are 
pro-fibrotic in a wound healing context, whereas TGF-β3 is anti-fibrotic (Shah, Foreman and 
Ferguson, 1995). 
Signalling through the SMAD complex is thought to drive a variety of pathological cell 
behaviours including the differentiation and persistance of myofibroblasts which produce 
excessive collagen and can be persistently contractile (Figure 1.6). Recently it has been shown 
TGF-β1 may drive a scar phenotype through upregulation of microRNA 21 (miR21) (Liu et al., 
2016). Equally, activation of downstream SMADs can drive a plethora of cell behaviours 
through transcription, including the production of profibrotic miRs and long non-coding RNAs 
(lncRNAs) (Meng, Nikolic-Paterson and Lan, 2016). Indeed, many miRs have been shown to 
regulate different stages of TGF-β/Smad signalling (Meng, Nikolic-Paterson and Lan, 2016). 
SMAD7 is a negative regulator of pro-fibrotic TGF-β signalling, and its disruption or lowered 
can also worsen fibrosis (Zhu, Chen and Chen, 2011). It has additionally been shown that there 
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is cross-talk between TGF-β signalling and other important fibrosis pathways including MAPK, 




Figure 1.6 - Schematic showing profibrotic TGF-β signalling ( adapted from Varga & 
Abraham). TGF-β1, often cleaved from a latent form bound to ECM, engages with TGFβ 
receptors to activate SMAD signalling, causing phosphorylation and nuclear localisation of 
SMAD proteins to drive target gene transcription. SMAD7 works as a negative regulator in this 





 1.3.3.2.  PDGF-BB 
 
The platelet derived growth factor (PDGF) family contains five isoforms, PDGF-AA, -AB, -BB, 
-CC and -DD which act by the two receptors PDGF-ɑ and -β (Fredriksson, Li and Eriksson, 
2004). Upregulation of both PDGF ligands and associated receptors has been reported in 
fibrosis (Bonner, 2004). PDGF has been described as the most potent driver of stellate cell 
proliferation in liver fibrosis, although the isoform was not stated (Pinzani et al., 1989). 
Different PDGF isoforms are postulated to be more important in the fibrotic process in certain 
organs, such as PDGF-BB in skin fibrosis (Bonner, 2004). Much less is known about PDGF-CC 
and -DD isoforms but they have been implicated in renal fibrosis (Eitner et al., 2003; Ostendorf 
et al., 2003). Interestingly, recombinant human PDGF-BB has been used clinically (known as 
becaplermin) to improve healing in diabetic foot ulcers (Fang and Galiano, 2008) 
PDGF can trigger ERK and PI3K/Akt signalling, but is also thought to overlap with TGF-β1 to 
drive fibrosis (Bonner, 2004). PDGF stimulation of hepatic stellate cells increases the 
profibrotic transcription of connective tissue growth factor (CTGF) which can be blocked with 
the neutralisation of TGF-β1 (Paradis et al., 1999). Additionally, TGF-β1 stimulation of SSc 
fibroblasts in culture can cause upregulation of PDGFRɑ (Yamakage et al., 1992). 
 
 1.3.3.3.  Th2 cytokines – IL-4/IL-13 
 
Cytokines that are associated with Th2 response, namely IL-4 and IL-13, are thought to drive 
fibrosis (Wynn, 2004). The strongest evidence for an elevation of these cytokines comes from 
SSc patients where IL-4 and IL-13 are increased in patient serum compared to healthy controls 
(Hasegawa et al., 1997). IL-4 and IL-13 share the co-receptor IL-4rα and both signal primarily 
through the signal transducer and activator of transcription factor 6 (Stat6) pathway (Oh, Geba 
and Molfino, 2010). Both cytokines have been shown to drive myofibroblast differentiation 
(Hashimoto et al., 2001) and cause increased collagen production in hepatic stellate cells 
(Sugimoto et al., 2005). IL-4 in particular has highly potent effects on dermal fibroblasts, with 
IL-4 stimulation of cells from normal skin or SSc patients causing over twice the amount of 
collagen production than an equivalent dose of TGF-β1 (Fertin et al., 1991). 
These cytokines have many important effects on matrix production, aside from collagen. IL-4, 
and particularly IL-13, have been shown to induce the production of the matrix protein periostin 
(Takayama et al., 2006; Izuhara et al., 2016) which has been shown to promote fibrosis in many 
organs including the heart (Zhao et al., 2014), lungs (Naik et al., 2012) and skin (Yamaguchi, 
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2014). Stimulation of fibroblasts with IL-4 also stimulates the production of fibronectin, an 
important component of scar matrix (Babu et al. 1989). In addition, it has been shown in mouse 
injuries that IL-4 triggers downstream signalling in M2-like macrophages that subsequently 
causes the induction of the enzyme lysyl hydroxylase-2 from dermal fibroblasts. This enzyme 
catalyses the production of cross linked, irregularly sized collagen bundles that are more 
resistant to degradation and therefore pro-fibrotic (Knipper et al., 2015).  
In addition to an increase in full length IL-4, a differentially spliced isoform called IL-4𝛿2  has 
also been identified in the blood of SSc patients (Sakkas et al., 1999). The functional effect of 
IL-4𝛿2 is not entirely clear but there is evidence to show that it does induce fibrotic behaviour 
of fibroblasts through hyper-proliferation and collagen production (Atamas and White, 1999; 
Atamas et al., 1999). 
IL-13 also appears to be a highly pro-fibrotic cytokine and can activate M2 macrophages to 
drive the development of fibrosis (Wynn and Barron, 2010). Overexpression of IL-13 in the 
lung showed development of fibrosis (Zhu et al., 1999) and conversely IL-13 inhibition 
attenuated models of fibrosis in the liver and lung (Chiaramonte et al., 1999; Murray et al., 
2014). It has additionally been demonstrated that IL-13 driven Th2 responses can drive fibrosis 
in the absence of TGF-β1 (Kaviratne et al. 2004). IL-33, an IL-1 family member, has also been 
shown to be correlative with fibrotic severity in disease including SSc (Yanaba et al., 2011) and 
is a well-recognised driver of Th2 responses through ST2 signalling (Murakami-Satsutani et al., 
2014) 
 
 1.3.3.4.  IL-17A 
 
IL-17A, also referred to as IL-17, is generally regarded as a pro-inflammatory cytokine 
produced by a CD4+ T cell subset known as Th17s, as well other innate immune cells including 
neutrophils (Jin and Dong, 2013). IL-17 has been found at increased levels in fibrotic liver, and 
IL-17R deficient mice show improved outcomes in a carbon-tetrachloride induced model of 
liver fibrosis which may be driven by a reduced neutrophil influx (Tan et al., 2013). This study 
also showed that IL-17 stimulation of murine hepatic stellate cells induces production of key 
fibrotic markers including IL-6, α-SMA and collagen (Tan et al., 2013) 
Conversely, whilst IL-17 expression is increased, both locally in the skin, and systemically in 
SSc patients, the level of the relevant receptor, IL-17R, is decreased in SSc fibroblasts 
(Nakashima et al., 2012). The authors suggests that, as these cells have a limited capacity to 
respond, IL-17 ligand is in fact acting in an anti-fibrotic manner in this system (Nakashima et 
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al., 2012). The role of IL-17 ligand in fibrosis is therefore unclear and may be related to the cell 
type affected. 
 
 1.3.3.5.  IL-6 
 
IL-6 is often referred to as a pro-inflammatory cytokine, however its function in vivo is 
distinctly pleiotropic (Scheller et al., 2011). The importance of IL-6 in wound healing has been 
shown with both IL-6 and IL-6r knockout mice showing wound healing defects (McFarland-
Mancini et al., 2010). However, persistent high levels of IL-6 is associated with fibrosis in a 
range of organs (Fielding et al., 2014). 
To respond to IL-6, cells must express both the co-receptor GP130, which is ubiquitously 
expressed across cell types, and the IL-6r whose expression is more stringent (Heinrich et al., 
1998). However, soluble IL-6r (sIL-6r) can also be produced by the cleavage of membrane 
bound receptor, or the expression of a spliced isoform lacking the transmembrane domain 
(Heinrich et al., 1998). The presence of soluble receptor therefore allows a greater spectrum of 
cells to respond to IL-6 in the environment. It has been shown that an inflammatory 
environment, which is also likely to have elevated levels of IL-6, can promote cleavage of IL-6r, 
especially from infiltrating neutrophils (Rose-John, 2012), causing a greater response from the 
local cellular environment. 
There is debate in the literature whether fibroblasts are capable of expressing IL-6r, or whether 
they may rely on sIL-6r in the environment in order to respond to IL-6. However, it has been 
shown that stimulating fibroblast cultures with IL-6 alone can promote proliferation and 
collagen production (Ghazizadeh et al., 2007) suggesting that fibroblasts do express IL6r. 
Downstream of IL-6r, IL-6 effects are largely though to be mediated by Jak/Stat3 signalling 
(Heinrich et al., 1998), which is purported to be highly pro-fibrotic (Zhang et al., 2005; Knight, 
Mutsaers and Prêle, 2011). However, IL-6 is known to be capable of triggering other pathways 
including Akt and Erk driven signalling which may explain its highly pleiotropic effects 





Figure 1-7 - Schematic demonstrating possible pathway activation downstream of IL-6. 
IL-6 ligand requires the presence of GP130 and IL-6r (membrane bound or soluble form, sIL-
6r) to signal. Signalling using sIL-6r is known as trans signalling, whereas signalling using the 
membrane bound IL-6r is known as classical signalling. After receptor engagement, 
dimerization and phosphorylation of Jaks can cause phosphorylation and downstream signalling 
through Stat3, PI3K/Akt and Raf/MEK/Erk to result in nuclear localisation of transcription 
factors and transcription can occur. A plethora of genes may be transcribed following this 
signalling event, including SOCS3 which can negatively regulate signalling by binding to 




1.4. Keloid scarring 
 
 1.4.1.  Scarring in the skin 
 
Erroneous control of the cutaneous wound repair process can cause a spectrum of abnormalities 
including the non-healing ulcers seen in diabetic patients to the formation of fibrotic scars 
(Martin, 1997). It is predicted that every year 100 million patients in the developed world alone 
form scars. The majority of human scars are normotrophic, forming after relatively minor 
wounds to the skin, and causing a very minor cosmetic issue (Bayat, McGrouther and Ferguson, 
2003; Verhaegen et al., 2009). These scars are generally flat and pale and are not associated 
with contracture or itching/pain (Bayat, McGrouther and Ferguson, 2003).  
Histologically, normal scars are distinct to the adjacent normal skin with a relatively clear 
border in the two tissue types (Figure 1.8). The scarred area has a flattened epidermis (Figure 
1.8), with loss of the usual rete ridge and dermal papillae structures (Rook, 1996), but the 
overall epidermis is a similar thickness to the normal skin (Limandjaja et al., 2017). The dermal 
area of scar has compact, smooth collagen (Figure 1.8) instead of the classical basket weave 
pattern of collagen bundles (Bayat, McGrouther and Ferguson, 2003). 
 
 
Figure 1.8 - Histological features of normal scar/normal skin. Formalin fixed, paraffin 
embedded normal skin/normal scar section stained with H&E. Dashed line denotes approximate 
normal skin/scar border. Typical scar pathology with loss of normal undulating epidermis and a 
dense matrix. Normal skin shows typical basket weave collagen in dermis and usual rete ridge 
structure in epidermis. Scale bar represents 250µm.  
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Although normotrophic scars are most common after wounding, scars can occur with a range of 
severity (Figure 1.9). Hypertrophic scars are a prominent scar that are confined within the 
original wound region and typically partially resolve with time (Muir, 1990). They often occur 
after full thickness wounds such as those obtained from surgical procedures or burns (Bayat, 
McGrouther and Ferguson, 2003). 
Keloid scars are a more severe form of scarring and can expand well outside of the wound 
margin, often causing a tumour-like mass (Bayat, McGrouther and Ferguson, 2003). These scars 
do not resolve with time and will frequently continue growing for many years post injury (Muir, 
1990). Susceptible individuals can generate a keloid scar in response to relatively minor wounds 
to the skin including insect bites and acne (Gauglitz et al., 2011). Keloid scarring is a distinct 
fibrotic condition, with excessive inflammation and deposition of matrix proteins leading to 
dysfunction of the tissue. As in other fibroses, this atypical matrix-dense environment can 
functionally contribute to atypical cellular responses (Wells, 2008; Rhee, 2009). The clinical 
distinction between hypertrophic and keloid scars is often difficult so scars are sometimes 























Figure 1.9 - Representation of scar types (from Sidwick et al 2015). a) A typical scar 
resulting from a common injury, known as a normotrophic scar, b) a more prominent scar often 
resulting from burns or surgical injury known as a hypertrophic scar, c) intermediate raised scar 




 1.4.1.  Epidemiology and genetic risk of keloid scarring 
 
Keloid scarring can affect any individual but is commonly associated with darker skin. In some 
populations, occurrence can be up to 16% (Rockwell, Cohen and Ehrlich, 1989). Keloids are 
reported to be more common in females with a possible hormonal influence (Gauglitz et al., 
2011). Evidence for a hormonal link is also supported by the observation of increased keloid 
risk during adolescence and pregnancy and decreased keloid risk post-menopause (Moustafa 
and Abdel-Fattah, 1975; Kim et al., 2013).   
In general, patients are not reported to present with any other clinical issues and show normal 
wound healing in all other organs. There have been a very small number of co-morbidity reports 
of keloids which although infrequent could indicate a genetic link to disease. One such 
condition is Rubinstein-Taybi syndrome (Van De Kar et al., 2014), which results from 
mutations in histone acetyltransferases CREB binding protein (CBP) and/or EP300 where 
around 57% of patients have been found to generate keloid scars (Stevens, Pouncey and 
Knowles, 2011).   
No clear genetic link has yet been established despite substantial anecdotal evidence of multiple 
family members suffering from the condition (Bayat et al. 2004). In general, there is a lack of 
large worldwide consortium genetics studies to inform on causative polymorphisms, however 
the pattern of keloid inheritance has been described to be consistent with an autosomal 
dominant disorder with incomplete penetrance (Marneros et al., 2001). TGFB1 or 
corresponding receptor polymorphisms were originally described in 1991 to be a likely culprit 
(Peltonen et al., 1991), however this has been since dismissed (Bayat et al. 2004) . A more 
recent study by Nakashima et al found 4 single nucleotide polymorphisms (SNPs) in NEDD4 
and FOXL2 and in two other unknown regions (Nakashima et al., 2010). The limitation of this 
study is the restriction of analysis to only Japanese keloid sufferers (824 patients and 3205 race 
matched controls) and it is likely that these polymorphisms may be race specific. The most 
statistically robust polymorphisms identified are in the human leukocyte antigen (HLA) 
domains which are likely to be important in controlling the immune response during wound 
repair, in particular HLA-DRB1*15 which has been identified in both Caucasian and Chinese 




 1.4.2.  Clinical presentation and treatment of keloid scars 
 
Keloid derives from the Greek word for ‘crab claw’ which illustrates the typical irregular, 
sprawling appearance of the scar as it grows outside of the original wound margin (Figure 1.9). 
Patients often suffer not only from aesthetic concerns but also pain, pruritus and loss of mobility 
if located over a joint (Davidson et al., 2009). Keloid formation has a stronger tendency to occur 
in distinct anatomical locations including the back of the head, face, neck, chest and shoulder 
regions (Figure 1.10) (Alster and Tanzi, 2003).  
Treatment for keloid scars is currently limited and variable in success. As a first point of call, 
clinicians will often attempt steroid injection with corticosteroids such as triamcinolone 
acetonide  (Andrews et al., 2016). It is estimated that around half of treated patients will be 
categorised as steroid non-responders and the explanation for this is not yet elucidated (Ud-Din 
et al., 2013). Aside from pharmacological success, there are also issues with patient compliance 
due to the pain associated with the procedure. Surgical removal is seen as a last-resort option 
due the risk of recurrence which is estimated to be at least 40% and up to 100% in some studies 
(Rockwell, Cohen and Ehrlich, 1989). Surgical approaches for removal differ, however 
generally a healthy tissue border will not be taken. Treatments are often combined, such as 
surgical excision followed by corticosteroid injection, to reduce recurrence risk (Andrews et al., 
2016). Other less invasive options include compression or silicone bandages, as well as laser or 
radiotherapy (Gauglitz et al., 2011) .  
The issue of drug delivery to keloid scars, as in solid oncogenic tumours (Sriraman, 
Aryasomayajula and Torchilin, 2014), is important to consider when developing new 
therapeutics. Discussions with dermatologists and surgeons have suggested a limited capacity 
for success in topical treatments due to the dense matrix composition of the scar, and even 
intralesional injection of steroids has presented issues in fully infiltrating the keloid tissue. 
Approaches including hyperthermia and ultrasound (Polat et al., 2011) are currently being 
researched in order to tackle the issue of permeation of tissue. Many alternative treatments are 
in research however an epigenetic approach may be more successful in reprogramming affected 













Figure 1.10 - Photographs showing examples of keloids in the commonly occurring 




 1.4.3.  Histopathology of keloid scars 
 
Histological analysis of keloid scars further reveals their abnormal composition (Figure 1.11). 
Keloid scars often show a thickened epidermal layer (Chua et al., 2011) and although not clear 
from histological staining, an unusual basement membrane structure is also formed with a 
disruption of the normal permeability of this layer (Hellstrom et al., 2014). Keloid dermis is 
highly cellular and rich with excessive and abnormal ECM with large bundles of hyalinised 
collagen structures and distinct clusters of immune cells (Figure 1.11).  The distinction between 
the reticular and papillary dermis seen in normal skin is also lost in keloids. Notably, toluidine 
blue staining gives the appearance of cartilage in some keloid samples suggesting a possible 
mis-differentiation of the tissue (Naitoh et al., 2005). 
 
 
Figure 1.11 - Histological features of keloid scar. Formalin fixed, paraffin embedded keloid 
section stained with H&E. Typical keloid pathology with thickened epidermis (E) (around 100-
200µm thick) with loss of normal rete ridge structure and a highly cellular dermis (D) with 
dense matrix characterised by swirling, hyalinised collagen bundles and distinct clusters of cells 
likely to be immune cells (examples highlighted with dotted lines). Scale bar represents 250µm.  
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 1.4.4.  Cellular makeup of keloid scars 
 
 1.4.4.1.  Keloid epidermal cells 
 
Despite an obviously abnormal epidermal layer in keloid scars, it is not well understood how 
keratinocytes in this layer are different to that of normal skin. Keloid keratinocytes do not 
appear to be more proliferative (Hahn et al., 2013; Limandjaja et al., 2017). Instead these cells 
may be abnormally differentiated with expression of the early differentiation marker involucrin 
throughout the epidermis rather than restriction to the granular epidermal layer as is seen in 
normal skin and a disorganised, immature stratum corneum (Limandjaja et al., 2017). 
Transcriptomic analysis of keloid keratinocytes has shown decreased expression of transcription 
factors, including family members of the frizzled transcription factor family, and cell adhesion 
components that are required for normal keratinocyte biology including intermediate filament 
genes synemin (SYNM) and VIM, and desmosome junction components JUP and PKP1. 
Whereas keloid keratinocytes showed elevated expression of genes associated with wound 
healing, migration and vascular development such as keratin 7 (KRT7), and lysyl oxidase 2 
(LOXL2) which has been implicated in ECM cross linking, tumour progression and cellular 
invasion (Hahn et al., 2013). All of these transcriptomic changes suggest these cells have a 
changed phenotype indicating a chronic stage of erroneous healing.  
The importance of cross-talk between the epidermis and dermis has been shown in the 
regulation of hair follicle development (Fu and Hsu, 2013) and it has already been proposed that 
the epidermis has a key role to play in dermal fibrosis in the context of hypertrophic scarring 
(Bellemare et al., 2005). There is evidence that keloid keratinocytes can influence fibroblasts in 
a pathological way, as normal fibroblasts cultured with keloid keratinocytes show increased 
keloidal collagen production which was not seen in culture with normal keratinocytes (Lim et 
al., 2002). A paracrine factor(s) released by keloid keratinocytes-fibroblast co-cultures could 
also enhance fibroblast collagen gel contraction (Mukhopadhyay et al., 2005). Keloid 
keratinocytes have additionally shown a fibroblast-like morphology in hypoxic conditions, 
suggesting enhanced epithelial-mesenchymal transition (EMT) potential compared to normal 
skin (Ma et al., 2015). 
No clear evidence has been found to show that melanocytes can drive keloid scar formation, but 
it has been hypothesised based on the higher incidence in darker skin (Gao et al., 2013) and a 
single research paper shows a downregulation of the α-melanocyte-stimulating hormone and its 
associated receptor, melanocortin-1 in keloid scar tissue (Luo et al., 2013).   
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 1.4.4.2.  Keloid immune cells 
 
Despite evidence that keloid scars are often very inflamed, and this inflammation is thought to 
drive keloid pathogenesis (Ogawa, 2017) the immune cell population in keloid tissue is not well 
defined. As seen in histological sections of keloids (Figure 1.11), immune cells appear to reside 
in distinct clusters in the papillary dermal layer and these clusters have been described in the 
literature as KALTs (keloid associated lymphoid tissue) (Bagabir et al. 2012a; Grant et al. 
2016), similar to the MALTS (mucosal associated lymphoid tissue) seen in the gut during 
intestinal inflammation (Lochner et al., 2011). This would suggest that these populations are 
long-lived and stable, providing paracrine factors that may cause, exacerbate, or prolong keloid 
establishment and growth. 
An immunohistochemical (IHC) approach by the Bayat group showed increases in almost all 
immune cell sub-types examined, including T-cells, B-cells, mast cells and macrophages, 
although no apparent difference in Langherhans cells (Bagabir et al. 2012a). However, some of 
the markers used may not offer enough specificity, for example, major histocompatibility 
complex II (MHC-II) can be expressed by a range of activated cells such as CD4 T-cells 
(personal communications, Esperanza Perucha). Attempts by our lab to better characterise the 
keloid immune cell population by FACS on fresh tissue have been technically challenging but 
has indicated a tipped balance towards M2 type macrophages (data not shown). A skew towards 
a M2 phenotype is likely to propagate the keloid pathology, with the production of M2 
associated factors including TNF-ɑ, and IL-6, which is a particular focus for this project and is 
likely to induce pathological fibroblast behaviour (Xue, McCauley and Zhang, 2000; Tosa et al., 
2005; Ghazizadeh et al., 2007) 
 
1.4.4.3.  Keloid fibroblasts 
 
Fibroblasts are the predominant cell type in the dermal layer of the skin, where keloid pathology 
is particularly prominent (Smith et al., 2008), as well as being a key effector cell in this disease. 
During the 1980s and 90s, a number of papers were published describing differing 
characteristics in keloid and normal dermal fibroblasts. These include a greater proliferative 
capability (Harper, 1989; Calderon, Lawrence and Banes, 1996), and production of pro-fibrotic 
markers including excessive ECM (Babu, Diegelmann and Oliver, 1989; Bettinger et al., 1996). 
Since then, the availability of larger scale analysis through ‘-omics’ studies has allowed for 
deeper analysis of these differences on a protein and genetic level. A microarray study 
comparing cultured normal scar and keloid scar fibroblasts indicated differential regulation of 
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around 500 of 38,000 genes analysed, showing increased insulin-like growth factor binding 
proteins, and decreased Wnt inhibitors and IL-1 inducible genes, indicating a pro-fibrotic 
phenotype (Smith et al., 2008). However, in general, although transcriptomic data has shown 
some common trends, such as inflammation and fibrosis associated pathways, gene lists tend to 
be inconsistent due to variability between study set-ups (Smith et al., 2008; Suarez et al., 2015; 
Jumper et al., 2017). There is still a need to further this research in order to control studies 
appropriately and correlate them to relevant phenotypic behaviours. 
Despite a lack of in vitro evidence for heightened keloid fibroblast proliferation, these cells have 
shown increased thymidine incorporation in a scratch “wound” assay in comparison to normal 
skin fibroblasts, suggesting these cells respond differently to damage cues (Calderon, Lawrence 
and Banes, 1996). Above just being more ‘activated’, it has been postulated that these cells may 
in fact be mis-differentiated away from a skin phenotype. There is evidence that keloid 
fibroblasts are de-differentiated, expressing a number of stem-like markers (Zhang et al., 2009; 
Grant et al., 2016), or differentiated to a more osteogenic or chondrogenic lineage (Naitoh et al., 
2005; Fuentes-Duculan et al., 2016). Interestingly, proteomic analysis from our lab alongside 
evidence of an increase in the chondrogenic transcription factor Sox9 (data not shown) provides 
more evidence that this could be true, pushing highly plastic dermal fibroblasts (Shaw and 
Martin, 2016) towards a chondrocyte-like fate producing abnormal ECM not usually seen in 
normal skin or normal scar. 
The source of the fibroblast population found in keloid scars is debated in the literature. They 
may originate from an existing fibroblast population that has become unnaturally proliferative 
and activated (Driskell et al., 2013), potentially because of the influence of the immune cell 
infiltrates in keloid scars (Ogawa, 2017). However, there are alternative hypotheses in the 
literature (Figure 1.12). Circulating fibrocytes may be recruited from the bloodstream (Abe et 
al., 2001), or transdifferentiated fibroblasts can be induced from epithelial cells through EMT 
(Yan et al., 2010). It has been shown that EMT can occur during cutaneous wound healing and 
marked by vimentin/E-cadherin double positive cells and high levels of Snail1 and MMP9; this 




















 1.4.5.  Current literature hypotheses on keloid aetiology 
 
The mechanisms behind keloid scar formation are currently unknown. However, it is an 
accepted paradigm that inflammation is a key driver in this pathology, due to the persistence of 
immune cells as previously described. Prolonged presence of immune cells can induce a pro-
inflammatory environment in the wound which can also promote scarring through activation 
and proliferation of fibroblasts (Wynn, 2004; White and Mantovani, 2013; Fielding et al., 
2014). Keloid scars in particular are associated with a high level of inflammation which can 
persist many years after the wounding event (Ogawa, 2017). Elevated levels of growth factors 
and cytokines have been shown to be present within keloids, with indication of raised cytokine 
levels also seen in the circulation of these patients (McCauley et al., 1992). Various studies 
have examined the secretory immune environment in keloids, and two factors that are 
consistently reported as increased are TGF-β1 and IL-6 (Xue, McCauley and Zhang, 2000; Tosa 
et al., 2005; Ghazizadeh et al., 2007; Uitto, 2007).  
The growth factor TGF-β1 is a proposed driver of keloid scarring due its recognised role in 
fibrosis (Varga, Rosenbloom and Jimenez, 1987; Leask and Abraham, 2004) with a critical 
increase in the ratio of TGF-β1 to TGF-β3 in the keloid environment that could tip the balance 
towards a fibrotic phenotype (Bock et al., 2005; Jagadeesan and Bayat, 2007). There may also 
be differences in TGF-β receptor expression on keloid fibroblasts that cause diverse signalling 
events in response to stimulation from different TGF-β isoforms (Bock et al., 2005). Given the 
classic pro-fibrotic association with downstream IL-6 signalling through Jak-Stat3 signalling 
(Heinrich et al., 1998), this is now been a focus for discussion in regards to therapeutic 
strategies (Ghazizadeh et al., 2007; Uitto, 2007) and will be further explored within this project. 
It is also thought that there is a diminished yet prolonged remodelling phase in keloid aetiology 
with a possible persistence of myofibroblasts causing tension within the wound (Chipev et al., 
2000). This persistent contractility, may cause pain, and may also cause sustained inflammation. 
There is also suggestions that there may be an increase in protease activity at the leading edge of 
keloids, which may allow for their continuous outgrowth (Sadick et al., 2008; Thielitz et al., 
2008). 
A variety of historical, less-supported theories for keloid formation include an auto-immune 
response to sebum after wounding (Yagi, Dafalla and Osman, 1964), elevated levels of 
histamine (Russell, Russell and Trupin, 1977) and defective induction of senescence in keloid 
fibroblasts (Blažić and Brajac, 2006). 
Evidence for the possible mis-differentiation of keloid fibroblasts, along with difficulties in 
finding definitive causative genetic loci for the disease despite familial inheritance being 
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reported, could suggest that there is an epigenetic level of regulation that may be responsible for 
keloid formation and this requires further investigation. 
 
1.5. Epigenetic control in wound healing and fibrosis 
 
Epigenetics is the term to describe the regulatory control of gene transcription and therefore cell 
behaviour and fate (Helin and Dhanak, 2013). This regulation occurs at multiple levels and 
allows strict control of cells in a dynamic environment. 
Dermal fibroblasts are eminently associated with a highly plastic phenotype (Osonoi et al., 
2011), hence their application in regeneration research and therapy (Wong, McGrath and 
Navsaria, 2007). These cells may have more flexibility in their behaviour and fate supported by 
a more flexible epigenetic signature (Plikus et al., 2015), which is particularly important in 
terms of their response to cutaneous wounding (Shaw and Martin, 2016). 
Epigenetic regulation may occur at a variety of levels, including directly on histones. For 
example, after wounding the leading edge keratinocytes show flexibility in their behaviour, 
marked by epigenetically “un-silencing” by removal of polycomb-deposited histone marks that 
normally control keratinocyte identity and behaviour (Shaw and Martin, 2009). However, 
deletion of EZH2, an important component of the polycomb complex, in cardiac progenitors 
caused hypertrophy and fibrosis (Delgado-Olguín et al., 2012) and its overexpression in IPF 
fibroblasts caused myofibroblast differentiation (Xiao et al., 2016), highlighting the need for 
tight, cell-specific control of its expression to regulate homeostatic cell behaviour.  
Increased flexibility of the epigenome through “open” chromatin can facilitate deleterious 
effects in response to insults (Yang, Tian and Brasier, 2017), including wounding (Neary, 
Watson and Baugh, 2015), regardless of genetic sequence. Various epigenetic signatures have 
been linked to fibrosis such as hypomethylation, which has been associated with fibrosis in the 
liver (Komatsu et al., 2012), lung (Huang et al., 2014), eye (McDonnell, O’Brien and Wallace, 
2014) and more recently in keloid scarring (Jones et al., 2015).  Myofibroblasts, which are 
thought to be a key driver of tissue fibrosis are also thought to be epigenetically regulated 
(Mann and Mann, 2013).  
MiRs are well discussed in recent literature in the context of wound healing (Banerjee and Sen, 
2015; Fahs et al., 2015) and are in fact vital during normal skin development (Yi et al., 2006). 
MiRs can both positively and negatively regulate every stage of wound repair (Fahs et al., 2015) 
with a fine balance to be struck. Therefore, mis-expression of specific miRs can have drastic 
impacts on cell behaviour and a knock on effect in disease. For example, 29 miRs were found to 
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be differentially expressed between scratched wounded diabetic corneal cells compared to 
healthy controls, and knockout of miR-146a or miR-424 in particular decreased wound closure 
(Funari et al., 2013). miRs have also been heavily implicated in fibrotic disease, and are of 
particular interest due to their often very tissue-specific effect.  
 
1.6. Epigenetic changes in keloid scarring 
 
The epigenetic influence in keloid aetiology is still not fully explored but some convincing 
evidence for epigenetic changes has been elucidated. Keloid fibroblasts have been shown to 
have differential DNA methylation and histone acetylation patterns compared to normal scar 
fibroblasts (Russell et al., 2010). Altered DNA methylation was also seen in keloid tissue, with 
685 CpG sites differentially methylated compared to normal skin (Jones et al., 2015). In 
addition, elevated levels of histone deacetylase 2 (HDAC2) has been shown in normal and 
keloid scars, which is thought to be driven by TGF-β1 and high cellular density (Fitzgerald 
O′Connor et al., no date).  
MiRs have also been identified as differentially expressed in keloid scar tissue, and specifically 
in fibroblasts (He et al., 2017). Despite some inconsistencies between studies, some were 
common across multiple studies including a decrease in miR-199a, a decrease in miR-200c and 
most convincingly (seen across three independent studies) an increase in miR-21 (He et al., 
2017). MiR-21 is thought to increase proliferation and decrease apoptosis through 
destabilisation of phosphatase and tension homolog (PTEN) with an consequential increase in 
downstream Akt signalling (Liu et al., 2014). Upregulation of certain miRNAs in response to 
sex specific hormones including oestrogen (Klinge, 2009) may give some explanation of the 
higher keloid occurrence in females and an increased risk of formation during pregnancy (Kim 
et al., 2013). 
Differential expression of over 1200 lncRNAs has also been seen in microarray analysis of three 
paired earlobe and normal skin samples (Guo et al., 2016). Notably, a lncRNA called H19, 
which is usually associated with oncogenic tumours, was increased in keloids compared to 
normal skin and scar tissue, and siRNA targeting of H19 decreased proliferation, mTOR and 
VEGF signalling (Zhang et al., 2016). 
All the epigenetic changes observed so far are likely to have functional relevance, and offer a 




1.7 BET protein family 
 
 1.7.1.  Bromodomain containing proteins 
 
Bromodomains (BRDs) are 110kDa regions within a number of proteins, including BET 
proteins (Figure 1.13). BRDs are structured as of a four-helix bundle forming a hydrophobic 
pocket in which acetylated lysine residues can bind (Zeng and Zhou, 2002). There are thought 
to be over 36,000 lysines that can be acetylated in human cells, as described by 
PhosphoSitePlus®. Although BRD interaction with acetylated lysine is commonly described on 
histones, functioning as epigenetic regulators, these proteins have also been shown to bind to 
non-histone associated lysine residues (Sanchez and Zhou, 2009). 
Many proteins contain BRDs, including histone acetyltransferases (HATs) such as CBP and 
EP300, transcription factors, and transcriptional silencers including transcription intermediary 
factors (TRIMs) (Muller, Filippakopoulos and Knapp, 2011). Proteins containing BRDs often 
contain other functional domains that drive the specificity of their interactions with chromatin 
and other proteins. For example BRD4 contains two BRDs but also contains an N-terminal 
domain region which interacts with positive transcription elongation factor b (P-TEFb) to 
recruit RNA polymerase II (RNA pol II) (Yang et al., 2005) and is thought to increase binding 





















Figure 1.13 - Network of bromodomain (BRD) containing proteins. Image from: 
https://www.horizondiscovery.com/cell-lines/all-products/explore-by-your-research-




 1.7.2.  BET members- BRD2, BRD3, BRD4, BRDT 
 
The BET protein family contains four human members: BRD2, BRD3, BRD4, and BRDT 
which is uniquely expressed in the testes. All four members are characterised by their overall 
structure with two BRDs and an N- extra terminal (NET) domain (Figure 1.14). BRD2, 
previously called RING3, was first reported as a nuclear kinase, with homology to a 
developmental gene in Drosophila called female sterile homeotic (Fsh) (Denis and Green, 
1996). BETs appear to be highly conserved, with proteins homologous to human BRD4 seen in 
mouse, Xenopus, and zebrafish as well as Drosophila (Toyama et al., 2008).  
 
 
Figure 1.14 - Schematic of typical BET protein structure. BRD = bromodomain, NLS = 
nuclear localisation signal and NET = N extra terminal domain. 
 
BETs are thought to be ubiquitously expressed and nuclear restricted proteins (Stonestrom et 
al., 2015). A number of isoforms, mainly through splicing, have been reported for all the BETs 
(Alsarraj et al., 2013; Hnilicová et al., 2013; Shao et al., 2016), although functionality of the 
various isoforms is uncertain. Further information on the varying BET isoforms is discussed in 
section 3.2, with particular attention on the isoforms of BRD2.  Their binding to chromatin is 
variable, meaning BETs can have dynamic but highly specific functions during development 





 1.7.3.  BET proteins in development and homeostasis 
 
BETs are thought to be crucial in developmental processes although the details of this are still 
not fully understood, especially for BRD3. It has been observed that Brd4 is associated with 
acetylated histones on mitotic chromosomes in early zebrafish embryos (Toyama et al., 2008). 
Equally, there is good evidence from mouse models that these proteins are highly important in 
development. Homozygous knockout of Brd2 (Shang et al., 2009) or Brd4 (Houzelstein et al., 
2002) in mice is embryonically lethal due to severe neural defects or lack of proper blastocyte 
development. 
Interestingly, mice with lowered expression of Brd2 have no gross developmental defects but 
suffer from extreme obesity in the absence of hyperinsulinemia, suggesting altered insulin 
signalling and enhanced adipogenesis (Wang et al. 2010; Zang et al. 2013). BRDT is also 
crucial for the normal development of male germ cells, hence the interest in BRDT inhibition as 
a form of male contraception (Matzuk et al., 2012). Overexpression studies are less common, 
but increased BRD2 expression specifically in lymphocytes causes B-cell lymphoma and 
leukaemia (Greenwald et al., 2004) and it has been observed that overexpression of BRD4 in 
human cancer tissues correlates with a poorer prognosis (Zhang et al. 2015; Hu et al. 2015). 
Characterisation of BRD3 function in mouse models has not yet been published. 
 
Table 1.2: Summary of BET manipulation in mouse models 
 Homozygous knockout Partial knockdown (lo) Overexpression 




lymphocytes causes B-cell 
lymphoma/leukaemia 
Brd3 - - - 
Brd4 Embryonically lethal - - 
 
Redundancy between BETs is apparent; for example in the context of erythrocyte development 
through GATA1 engagement, Brd2 depletion limits development, Brd3 depletion has no effect, 
whilst depletion of both Brd2 and Brd3, or Brd4 alone, completely prevents erythrocyte 
development (Stonestrom et al., 2016). Equally, BRD2 and BRD4 have been shown to co-
regulate Th17 cell differentiation through functionally independent mechanisms, BRD2 through 
direct interaction with STAT3, and BRD4 through indirect interactions with RNA pol II 
(Cheung et al., 2017).   
56 
 
 1.7.4.  BET proteins in disease and their therapeutic inhibition 
 
BET proteins, in particular BRD4, have been heavily studied in two main disease themes: 
cancer and inflammation. Firstly, in the context of cancer, aberrant translocation events have 
been discovered in the nuclear protein in testis gene (NUTM1), causing the formation of BRD3 
or BRD4 NUT fusion proteins (French et al., 2008) These BET oncogene fusion proteins can 
then drive highly aggressive, squamous cell carcinoma known as NUT carcinoma through 
blocking of differentiation pathways and uncontrolled cell cycling (French et al., 2008). 
Additionally, BRD4 has been found to mediate the transcription of the oncogene MYC, which is 
a key driver of numerous cancers (Delmore et al., 2011). BET proteins are also known to be 
important for the inflammation response with BRD2 and BRD4 recruited to inflammatory gene 
promoters (Belkina, Nikolajczyk and Denis, 2013) and BRD4 associated super-enhancer 
formation driven by NF-κB activity (Xu and Vakoc, 2014). In this way, BETs have been 
associated with chronic inflammatory responses that are deleterious in vivo, such as the cytokine 
storm seen in sepsis (Nicodeme et al., 2010).   
The association of BET proteins with a variety of diseases has driven the development of small 
molecule BRD inhibitors, which were first developed to target the BRDs of CBP as it was found 
to bind to, and modulate the activity of the tumour associated gene p53 (Sachchidanand et al., 
2006). However, shortly afterwards focus shifted towards inhibitors targeting BRDs of BETs. 
The Bradner lab has been at the forefront of this development, creating the original JQ1 
compound (Filippakopoulos et al., 2010). Since then, various modifications to this structure 
have been developed to increase stability and potency (Garnier, Sharp and Burns, 2014). 
Somewhat misleadingly, these inhibitors are often referred to as BRD4 inhibitors, suggesting 
that the effects of treatment are exclusively due to BRD4, when in fact they are the result of a 
pan-BET inhibition. Seven BET inhibitors are now in clinical trials for cancers, including NUT 
carcinoma, triple negative and oestrogen-receptor positive breast cancer, castration resistant 
prostate cancer, and multiple myeloma (Andrieu, Belkina and Denis, 2016)  
Due the broad effects of anti-inflammation and anti-proliferation after BET inhibition, these 
drugs are now being tested in a range of contexts. Beyond cancer (Table 1-3), the effect of BET 
protein inhibition has been investigated in a range of other diseases including auto-immunity, 
infection, inflammation and fibrosis (Table 1.4). Of particular interest to this project is the 
beneficial effects seen in fibrosis models, including reduced cell proliferation, reduced 
expression of ECM and cytokines and a lessened myofibroblast phenotype (Tang et al., 2013a; 
Ding et al., 2015; Zhou et al., 2017)    
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Table 1-3 - BET inhibitor cancer literature (as correct in April 2017) 




Prostate cancer cell line 
Prostate cancer model 
Reduced proliferation and oncogenic transcription 
Reduced tumour size 












Myeloma cell lines 
Primary myeloma cells 
Myeloma model 
Induced cell cycle arrest and apoptosis 
 
Decreased proliferation and increased survival 





Primary leukaemia cells 
Leukaemia cell lines 
Leukaemia model 
Induced cell cycle arrest 
Reduced tumour growth 
Costa et al, 2013 
JQ1 
OTX015 
Human Leukaemia cell lines Induced cell cycle arrest and apoptosis Coudé et al, 2015 
JQ1 Human 
Triple negative breast 
cancer cells (TNBC) 
TNBC xenograft 








Multiple myeloma cell lines 
Multiple myeloma model 
Reduced MYC driven transcription 
Induced cell cycle arrest and senescence 




Castration resistant protease 
cancer model 




NUT cancer cells 
NUT cancer model 
Induces differentiation and cell cycle arrest 
Reduced tumour growth and increased survival 
Filippakopoulos et al, 
2010 





Primary colon epithelial 
cells 
Colon cancer cell lines 
Liver metastasis model 
Reduced epithelial-mesenchymal transition 
Reduced proliferation, migration and invasion 
Reduced tumour growth and metastasis 




Multiple myeloma cells 
Multiple myeloma model 
Reduced proliferation and induced apoptosis 
Prolonged survival 
Imayoshi et al, 2017 
JQ1 
OTX015 
Mouse Glioblastoma model 
Reduced proliferation and increased cell death and 
stress response 
Ishida et al, 2017 
JQ1 Human 
Human colon cancer cell 
line 
Downregulated c-myc and decreased growth Kitazawa et al, 2017 
I-BET151 Mouse Medulloblastoma model 
Reduced oncogenic Hedgehog signalling 
Reduced tumour growth 
Long et al, 2014 
JQ1 Human 
Leukaemia, glioblastoma 
and lung cancer cell lines 
Reduced super-enhancer induced oncogenic 
transcription 
Lovén et al, 2013 





Primary ovarian cancer cells 
Ovarian cancer cell lines 
Ovarian cancer model 
Reduced proliferation and induced senescence and 
apoptosis 
Reduced oncogenic metabolism and tumour growth 





Melanoma cell lines 
Melanoma model 




Multiple myeloma cells 
Multiple myeloma model 
Induced cell death 
Improved survival 





Lung carcinoma cell lines 
Lung carcinoma models 
 
Reduced proliferation and induced cell cycle arrest 
Decreased ‘stemness’ markers 
Reduced tumour growth 




Ovarian cancer cell line 
Ovarian cancer model 





Table 1.4 - BET inhibitor non-cancer literature (as correct in April 2017). 
Tool Host Cell type Effect seen Reference 
JQ1 Mouse Osteoporosis model Reduced osteoclast differentiation and activity Baud’huin et al, 2016 
I-BET762 Mouse Primary CD4+ T cells 
 
Neuroinflammation model 
Reduced pro-inflammatory and increased anti-
inflammatory gene transcription 
Reduced T-cell mediated macrophage recruitment 
Bandukwala et al, 2012 
I-BET151 Mouse Macrophage cell line Reduced LPS induced IL-6 production Barrett et al, 2014 
JQ1 Mouse Primary macrophages 
Sepsis model 
Reduced LPS induced cytokine production 
Reduced LPS induced mortality 
Belkina et al, 2013 
I-BET151 Human Primary monocytes Reduced cytokine induced transcription 
Reduced downstream cytokine signalling 
Chan et al, 2015 
JQ1 Rat Pancreas cell line Increased insulin secretion Deeney et al, 2016 
JQ1 Mouse Primary hepatic stellate cells 
Liver fibrosis model 
Reduced proliferation and induced senescence 
Reduced pro-fibrotic transcription and 
differentiation 
Reduced disease progression 
Ding et al, 2015 
RVX 208 Human Human clinical trials Reduced major adverse cardiovascular events Ghosh et al, 2017 
JQ1 Human 
Mouse 
Endothelial cell line 
Angiogenesis model 
Reduced VEGF-induced angiogenesis and vascular 
permeability 
Huang et al, 2015 
JQ1 
PFI-1 
Human Primary lung epithelial cells Reduced IL-1β induced inflammation Khan et al, 2014 
I-BET151 Human Primary rheumatoid arthritis 
synovial fibroblasts 
Reduced cytokine and TLR ligand induced 
inflammation and MMP production 
Klein et al, 2014 
JQ1 Mouse Lung disease model Reduced inflammation through upregulation of 
SIRT1 
Kokkola et al, 2015 
JQ1 Mouse Acute retinal ganglion cell 
death model 
Prevented cell death and reduced inflammatory 
cytokines 
Li et al, 2017 
JQ1 Mouse Alzheimer’s model Reduced splenomegaly and neuroinflammation Magistri et al, 2016 
JQ1 Human Primary COPD alveolar 
macrophages and PBMCs 




Primary T cells 
Primary T cells 
Autoimmune models 
Reduced IL-17 driven cytokine production 
 
Reduced Th17 cell differentiation 
Mele et al, 2013 
JQ1 Mouse 
Mouse 
Macrophage-like cell line 
Periodontitis model 
Reduced LPS induced cytokine and osteoclast 
production 
Meng et al, 2014 
JQ1 Human Primary airway smooth 
muscle cells 
Monocyte cell line 
Induced Nrf2-dependent transcription 
Reduced H2O2 induced ROS production 
Michaeloudes et al, 
2014 
JQ1 Mouse Psoriasis model Reduced RORC/IL-17A induced inflammation Nadeem et al, 2015 
I-BET151 Mouse Primary macrophages 
LPS/inflammation model 





Chondrogenic cell line 
Zebrafish model 
Suppressed chondrocyte differentiation 
Decreased zebrafish growth 
Niu et al 2016 
I-BET762 
JQ-1 
Human Primary airway smooth 
muscle cells 
Reduced TGF-β1 induced cytokine production and 
proliferation 
Perry et al, 2015 
JQ1 Rat Primary myocytes Reduced pathological cardiac hypertrophy Spiltoir et al, 2013 
JQ1 Rat Heart injury model Reduced injured induced TLR4/TRAF6/NF-κB 
signalling 
Sun et al, 2015 
JQ1 Human Primary lung fibroblasts Reduced proliferation, migration, cytokine 
production, ECM and ɑ-SMA expression 
Tang et al, 2013b 
JQ1 Human 
Mouse 
Primary fibrotic lung 
fibroblasts 
Lung fibrosis model 
Reduced proliferation, migration and cytokine 
production 
Reduced inflammation and disease severity 
Tang et al, 2013a 
JQ1 Mouse Influenza model 
Colitis model 





Primary renal fibroblasts and 
epithelial cells 
Renal fibrosis model 
Reduced ECM and ɑ-SMA expression 
Reduced fibrotic signalling 
Reduced fibroblast activation and macrophage 
infiltration 
Xiong et al, 2016 
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1.8. Project overview and objectives 
 
The overarching objective for this project is to explore the effect of BET proteins in a keloid 
scar context, with particular focus on dermal fibroblasts, given that this cell type drives the bulk 
of keloid pathology. We have access to a pre-clinical BET inhibitor from our collaborators at 
GSK, called I-BET151, and will be using this compound to interrogate the function of BET 
proteins in dermal fibroblasts. The three main aims are to firstly examine BET expression in 
keloids and then to explore the effect of BET inhibition, with particular attention to the impact 
on IL-6 signalling, which is likely to be highly relevant for therapeutic targeting in keloids as 
IL-6 is frequently reported to be a key biomarker and possible mediator of keloid pathology 
(Figure 1.15). 
We hypothesise, given the reported anti-proliferative and anti-inflammatory effects of BET 
inhibition, that we may be able to mediate key drivers of pathology including cell cycling and 
IL-6 production in keloid fibroblasts. The effect of BET inhibition will also be investigated in 
other potentially important cellular parameters that have not yet been explored in the literature, 
including contraction and protease activity. 
 





Chapter 2: Material and Methods 
 
2.1. Cell and tissue culture methods 
 
 2.1.1.  Tissue collection  
 
Normal skin, normal scar and keloid scar tissue were collected from consenting patients with 
the assistance of Mr Soldin, St George’s Hospital London and Dr Mallipeddi, Mr-Mackenzie-
Ross and Mr Ng, Guys and St Thomas’ Hospital under Study Title: The Molecular Mechanisms 
of Tissue Repair; REC Ref 14/NS/1073. The study was institutionally sponsored by St George’s 
University London, and institutionally approved at KCL/GSTT (R&D ref RJ115/N032). Where 
possible, a patient information sheet was completed and collected alongside the sample to give 
important information about patient and scar details (example in Appendix, Figure 7.1). 
Samples were promptly processed in the tissue culture lab at King’s to preserve tissue 
characteristics and cell viability. Primary cells were isolated from the tissue by an enzymatic 
digestion or ex vivo culture method, as subsequently described.  
 
 2.1.2.  Primary dermal cell isolation by enzymatic digestion 
 
Whole tissue, including epidermis and dermis, was trimmed of fat and cut into small pieces 
(~1cm2) before being disinfected in a series of washes of iodine and 70% ethanol. The tissue 
was then incubated in 0.1mg/ml Primocin (InvivoGen) in Hank’s Buffered Salt Solution 
Modified (HBSS) for 30 minutes at RT in order to remove any fungal and bacterial 
contamination, including mycoplasma.  
Tissue was incubated with Dispase II diluted in HBSS to a final concentration of 100µg/ml for 1 
hour at 37°C. After this incubation, the epidermis was removed and the remaining dermis was 
finely minced (~1mm2) and incubated in an enzyme digestion mix from the Miltenyi Skin 
Dissociation Kit overnight at 37°C.  
After 12-18 hours of incubation, the digested suspension was filtered through a 100µm cell 
strainer in order to remove debris, and cells were counted with a haemocytometer. Cells were 
either used immediately, or cryopreserved. Cells were cryopreserved by centrifugation at 400xg 
for 5 minutes and resuspension in freezing media in cryovial aliquots of ~1 X 106 cells. 
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Freezing media comprised of 40% v/v foetal calf serum (FCS), 10% v/v dimethyl sulfoxide 
(DMSO) and 50% complete DMEM (cDMEM), which consisted of Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% v/v foetal calf serum, 4mM L-glutamine (L-glut) 
and 1% v/v penicillin-streptomycin (P/S) giving a final concentration of 100 units/ml penicillin 
and 0.1mg/ml streptomycin. Cell suspensions were gently frozen at -80°C in a Mr Frosty™ 
freezing container containing isopropanol, before being moved into liquid nitrogen for long 
term storage.  
 
 2.1.3.  Primary dermal fibroblast isolation by explant culture 
 
Firstly, wells of a 6 well plate were coated with 0.1% gelatin in sterile water for ~1 hour before 
aspiration of the liquid and washing with PBS (10mM PO43-, 137mM NaCl, 2.7mM KCl). 4mm  
whole tissue biopsies, including dermis and epidermis, were taken from the sample using a 
disposable biopsy punch and cut into 9-12 pieces. These tissue pieces were then carefully placed 
into the coated wells. 1ml of high serum cDMEM (20% FCS) was then added to each well. 
Media was changed every day thereafter with media volume increased to 2ml once cells were 
observed to be migrating out of the tissue. Keratinocytes were initially observed to migrate out 
of the tissue but were then outgrown by fibroblasts by ~2 weeks of culture. After confluency 
was reached, cells were pooled and split into 2 x T75 flasks for around 1 week of culture and 
then split into 3 x T175 flasks for a further 1 week of culture in normal serum levels (10%). 
Once confluency was reached, these 3 x T175 flasks were cryopreserved, as previously 
described, into 15 cryovial aliquots. 
 
 2.1.4.  Ongoing primary dermal fibroblast culture 
 
Fibroblasts were seeded and maintained in cDMEM (see above). Frozen aliquots of cells were 
quickly defrosted in a water bath before seeding into a T75 flask with 10ml of cDMEM pre-
warmed at 37°C. Media was changed at ~ 24 hours or after cell adherence and then every 3-4 
days until the flask reached ~80% confluency. Cells were split at this point in order to avoid 
effects of contact inhibition (Abercrombie, 1970). Cells were split by removing the media, 
washing with PBS and incubating with Trypsin-EDTA solution, 1ml or 3ml for a T75/T175 
flask respectively, for 5-8 minutes at 37°C. After cells were observed to be in a single cell 
suspension, cDMEM was added in order to neutralise enzymatic activity and the resulting cell 
suspension was used to continue passaging of the cell line. Typically cells were split 1:4-1:10 in 
order to reach confluency in 3-7 days. Culturing of cells was continued until passage 10 when 
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the effects of in vitro culturing were thought to be significant (Allahbakhshian-Farsani et al., 
2014).   
 2.1.5.  Ex vivo tissue culture 
 
Due to the volume of collagen needed, a stock of collagen I was created. Rat tails obtained from 
surplus adult rats at King’s College London Biological Services Unit were soaked in 70% 
ethanol before dissection of tendons of pure collagen I. 1.5g of tendons were washed 
extensively in DI water and added to 100ml of 0.05% glacial acetic acid in deionised (DI) water 
supplemented with 2.5µg/ml of Amphotericin B to prevent fungal growth. This mixture was 
stirred gently at 4°C for at least two weeks. 
The resulting viscous liquid was then centrifuged at 3000xg for 15 minutes, before this 
supernatant was further centrifuged at 35,000xg for 1 hour at 4°C. The collagen solution was 
kept in a sterile duran bottle for up to 6 months at 4°C. The collagen I preparation was run on an 
SDS-PAGE gel and stained with Coomassie Blue in order to compare to a commercially 
available collagen I solution (Figure 2.1), which indicated a very similar staining pattern and 












Figure 2.1 - Coomassie Brilliant Blue stained SDS-PAGE gel examining lab-prepared 




To set up the ex vivo tissue model as published in (Bagabir et al. 2012b), 4mm whole tissue 
punch biopsies, including epidermis and dermis, were taken from normal and keloid tissue and 
soaked for at least 30 minutes in HBSS supplemented with 0.1mg/ml Primocin to remove 
contaminating microorganisms. Media was comprised using William’s E media supplemented 
with 0.1mg/ml insulin, 10ng/ml hydrocortisone, 4mM L-glut and 1% v/v P/S, giving a final 
concentration of 100 units/ml penicillin and 0.1mg/ml streptomycin. 
A base layer of media-gel was set into a 24 well plate using 250µl media with 1µM I-BET151 
or DMSO vehicle, 250µl collagen I solution and 4µl of 1M NaOH and incubated for ~15 
minutes at room temperature. Once this layer was set, a tissue biopsy was added to the set 
media-gel layer and further media-gel solution was added to embed the tissue leaving the 
epidermis at the air liquid interface (ALI) (Figure 2.2) 
Once set, 200µl of William’s E media containing 1µM I-BET151 or DMSO vehicle was added 
to the surface of the gel. This media was collected at 24 hours for supernatant analysis and 
refreshed every 2-3 days thereafter. After 1 week of culture biopsies were fixed in 4% 




Figure 2.2 - Photograph of ex vivo tissue culture set up as published in Bagabir et al, 
2012b. 4mm keloid biopsies are set-up in technical triplicate with control (0.01% DMSO) or 




2.2. Fibroblast functional phenotype experiments 
 
 2.2.1.   Pharmacological BET inhibition 
 
The BET proteins were pharmacologically inhibited through the use of I-BET151, a small 
molecule inhibitor compound from GlaxoSmithKline. This compound was made up in DMSO 
to a stock concentration of 10mM. Dose dependent experiments were carried out but in general 
practise a dose of 1µM was used with a vehicle control of 0.01% DMSO. 
 
 2.2.2.  Cell counts for proliferation 
 
Typically, cells were seeded into 6 well plates at a concentration of 1-5 X 104 cells/well in 2ml 
media. After adherence (~5 hours later) media was removed and replaced with either inhibitor 
or vehicle supplemented media. Media was refreshed every 24 hours in order to maintain 
optimum inhibitor efficacy. After 72 hours of culture, cells were trypsinised and counted in 
technical duplicate using a haemocytometer or multi-chamber FastRead counting slides. 
 
 2.2.3.  Contraction gel assay 
 
Fibroblasts were seeded into collagen gels by mixing 500µl of cell suspension at 1.5 x 105/ml, 
200µl of collagen I solution and 6µl of 1M NaOH in order to neutralise and set the gel. This 
suspension was dispensed into a well of a 24 well plate and left for ~15 minutes at room 
temperature to set. The collagen gel was then released from the edge of the well with a p20 
pipette tip in order to examine contraction potential in free floating gels. 24 well plates holding 
collagen gels were imaged at 72 hours using the BioRad Gel Doc+ imaging system. Collagen 




2.3. Protein assays 
 
 2.3.1.  Protein lysis and western blotting 
 
Lysates were prepared from cell pellets or homogenised de-epithelised tissue diluted into 
radioimmunoprecipitation (RIPA) buffer (50mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 150mM NaCl and 1mM EDTA) with freshly added protease and phosphatase 
inhibitors (Table 2.1). Lysates were incubated on ice in 1.5ml microcentrifuge tubes for 20 
minutes with frequent vortexing before being centrifuged at 10,000 x g for 5 minutes to pellet 
cell debris. The resulting lysate supernatants were moved to new 1.5ml microcentrifuge tubes. 
 









Lysate protein levels were quantified using a BCA kit (Santa Cruz). Briefly, 25µl of each 
sample, diluted 1:5 in PBS, and 25µl of a BSA standard dilution was added in duplicate to each 
well of a 96 well plate. The plate was incubated for 30 minutes at 37°C. A colour change from 
green to purple indicated presence of protein. Colour intensity was then measured on a 
spectrophotometer plate reader at 562nm and Microsoft Excel was used to make a standard 
curve and subsequently calculate protein concentrations in the tested samples. Samples to be 
analysed by western blot were made up to a defined quantity of protein (5-15µg) in a total 
volume of 20-25µl in water including 4-5µl 5X loading buffer (0.25% bromophenol blue, 0.5M 
DTT, 50% glycerol, 10% SDS in 0.25M Tris-HCl, pH 6.8). These samples were frozen at -20°C 
until use, if not run immediately. 
 Final concentration Purpose 
Leupeptin 1µg/ml Protease inhibitor 
Apropeptin 1µg/ml Protease inhibitor 
Pepstatin 1µg/ml Protease inhibitor 
NaF 1mM Phosphatase inhibitor 
Na3VO4 1mM Phosphatase inhibitor 
PMSF 1mM Protease inhibitor 
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Prior to running the western blot, samples were briefly boiled to denature the sample and then 
cooled before being loaded onto precast gradient gels from Nugen or BioRad, with 7µl of 
BioRad protein standard ladder in order to identify protein size. Gels were run at 120V-200V 
for 40-120 minutes in order to separate protein bands of interest. Gels were then transferred in 
transfer buffer (25mM Tris-HCl, 200mM glycine, 20% ethanol) at 112V for 90 minutes onto 
nitrocellulose membrane. After transfer, membranes were briefly stained with Ponceau Red 
solution (0.1% w/v Ponceau S in 5% acetic acid) in order to identify lanes and check successful 
transfer. Membranes were trimmed and cut where appropriate and blocked in 5% skimmed milk 
powder in TBS (20mM Tris, 150mM NaCl, pH 7.6) with 0.1% Tween 20 (TBS-t) for 1 hour at 
room temperature to prevent non-specific antibody binding. After blocking, primary antibody. 
generally diluted 1:1000 in antibody diluent (0.02% sodium azide, 1% BSA in TBS-t), was 
added to blots in sealed plastic packets and incubated on 4°C rocker overnight. As well as the 
protein of interest, a loading control (GAPDH/HDAC1/α-tubulin) was included to confirm 
equal protein loading. 
After primary antibody incubation, blots were washed in TBS-t and incubated with HRP-
conjugated secondary antibody diluted in 1:5000 in TBS. The secondary antibody species was 
targeted to the host species of the primary antibody, either rabbit or mouse (Jackson 
ImmunoResearch Laboratories, Inc.). Blots were incubated with secondary antibody on the 
room temperature rocker for 1 hour. After incubation, blots were washed extensively with TBS-
t, followed by a final TBS wash. The Clarity™ Western ECL substrate kit (Bio-Rad) was used 
to visualise antibody binding. The peroxidase and luminol reagents were mixed 1:1 and a small 
amount (~1ml for full size membrane) was added to the blot and incubated for 5 minutes at 
room temperature. Chemiluminscent images were captured on the BioRad Gel Doc+ system for 
between 2 and 20 minutes, as well as a light photograph for overlay of the protein size ladder to 
determine band weights. 
Band sizes of the protein of interest and the loading control were quantified in each sample 







Table 2.2 - Antibodies used in Western Blotting.  
Target Species Mono/poly-clonal Supplier 
GAPDH Rabbit Poly Abcam 
ɑ-tubulin Mouse Mono [DM1A] Abcam 
ɑ-SMA Rabbit Poly Abcam 
pStat3 (Thy705) Rabbit Mono [D3A7] CST 
Stat3 Rabbit Mono [D3Z2G] CST 
pAkt (Ser473) Rabbit Mono [D9E] CST 
Akt Rabbit Poly CST 
pErk1/2 (Thr202/Tyr204) Rabbit Mono [D13.14.4E] CST 
Erk1/2 Rabbit Mono [137F5] CST 
BRD2 Rabbit Poly GSK 
BRD3 Rabbit Poly GSK 
BRD4 Rabbit Poly GSK 
Ki67 Rabbit Mono [SP6] Abcam 




 2.3.2.  Enzyme linked immunosorbent assay (ELISA) 
 
The production of IL-6 and sIL-6r was measured by Human DuoSet ELISA, from R&D 
Systems as per manufacturer’s protocol, in high binding 96 well plates. 
Briefly, plates were coated with capture antibody diluted in PBS as per lot instructions, plates 
were sealed and incubated at room temperature overnight. The following day, wells were 
blocked with 300µl reagent diluent (1% BSA w/v in PBS) for 1 hour before three washes with 
wash buffer (0.05% Tween in PBS). A standard curve was made by re-suspending the supplied 
lyophilised standard as per lot instructions, then serially diluting 2-fold in reagent diluent to 
create a seven-point standard curve. 100µl of duplicate standards and 100µl of samples (plated 
neat and 1:10 diluted in reagent diluent) were added to the plate, sealed and incubated for 2 
hours at room temperature. 100µl of detection antibody diluted in reagent diluent, as per lot 
instructions, was added to wells after three washes with wash buffer and incubated for 2 hours 
at room temperature. Streptavidin-HRP was diluted 1:40 in reagent diluent and 100µl was added 
to wells after three washes with wash buffer and incubated for 30 minutes. TMB substrate was 
created by mixing a 1:1 solution of Reagent A and B from the R&D kit and 100µl was added to 
each well after three washes and incubated at room temperature. The addition of TMB substrate 
caused a gradual colour change to blue, and this reaction was terminated after 5 – 20 minutes 
when the lowest standard appeared bluer than the negative control well. The reaction was 
stopped with the addition of 50µl of 0.16M sulfuric acid per well and colour intensity was 
measured at 420nm on a spectrophotometer plate reader. 
A standard curve was constructed by plotting the log10concentration against absorbance and a 4 
parameter logarithmic curve was fitted to the data. Absorbances for samples were interpolated 
as unknown X values, inverse-logged and multiplied by the dilution factor, if appropriate, to 




 2.3.3.  Luminex Analysis 
 
Luminex is another antibody based technology to detect analytes in solution, however Luminex 
has the advantage over ELISA that antibodies can be multiplexed in order to simultaneously 
detect multiple analytes in the same experiment. A magnetic bead Luminex kit from R&D 
Biosystems was used for this analysis to measure MMP1, MMP3, MMP7, MMP8, MMP9, 
MMP10, MMP11, MMP12, MMP13 and another kit to test for analytes TIMP1, TIMP2, TIMP3 
and TIMP4 in 24 hour supernatants from ex vivo models and fibroblast cultures +/- I-BET151. 
The kit was able to detect both pro and activated forms as well as MMP-TIMP complexed 
forms of protein. 
The kit supplied a mix of magnetic beads each coated with antibodies specific to an analyte of 
interest and labelled with a unique dye on the red to far-red spectrum. The kit also supplied a 
standard mix of all analytes which was diluted 3 fold to produce a 6 point standard curve to 
estimate concentration of unknown samples as in an ELISA. Samples were diluted 1:10 and 
1:50 in order to capture the variation in possible analyte expression between the different 
samples. 
The protocol was then followed as instructed by the product data sheet. Briefly, standards and 
diluted samples were incubated with the magnetic bead mix in a 96 well plate format for 2 hours 
at room temperature on an orbital shaker protected from light. A magnetic device designed for 
96 well plates was then used to hold the beads to the bottom of the plate to allow washing of 
beads in wash buffer (0.05% Tween in PBS). 3 x 1 minute washes were conducted, removing 
the magnet before the addition of new wash buffer to ensure thorough washing of the beads. 
Biotinylated secondary antibody mix was then added to the beads and incubated for an hour in 
the same conditions before another 3 washes. Streptavidin-PE was then added to the beads for a 
further 30 minutes in the same conditions before another 3 washes and a final resuspension in 
wash buffer. 
Plates were then read using a Luminex analyser (Flexmap 3D) which acquired 50 events per 
analyte in each well with a fast flow rate (60µl/minute). This analyser uses flow cytometry to 
singularise beads and lasers are used to identify the bead colour (to identify the analyte) and the 
streptavidin reporter intensity to quantify the secondary signal (to identify the quantity of 
analyte that has bound). Results are analysed in a very similar way to how ELISA data is 
processed, however a 5-parameter curve is used as this type of curve fitting makes fewer 





 2.3.4.  Zymography assay 
 
7µl fibroblast supernatant was incubated with 10µl of 10x assay buffer (500mM HEPES, 
100mM CaCl2, 0.5% Brij-35, 10mM DTNB [also known as Ellman’s reagent], pH to 7.0), 
5mM thiopeptide (pan-MMP chromogenic substrate, Enzo Biosciences) and 90µl of water in 
triplicate in a 96 well plate. Media only and water only wells were also included as negative 
controls.  
Plates were incubated in the dark at 37°C and active proteases within the supernatant were able 
to cleave the MMP substrate, releasing a thiol group which was free to reduce DTNB causing 
the conversion from a colourless to a yellow-coloured substance which could be detected by 
spectrophotometry. Plates were read at 412nm at 0, 6, 24 and 48 hours of incubation and 
absorbance values were normalised to controls to give a relative value of protease activity.  
 
 2.3.5.  Immunofluorescent staining 
 
For immunofluorescent staining, cells were grown on poly L-lysine coated coverslips. Circular 
coverslips were first acid washed by gentle stirring in 1M HCl at 60°C overnight. Following 
acid washing, coverslips were extensively washed in DI water and then 95% ethanol where they 
could be stored for several months before coating. Coverslips were incubated in 0.1mg/ml poly 
L-lysine solution in petri dishes for 1 hour at room temperature in the tissue culture hood. 
Coverslips were then washed three times in PBS and dried on filter paper in the tissue culture 
hood before being stored in a sterile 50ml falcon tube. 
Cells were seeded onto coated coverslips placed in the wells of 24 well plates. Cells were grown 
in the presence of 0.01% DMSO vehicle or 1µM I-BET151 supplemented cDMEM. After 24 
hours of treatment, coverslips were washed with PBS before fixation in 4% PFA at 37°C for 10 
minutes. Fixed coverslips were washed several times in PBS and were stored at 4°C until 
staining. 
For immunofluorescent staining, cells were washed in PBS before incubation in 0.1M glycine in 
PBS to reduce background fluorescence by quenching formaldehyde cross-linking. Cells were 
then washed and permeabilised in 1% Triton X100 in PBS, and then washed with PBS before 
blocking for 30 minutes at room temperature in 10% chicken serum and 0.5% BSA in PBS. 
Primary Ki67 antibody (Table 2.2) diluted 1:50 was then added in a mild blocking solution of 
1% chicken/goat serum and 0.5% BSA in PBS overnight at 4°C. Fluorescently conjugated 
secondary antibody was added, diluted 1:750 in the mild blocking solution at room temperature 
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for 1 hour protected from light. DAPI diluted 1:1000 in PBS was then added for 10 minutes at 
room temperature before washing and mounting onto slides with Dako Fluorescent mounting 
media. Slides were imaged on a Zeiss Axioplan2 fluorescent microscope and pictures were 
taken using the x10 objective lens. Using Image J, a count of DAPI and Ki67 positivity was 
taken in 3 frames of view per coverslip in order to calculate the proportion of Ki67 positivity 
and hence the degree of active proliferation in the population. 
 
 2.3.6.  IL-6r flow cytometry 
 
Flow cytometry was used to examine IL-6r expression in fibroblasts. Fibroblasts were cultured 
in the absence or presence of serum for 24 hours prior to trypsinisation and PBS washing. Cells 
were stained for IL-6r and viability by incubation in 100µl of master mix, made of FACS buffer 
(5mM EDTA, 5% FCS in PBS) containing 1% v/v REAfinity™ phycoerthyhin (PE) conjugated 
IL-6r antibody from Miltenyi Bio (clone REA291) and 0.1% v/v eBioscience™ Fixable 
Viability Dye eFluor™ 506. Following staining, cells were then fixed in 2% PFA for 15 
minutes at 4°C prior to 3 x washes in FACS buffer as previously defined. Each sample was then 
split in half, where half was kept in FACS buffer in dark 4°C conditions prior to acquisition and 
one half was permeabilised for intracellular staining. Cells to be permeabilised were washed 
twice in 0.5% saponin in PBS to temporarily allow antibody internalisation by disrupting 
cholesterol components within the plasma membrane followed by another 30 minute incubation 
of 1% v/v IL-6r antibody in 0.05% saponin. 3 x FACS buffer washes were completed before all 
samples were re-suspended in 500µl FACS buffer and transferred to polystyrene round bottom 
FACS tubes.  
A number of controls were needed in this process, firstly for use as an IL6r positive control 5µl 
of OneComp eBeads™ Compensation Beads were stained for 30 minutes alongside cells before 
2 x FACS buffer washes. Negative controls were also included, to account for the 
autofluorescence of fibroblasts and possible size and fluorescence changes caused by 
permeabilisation. Therefore an unstained and Live/Dead stained only control was included for 
each condition. Data was acquired on the FACSCanto II flow cytometer and resulting .fcs files 
were analysed using Flow Jo V.10. To analyse IL-6r expression, cells were gated stringently as 
shown below in the representative plot generally using the Live/Dead only controls Figure 2.3). 
Briefly, events were gated on cells, singlet cells, and live cells, before IL-6r expression by PE 
fluorescent signal was expressed as a histogram. Overlayed histograms were used to visualise 
shifts in staining compared to controls or compared to different cells/conditions. A geometric 
mean of mean fluorescent intensity (MFI) was also calculated in FlowJo for each sample and 






















Figure 2.3 - Representative gating strategy for analysis of IL-6r expression. Events were 
gated on cells by SSC-A (side scatter area) and FSC-A (forward scatter area), live cells 
(live/dead dye APC negative) before plotting IL-6r expression (PE mean fluorescence intensity, 
MFI) as a histogram to analyse IL-6r levels in each sample.   
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2.4. Tissue staining 
 
 2.4.1.  Tissue fixation, embedding and sectioning 
 
Tissues were fixed in 4% PFA for 18-24 hours before being rinsed and stored in 70% ethanol 
within histology cassettes. Samples were loaded into the Leica TP1020 processing machine in 
the lab of Carl Hobbs, Wolfson Centre for Age Related Diseases, KCL. The machine contained 
9 sequential stations:  
1. 90% IMS (Industrial Methylated Spirit) 
2. 100% IMS 
3. 100% IMS 
4. 100% IMS 




9. Paraffin wax 
Samples were incubated in each station for 60 minutes and kept in molten paraffin wax until 
embedding. Tissue was then embedded in paraffin wax between a metal mould and histology 
cassette and cooled slowly to prevent wax cracking. Once set, the paraffin blocks were removed 
from the metal moulds and stored at room temperature. 
Blocks were cooled on ice for around 5 minutes prior to sectioning and a microtome was then 
used to section into the block. The depth of cutting was decreased to 3-5µm once the tissue 
reached the face of the blade and the wax was easily ribboning. Sections were then floated in a 
60°C water bath and slides were lifted to the surface of the water to attach sections. Slides were 
labelled, dried in a slide rack at room temperature and then baked at 60°C for 1 hour to adhere 




 2.4.2.  Haemotoxylin and Eosin staining 
 
Haemotoxylin and eosin (H&E) staining was carried out on de-waxed and rehydrated sections 
in order to analyse general tissue morphology. Slides were de-waxed and rehydrated by 2 x 5 
minutes in xylene before sequential washes in decreasing concentrations of IMS for 1 minute 
each before incubation in distilled water until staining. Slides were then incubated in Mayer’s 
haemotoxylin stain for 5 minutes, rinsed in tap water until ‘blued’, differentiated for 30 seconds 
in 0.1% acid alcohol, rinsed once again in water before bluing in ammonia water and further tap 
washing. Slides were then incubated in eosin for 30 seconds to 1 minute before being 
submerged into 95% ethanol to differentiate staining and then coverslips were mounted with 
DPX.  
 
 2.4.3.  Haemotoxylin Van Gieson staining 
  
Haemotoxylin Van Gieson (HVG) staining was conducted by Carl Hobbs, Wolfson Centre for 
Age-Related Diseases on de-waxed and rehydrated sections as previously described. Slides were 
held in distilled (DI) water before treatment with iron alum for 5 minutes and washing again in 
DI water. Slides were then stained in Mayer’s haematoxylin for 5 minutes before blueing in tap 
water and rinsing in DI water. Slides were then stained in Van Gieson stain for 5 minutes (1% 
acid fuchsin, saturated picric acid in distilled water) before rinsing in 100% IMS and coverslip 
mounting with DPX. 
 
 2.4.3.  Immunohistochemistry at GSK 
 
3,3’-diaminobenzidine (DAB) immunohistochemistry was carried out on n=10 normal skin, 
normal scar and keloid scar although not all samples were of a good quality to be scanned due 
to tissue damage during processing. The Ventana system was used to automatically stain tissues 
to achieve a more consistent and therefore highly comparable set of stained slides. The Ventana 
system could accommodate 30 slides per run. 
Briefly slides were de-waxed ‘offline’ in Xylene as the Ventana de-waxing protocol was based 
on high heating and was found to damage our tissue sections substantially. Slides were therefore 
‘wet loaded’ with PBS over the sections to keep them hydrated. Antigen retrieval was 
conducted with pH 8.5 Cell Conditioning Solution 1 (Ventana Medical Systems Inc.), at 95°C 
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for 4 cycles of 4 minutes. Slides were washed and primary BRD2 or BRD4 antibody (both 
polyclonal, Bethyl Laboratories Inc.) was hand applied with 50µl per slide diluted 1:200 in 
DISCOVERY Antibody Diluent (Ventana Medical Systems Inc.) and incubated for 32 minutes 
at 37°C. After further washing, Discovery™ Universal Secondary Antibody (Ventana Medical 
Systems Inc.) was automatically added by the machine and incubated for another 32 minutes at 
37°C. After further washes, the on-board DISCOVERY DAB Map Detection Kit (Ventana 
Medical Systems Inc.) was used to stain antibody complexes brown to visualise BRD2 and 
BRD4 staining. Slides were then counterstained with Mayer’s haemotoxylin before rinsing in 
water. After staining, slides were mounted by hand with coverslips using DPX.  
 
 2.4.4.  Slide scanning 
 
To capture high magnification, whole-slide images of histological staining, slide scanning was 
conducted using a Hamamatsu NanoZoomer 2.0-HT Whole Slide Imager located in the Centre 
for Stem Cell and Regenerative Medicine Research, Guy’s Hospital, King's College London.  
Slides were manually loaded in batches of 10 and were initially quick scanned in order for the 
user to draw a region of interest and to add focal points for the auto adjustment of focus by the 
machine. A detailed scan was then taken taking between 5 and 25 minutes per slide. Slides were 
saved as .ndp files and visualised in NDP.view2 software where images could be created and 




2.5. Nucleic acid assays  
 
 2.5.1.  RNA extraction from cells 
 
For RNA extraction from fibroblasts, cells were collected in RLT buffer (350µl used for up to 1 
X 106 cells) and stored at -80°C until extraction. Samples were thoroughly lysed through a 20 
gauge needle before extraction to maximise RNA yield. RNA was extracted using the Qiagen 
RNeasy mini kit with an optional step of on-column DNAse removal included in the protocol. 
The resulting RNA samples were eluted in 30µl RNAase-free water. 
 
 2.5.2.  RNA extraction from tissue 
  
RNA extraction from tissue was a similar process to above, as the Qiagen RNeasy Fibrous 
Tissue Mini Kit was used. 4mm whole tissue biopsies, including epidermis, were used, as a 
small pilot experiment showed a substantial loss in RNA integrity after a 1 hour dispase step to 
remove epidermis. It was also noted that the time between removal from patient and 
preservation in RNAlater solution needed to be minimal. Therefore, a targeted sample collection 
was conducted with local sources (i.e. Guy’s campus) to preserve tissue as quickly as possible. 
To extract RNA, a 4mm biopsy of tissue stored in RNAlater was placed into a 2ml 
microcentrifuge tube containing a nuclease-free stainless bead and 300µl RLT lysis buffer. 
Eppendorfs were then loaded and clamped into the TissueLyser II machine which oscillated 
samples at 30Hz for 2 x 5 minutes to homogenise tissue. The resulting tissue homogenates were 
incubated in Proteinase K solution (1mg/ml in PBS) at 60°C for 10 minutes to further break 
down the tissue, especially the fibrous keloid matrix. Lastly, these lysates were spun at full 
speed through QIAshredders for 5 minutes for a final homogenisation step. RNA extraction was 
then carried out in the same way as above following the kit instructions, and samples were 




 2.5.3.  RNA Quality Analysis 
 
To firstly quantify and assess purity of the RNA, 1µl of RNA was loaded onto the NanoDrop 
2000 after nuclease water was used as a blanking solution. Purity was analysed by the A260/280 
ratio, with an ideal value of 2, samples tended to range from 1.9 to 2.1 and were deemed 
acceptable. NanoDrop analysis also gave an estimated concentration, although the accuracy of 
this was thought to be decreased when the concentration fell below 20ng/ml. To analyse the 
integrity of the RNA that was extracted, especially that from tissue which is prone to nuclease 
degradation, 1.5µl of RNA was denatured at 60°C for 2 minutes before being tested using an 
automated capillary gel electrophoresis machine, an Agilent 2100 Bioanalyzer. 
The Agilent RNA 6000 Nano kit was used, with an mRNA detection range of 25–250 ng/µl. 
The analysis chip was loaded with gel-dye mix, before the loading of 1µl RNA 600 Nano 
marker in each analysis well and then the loading of 1µl of sample RNA or 1µl of supplied 
RNA ladder. The chip was then mixed in the chip vortexer and loaded onto the Bioanalyzer for 
analysis within 5 minutes. 
The experimental took around 30 minutes, producing an estimated concentration that is more 
sensitive than NanoDrop analysis, as well as an RNA integrity number (RIN). The RIN was 
automatically calculated based on the RNA electropherogram trace generated for each sample, 
with the ratio of 18S to 28S ribosomal RNA (rRNA) peaks being particularly important in this 
analysis as these should be the most abundant in the extracted RNA. RIN values change from 1 
to 10, with 10 being the highest integrity and 1 being the most degraded. The electrophoresis 
track for each sample was also generated as an image, where degraded samples were clearly 
















Figure 2.4 - Example of Bioanalyzer results with electrophoresis image, electrogram trace 




 2.5.4.  Reverse transcription of RNA to cDNA 
 
Samples for reverse transcription were made up to a defined quantity of RNA (100-250ng) in 
nuclease-free water to a volume of 11.5µl, 1µl of random primers were then added to each 
sample to a final concentration of 1µM. Tubes were incubated at 65°C for 5 minutes before the 
addition of 7.5µl of master mix (Table 2.3). A thermocycler was then used to incubate the 
samples for 10 minutes at 25°C, 60 minutes at 42°C and then 10 minutes at 70°C before cooling 
on ice. The resulting cDNA was frozen at -20°C until qPCR analysis. 
 






 2.5.5.  PCR primer design 
 
Firstly, a standard curve was constructed with pooled cDNA from a range of fibroblast cultures 
grown under different conditions, serially diluted 5-fold in nuclease free water to create a 7 
point standard curve. In practise, the 1:5 dilution was used as the ‘top standard’. cDNA samples 
to be quantified were diluted 1:10. 
A publicly available database (https://pga.mgh.harvard.edu/primerbank/) of somewhat validated 
PCR primers was searched for target genes. These primers were entered into NCBI Primer Blast 
to check specificity and amplicon size. If these primers were deemed unsuitable (e.g. amplicon 
size too large for qPCR), or the database returned no results, primers were designed from 
scratch. qPCR primers were designed using the NCBI Primer Blast website tool, an amplicon 
size limit of 150bp was selected with an optimum melting temperature of around 60°C. Primers 
were also specified to span an exon-exon junction to prevent amplification of contaminating 
genomic DNA. Primer sets were picked from the generated list on the basis of the lowest self-
complementarity. Primers were diluted to create a 10µM forward/reverse mix and then tested 
against the standard curve.  
Reverse transcription master mix (n= number of samples plus 1) 
5X RT buffer (Thermo Scientific) n x 4µl 
Nuclease-free water n x 1.5µl 
Ribolock RNAase inhibitor (Promega) n x 0.5µl 
RevertAid Reverse Transcriptase (Thermo Scientific) n x 0.5µl 








Gene Forward sequence Reverse sequence 
B2M TTCTGGCCTGGAGGCTATC TCAGGAAATTTGACTTTCCATTC 
ESP8 CGACCAAGGGGACTTTGAG TGCCATCATCTCAGGTGTTT 
P4HB GGAATGGAGACACGGCTTC TTCAGCCAGTTCACGATCTC 
BRD2 GTCAAACTGGGTCTACCGGATT CTTTTCCAGCGTTTGTGCCA 
BRD3 TCA AATTGAACCTGCCGGATT TGCATACATTCGCTTGCACTC 
BRD4 ACAACAAGCCTGGAGATGACA GTTTGGTACCGTGGAAACGC 
BRD4L CCGGAAATGAAGCCTGTGGAT TTTTCAGGTCCTTTTTGGGCG 
MMP1 GAGCAAACACATCTGAGGTACAGGA TTGTCCCGATGATCTCCCCTGACA 
MMP3 CCCTCTATGGACCTCCCCCT ATTTGCGCCAAAAGTGCCTG 
ASMA CCGACCGAATGCAGAAGGA ACAGAGTATTTGCGCTCCGAA 
COL1A1 CTTTGCATTCATCTCTCAAACTTAGTTTT CCCCGCATGGGTCTTCA 
COL3A1 CCATGAATGGTGGTTTTCAG GTGTTTAGTGCAACCATC 
FN TGGACCAGAGATCTTGGATGTTC CGCCTAAAACCATGTTCCTCAA 
SOCS3 CCTGCGCCTCAAGACCTTC GTCACTGCGCTCCAGTAGAA 
IL6 CCATCTTTGGAAGGTTCAGGTTG ACTCACCTCTTCAGAACGAATTG 
IL6R CAGCTGAGAACGAGGTGTCC GCAGCTTCCACGTCTTCTTGA 
GP130 CGGACAGCTTGAACAGAATGT ACCATCCCACTCACACCTCA 
ADAM17 GACTCTAGGGTTCTAGCCCAC GGAGACTGCAAACGTGAAACA 
STAT3 ACCAGCAGTATAGCCGCTTC GCCACAATCCGGGCAATC 
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 2.5.6.   SYBR-Green RT-qPCR 
 
Successfully designed primers were identified on the basis of specificity, by amplification of a 
single product by melt curve, and efficiency through a standard curve fit coefficient (R2) of over 
0.98. In cases where the expression of the target gene was low in fibroblast cultures, standard 
curves were often only linear over the first 4-5 dilutions so were still deemed acceptable for use 
in assays.  
For each qPCR run, a master mix for each gene to be analysed was made with n x 5µl of 
SensiMixTM SYBR® No-Rox (BioLine) and n x 0.2µl of 10µM forward/reverse primer mix, 
where n = number of samples and standard tubes plus 1. 5.2µl of this master mix and 4.8µl of 
standard/sample were added to each strip mini tube. A negative control reaction containing 
master mix, primers and nuclease free water was also included in each run to identify any 
contamination of reagents or non-specific amplification. Tubes were then added to the Qiagen 
Rotor-Gene-Q qPCR machine which pre-incubated at 95°C for 10 minutes in order to activate 
the hot start polymerase in the master mix, followed by a 45 cycle run (95°C for 15 seconds, 
60°C for 30 seconds, 72°C for 30 seconds) to amplify target cDNA, followed by ramp from 
72°C to 95°C melt curve to examine primer specificity. All samples analysed for genes of 
interest were normalised against the levels of at least one references gene from: B2M, ESP8, 
and P4HB. 
 
 2.5.7.  IL-6r RT-PCR 
 
RT-PCR was used to semi-quantitatively analyse the levels of the full length (219bp) and the 
cleaved isoform (125bp) of IL-6r mRNA in fibroblast cultures using previously published 
primer sequences that amplify across the spliced intron (Vermes et al., 2002). cDNA from 
fibroblast cultures was used for a PCR reaction in the GeneAmp® PCR System 9700 
thermocycler. Reactions were run in 8-tube PCR strip tubes and included a negative control tube 
(water instead of cDNA) and a positive control tube (THP-1 cDNA). Each reaction contained 
12.5µl 2x GoTaq® Green Master Mix (Promega), 2µl 10µM forward/reverse primer mix, 2.5µl 
cDNA and 8µl nuclease free water. Each sample was analysed using IL-6r primers and ESP8 
primers as a reference gene. 
The cycling conditions were: an initial incubation at 94°C to activate the polymerase, before a 
cycle of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 45 seconds (repeated for 30 
cycles), and a final incubation at 72°C for 5 minutes before cooling to 4°C. 
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The PCR product was assessed by electrophoresis on a 1.5% agarose gel (1.5g agarose in 100ml 
1X TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA) with 10µl of Diamond™ Nucleic 
Acid Dye. The molten agarose was mixed thoroughly by swirling and then poured into a gel 
mould containing well comb/s. Gels were left to set for ~30 minutes before the removal of the 
well combs and placement into the tank chamber. 1X TAE buffer was added to the tank 
chamber to cover the gel by ~5mm. 
10µl of each PCR reaction was loaded per gel lane, alongside one lane containing 5µl of Quick-
Load® Purple Low Molecular Weight DNA Ladder (New England BioLabs) for the estimation 
of PCR band sizes. Gel electrophoresis was generally conducted at 100V for between 1 and 2 
hours to separate bands enough to identify the 219bp and 125bp bands. Gels were imaged using 
the SYBR-Green protocol for Prominent Bands on the BioRad Gel Doc+ system. 
Band sizes of the fragments of interest and the reference gene were quantified in each sample 
using the BioRad ImageLab 3.1 software, allowing normalisation and semi-quantitative 










Whilst the make-up of keloids is recognised to be distinct from normal tissue, this is not well 
characterised in current literature and many conflicting findings are reported. Furthermore, the 
differences between dermal fibroblasts isolated from normal skin and keloid scar, and whether 
these differences are retained in vitro, are not fully described. There is evidence in the literature 
for epigenetic changes in keloid fibroblasts including altered histone methylation and 
acetylation (Russell et al., 2010) and overexpression of acetylation modulating enzymes 
(Fitzgerald O’Connor et al., 2012) which is likely to cause transcriptional and behavioural 
changes. This project investigated the role of a family of epigenetic regulator proteins called 
BETs, which interact with acetylated lysines predominantly on histone proteins to modulate 
transcription factor and transcriptional machinery binding as was introduced previously. 
The BET protein family contains four members: BRD2, BRD3, BRD4 and BRDT, but BRDT is 
exclusively expressed in the testis (Matzuk et al., 2012). BRD2, BRD3 and BRD4 are 
ubiquitously expressed nuclear proteins produced by a wide range of cell types including those 
in the skin (Stonestrom et al., 2015).  Information reported by The Human Protein Atlas 
describes expression, as determined by RNA seq, in a range of cells in the skin, predominantly 
in keratinocytes, although IHC data does not always confirm protein expression. However, there 
is information from the literature that does suggest the presence of BET proteins in dermal 




Table 3.1 - Summary of BET expression data from Human Protein Atlas.  
 
 
Although BET proteins appear to have an important role in normal development and 
homeostasis (Houzelstein et al., 2002; Belkina et al., 2014; Stonestrom et al., 2016), their 
overexpression and/or differential activity has been associated with a variety of diseases 
including fibrosis in various organs. For example, BRD4 is highly enriched at fibrosis-
associated enhancer regions in human stellate cells, suggesting that BRD may play a role in 
regulating liver fibrosis (Ding et al., 2015). The binding of BRD4 was also found to be 
associated with a number of profibrotic transcription factors such as SRF (serum response 
factor), SMAD3 and NF-κB (Ding et al., 2015). These are transcription factors that also appear 
in keloid literature (Messadi et al., 2004; Phan et al., 2005; Velasquez et al., 2013) and 
therefore may indicate some role for BRD4 in keloid pathology. Recently it has even been 
shown that TGF-β1 treatment of dermal fibroblasts induces BRD4 interaction with SMAD3 
which can promote myofibroblast differentiation (Ijaz et al., 2017).  
Increased Brd4 expression was also seen by IHC in experimentally obstructed kidneys (which 
would go on to become fibrotic) and also in tissue from patients suffering fibrotic kidney 
conditions (Xiong et al., 2016). Both the liver and the kidney fibrosis papers acknowledge that 
the beneficial effect of BET family inhibition in disease models they observe may not be 
exclusively due to inhibition of BRD4, and that BRD2 and/or BRD3 may also have important 
roles, although they do not explore this further. Interestingly, the Ijaz study noted that BRD4 
suppression could not suppress all myofibroblast associated transcription, unlike BET 
inhibition, which indicates a role for BRD2 also (Ijaz et al., 2017).  
Another study showed that both BRD2 and BRD4 were highly important in regulating the 
fibrotic response of human lung fibroblasts to growth factor stimulation and again that 
pharmacological inhibition was beneficial by diminishing bleomycin-induced lung fibrosis in 
mice (Tang et al., 2013a). Therefore, this project aimed to have a broad approach by 
Member Protein (IHC) Transcription (RNA-seq) 
 
BRD2 
Not detected in any cells (tested two  
antibodies) 
Expression in a range of cells 




Medium positivity in fibroblasts, 
keratinocytes, Langerhans. High positivity in 
melanocytes. 
Expression in a range of cells 




Heterogeneous results, some samples show 
high expression in fibroblasts, keratinocytes, 
Langerhans and melanocytes. 
Expression in a range of cells 




investigating BRD2, BRD3, and BRD4 in keloid pathology rather than focussing on one 
member of the family.  
Preliminary data from our lab suggested that BRD2 and BRD4 may be overexpressed in keloid 
tissue by IHC and here the aim was to further investigate the expression of BET proteins in cells 
and tissue in normal skin and keloid scars with the hypothesis that some or all BET protein 
members may be upregulated in keloid tissue and this may contribute to disease.  
The main objectives were: 
1. To better characterise the fibrotic environment of keloid tissue. 
2. To investigate BET expression in normal and keloid tissue with particular focus on the 
dermal compartment. 







 3.2.1.  Keloid patient information 
 
Firstly, to understand the demographic details of the keloid patients in our study, data from the 
Patient Information Sheets (Figure 7.1) from consented patients were assimilated. In total 27 
keloid patient information sheets were collected. 
It was found that more keloid patients in our study were female (24/37), with the majority of 
patients being under the age of 40 (Figure 3.1A). The mean duration of keloid scars was 5.95 
years and the median duration was 5 years, although the majority of keloid scars were less than 
5 years old, with one patient estimating that their keloid was over 15 years old (Figure 3.1B). 
Over 67% (25/37) of patients had more than one keloid scar (Figure 3.1C) and over 40% 
(15/37) of patients had some family history of keloid formation (Figure 3.1D). Seven patients 
reported that their keloid scars were itchy and seven additional patients reported that their keloid 
scars were both itchy and painful. Interestingly, no patients reported pain in the absence of 




Figure 3.1 - Keloid patient information based on completed information sheets. (A) Sex 
and age of patients, mean +/- SEM. (B) Sex and age of keloid scar, mean +/- SEM. (C) 
Proportion of patients with a single or multiple keloids. (D) Proportion of patients with a family 
















 3.2.2.  Fibrotic environment of keloid tissue 
 
In order to visualise first-hand the well documented and grossly obvious fibrotic reaction in 
keloids, the matrix appearance of normal skin, normal scar and keloid scars was examined 
histologically with Haematoxylin Van Gieson’s staining. Van Gieson’s stain was developed in 
1889 as a staining method to visualise connective tissue, with collagens staining in red/pink and 
cytoplasm in yellow (Segnani et al., 2015). Staining was conducted by Carl Hobbs (Wolfson 
Centre for Age Related Disease, King’s College London) on formalin fixed, paraffin embedded 
sections from three normal skin, two normal scar and two keloid scar patient samples. Stained 
slides were imaged using the Hamamatsu NanoZoomer-XR digital slide scanner. Image J was 
used to analyse the amount of ‘white space’ in a field of view within the dermis, avoiding 
dermal appendages and damage to tissue, using colour thresholding. White space was measured 
to assess the loss of basket weave patterning in normal skin and to attempt to quantify the 
qualitative differences seen between normal scar and keloid scar dermal staining. For each 
sample, 3 independent fields of view with the x20 objective were randomly selected within 
500µm of the epidermal layer whilst avoiding appendages.  
There was an increase in the intensity of staining with a denser distribution of staining in scar 
tissue (both normal and keloid) compared to normal skin (Figure 3.2). Moreover, there was 
more white space in normal skin, indicative of the classic basket-weave pattern of collagen that 
gives skin tensile strength and flexibility (McGrath, Eady and Pope, 2004) . Interestingly, the 
keloid scar samples examined appeared to have slightly more white space than normal scar, 
suggesting that the arrangement of collagen fibres may be different. Upon examining keloid 
dermis at a greater magnification, a patchwork pattern became apparent, with dense pink 

























Figure 3.2 - Haematoxylin Van Gieson (HVG) staining of dermal tissue. HVG was 
conducted on formalin fixed, paraffin embedded tissue from 3 normal skin, 2 normal scar and 2 
keloid scar samples, scale bar = 250µm. (A) Staining in a representative normal scar sample 
(NS) with a normal skin border (left hand side of the image), (B) Staining in the dermis of a 
representative keloid scar sample (KS). (C) Quantification of ‘white space’ within the dermis of 
HVG stained samples, n= 3 technical replicates where each replicate is an independent field of 
view with x20 objective. 
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To further explore the production of factors important to the formation of this fibrotic matrix, 
ECM transcripts were investigated by RT-qPCR. 
RNA was extracted from 12 samples in total (Table 3.2). These samples were collected during a 
targeted collection period of ~4 months from local sources of tissue i.e. Cancer Centre keloid 
clinic at Guys, in order to minimise sample processing time and therefore increase RNA 
integrity.  Homogenisation of the tissue, even with the TissueLyser, was difficult and therefore 
yield was lower than expected. However, RINs were better than previously achieved; normal 
skin all showed high integrity RNA that would even be suitable for RNAseq analysis (i.e. ≥ 7-
8). Keloid RNA integrity was more variable with RINs ranging from 1 to 8. 
A 200ng reverse transcription reaction was conducted on 10 of the 12 samples, excluding the 
two samples that had an undetectable RIN or extremely low RIN (1). Relative expression for 
each primer pair was calculated from extrapolation to a standard curve, and normalisation to the 
reference gene P4HB. Keloid tissue had significantly higher levels of fibronectin (FN), collagen 
1a1 (COL1A1) and collagen 3a1 (COL3A1) compared to normal skin and significantly lower 
levels of ɑSMA (ACTA2) (Figure 3.3).  
 
Table 3.2 - Summary of tissue RNA extractions.  
Type of tissue Sample ID RIN Conc (ng/µl) 
Normal Skin N160517 8.9 50 
Normal Skin N130317 8.2 46 
Normal Skin N150517 7.9 59 
Normal Skin N040317 7.5 28 
Normal Skin N070317 Undetectable <1 
Adjacent keloid skin KN130317* 8.4 35 
Keloid scar K130317* 6.1 98 
Keloid scar K080217 1 11 
Keloid scar K200217 4.6 47 
Keloid scar K060317 4.4 101 
Keloid scar K230317A** 8.4 130 
Keloid scar K230317B** 6.6 21 
* = matched keloid and adjacent skin, **= same patient with two keloids on left and right ear 
lobes. Blue samples are those used in all qPCR analysis, orange samples are additional 





 Figure 3.3 - RT-qPCR for fibrosis associated genes in normal skin and keloid tissue. RT-
qPCR was conducted on 4 normal skin and keloid scar tissue samples which were normalised to 
the reference gene P4HB. All four transcripts were quantified based on standard curve and 
showed a statistically significant difference (*p<0.05) by a non-parametric, unpaired testing 





 3.2.3.  Expression of BET mRNA in tissue 
 
mRNA extracted from normal skin and keloid scar tissue was then used to examine the 
expression of BET proteins, BRD2, BRD3 and BRD4 (Figure 3.4). A subset of keloid tissue 
had higher BRD2 expression than normal skin. Interestingly, the two keloids that showed 
similar levels to normal skin were two samples from the same patient. Normal skin and keloid 
scar appeared to have similar levels of BRD3. Normal skin had a slightly higher amount of 
BRD4. No significant difference was found between normal skin and keloid scar in the 
expression of any of the BET proteins, as analysed by Mann Whitney test (BRD2 p=0.1506, 


























Figure 3.4 - mRNA expression of BRD2, BRD3 and BRD4 in tissue. qPCR was conducted 
on 5 normal skin and keloid scar tissue samples which were normalised to the reference gene 
P4HB. All four transcripts were quantified based on standard curve. 5 biological replicates in 




 3.2.4.  BRD2, BRD3 and BRD4 protein expression in tissue 
 
As there was some indication that there may be differences in BRD2 and BRD4 mRNA 
expression, further analysis was conducted to quantify and localise the proteins. In order to 
focus on the dermis of the tissue, which is where the majority of the pathology of keloid 
unfolds, de-epithelised tissue from both keloid scars and normal skin was homogenised and 
protein was extracted and quantified. Western blots were then run with equal quantity of protein 
from n=4-6 keloid scar dermis and normal skin dermis and probed for BRD2, BRD3, BRD4 
(rabbit polyclonal antibodies, GSK) and GAPDH for a loading control. 
A low basal expression of BRD2 was seen in all patient samples, with overexpression in a 
number of keloid samples. Interestingly, where two keloids from the same patient were 
examined (K1 and K2, and K4 and K5), there was overexpression in both patients (Figure 3.5). 
BRD3 results showed relatively consistent expression across all patient samples, except for a 
single keloid sample (K4) which had approximately double the amount of BRD3. This keloid 
sample was also the highest expresser of BRD2. Mirroring what was seen at the mRNA level, 
BRD4 expression seemed to be higher in normal skin (especially samples 3-6) (Figure 3.5). 
The banding patterns of the BET proteins were not the size expected based on Ensembl.org size 
predictions, with all BET protein bands between ~60-70kDa, whereas full-length BRD2 was 
expected to be ~88kDa, BRD3 to be ~80kDa and BRD4 to be ~155kDa (protein sequence to 





Figure 3.5 - Expression of BET proteins in dermal tissue lysate. Western blot of normal skin 
and keloid scar dermal tissue lysates probed for BRD2, BRD3 and BRD4, and GAPDH as a 





 3.2.5.  BET expression in a range of cell types 
 
Due to the apparent overexpression of BRD2 protein in several keloid dermal lysates with an 
unexpected molecular weight, a range of cell types were analysed by western blot to examine 
antibody banding patterns for BRD2. As the purpose of this experiment was to qualitatively 
examine BET expression in these cells types, protein lysates were not quantified prior to 
loading. 
BETs were detected in all the cells types tested but with differential banding (Figure 3.6), 
which is summarised in Table 3.3.  
 







Approximate banding sizes were estimated by western blot as compared to the Precision Plus 
Protein™ Dual Color Standards protein ladder #1610374. 
 
  
Cell name Cell origin Species Brd banding (~kDa) 
NDF Primary dermal fibroblasts Human 60, 65 
KERA308 Keratinocyte Mouse 90, 120, 160 
HUVEC Umbilical vein endothelial cells Human 65, 120, 140 
SK-OV-3 Ovarian cancer Human 120, >250 
MDCK Kidney Canine 40, 45, 120, >260 
HMRSV5 Peritoneal mesothelial cells Human No bands detected 
RAW264.7 Macrophage Murine <37, 40, 45 
HEK-293 Embryonic kidney cells Human Smear from <37 to 42 







Figure 3.6 - Western blot showing BRD2 protein expression patterns in a range of cell 
lysates. Lysates were created from a range of cell types to evaluate specificity of the BRD2 




 3.2.6.  Protein expression pattern of BRD2 and BRD4 in 
tissue 
 
The westerns showed BET expression in the dermis, but with our particular interest in 
expression by dermal fibroblasts, the localisation of BET proteins were investigated by 
immunohistochemistry (IHC). DAB-IHC staining for BRD2, BRD3 and BRD4 was carried out 
using the Ventana automated staining system. This system offered a highly controlled staining 
process increasing the ability for comparison between tissue types. 
Initially this staining was intended to be analysed quantitatively in the dermis using Definiens 
image analysis software, however there was extensive damage to tissue sections, particularly 
during antigen retrieval, which was found to be necessary for optimal staining. Unfortunately, 
despite testing a range of BRD3 antibodies including commercially available and the polyclonal 
antibody used for western blots, there was no adequate IHC staining.  
In contrast to what is currently reported by the Human Protein Atlas (Table 3.1), many cells in 
the dermis tested appeared to show moderate to high positivity for BRD2. Immune cells were 
generally positive for both BRD2 and BRD4 (data not shown). Fibroblasts, indicated by their 
distinctive elongated nuclear shape, appeared to be almost all positive for BRD2 in keloid scar 
tissue, whereas they showed lower levels of staining in normal scar and variable staining in 
normal skin (Figure 3.7). The staining pattern of BRD2 also indicated the possibility for 
presence of this protein in the cytoplasm. BRD4 expression was strong in normal skin, normal 
























Figure 3.7 - BRD2 expression in normal skin, normal scar and keloid scar dermis. Two 
representative images for each tissue type demonstrating the expression pattern of BRD2 
following DAB-IHC using the Ventana staining system. Brown staining denotes BRD2 







Figure 3.8 - BRD4 expression in normal skin, normal scar and keloid scar dermis. Two 
representative images for each tissue type demonstrating the expression pattern of BRD4 
following DAB-IHC using the Ventana staining system. Brown staining denotes BRD4 
expression, blue staining shows nuclei by haematoxylin staining. Scale bar = 25µm.  
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 3.2.7.  BRD2 and BRD4 expression in cultured fibroblasts 
 
Following the indication from the IHC experiments that fibroblasts expressed moderate to high 
levels of BRD2 with a possible increase in expression in keloid fibroblasts, protein and RNA 
was isolated from normal dermal fibroblast (NDF) and keloid dermal fibroblast (KDF) cultures 
to examine BRD2 expression in vitro. Cells were also fixed in 4% PFA on poly-L-lysine coated 
coverslips for immunofluorescent staining to investigate cellular localisation of BRD2 protein. 
Firstly, western blots were run for 6 NDF and 6 KDF protein isolations, probing with the rabbit 
polyclonal BRD2 antibody from GSK used in Figure 3.5. This showed equal protein expression 
of BRD2 in these cultures (Figure 3.9A). Immunofluorescent staining also showed similar 
staining intensity between the NDF and KDF tested, with nuclear staining as expected, but 
again some indication of cytoplasmic localisation of the protein (Figure 3.9B). 
NDF and KDF mRNA was also analysed for all the BET family members by qPCR, with results 
normalised to the reference gene B2M. Primers for BRD2, BRD3 and the short and long 
isoforms of BRD4 (BRD4S and BRD4L respectively) were used. This also showed no marked 
difference in expression between NDFs and KDFs (Figure 3.10A), including no difference in 
the ratio of BRD4S to BRD4L. There was medium to strong correlation of all BET members 












Figure 3.9 - Expression of BRD2 proteins in cultured dermal fibroblasts. (A) Western blot 
of cultured NDF and KDF lysates probed for BRD2 and GAPDH as a loading control, n=6. (B) 
Immunofluorescence BRD2 staining of cultured NDF114 (keloid patient matched ‘normal’ 























Figure 3.10 - BET mRNA expression in NDFs and KDFs. (A) Relative expression of BRD2, 
BRD3, BRD4 and BRD4L were normalised to the reference genes B2M. All four transcripts 
were quantified based on standard curve. 5 biological replicates in technical duplicate, n=5, 







 3.2.8.  Expression of BRD2 protein following stimulation of 
cultured fibroblasts 
 
As BRD2 has been shown to potentially be expressed in fibroblast-like cells by IHC and within 
keloid dermal tissue, to examine the regulation of BRD2 fibroblast cultures were treated with a 
range of cytokines and growth factors to examine whether this might be able to induce 
expression in fibroblasts. An NDF line was treated for 72 hours with 10ng/ml IL-6, 10ng/ml IL-
17A, 10ng/ml TGF-β1 and 20ng/ml PDGF-BB and protein was harvested for western blot 
analysis. These factors were chosen as they have all been to linked to keloid pathology. It was 
found that the keloid associated factors may induce a small increase in BRD2 expression 
(Figure 3.11A). 
Lysates from NDFs treated with other inflammatory type factors were generated by Shuhanaz 
Begum (MSc student) were also used for western blot analysis of BRD2 expression and it was 
found that lipopolysaccharide (LPS) and tumour necrosis factor alpha (TNFɑ) were capable of 
increasing levels of BRD2 in two NDF lines (one representative blot shown) (Figure 3.11B). 
Lastly, lysates from an NDF and KDF line were treated for 24 hours with conditioned media 
taken from tissue ex vivo models and diluted 1:3 (due to the limited volume of conditioned 
media available (Figure 3.11C). Culture with normal skin ex vivo conditioned media (N-CM) 
appeared to have no effect on BRD2 protein expression in the NDF line, but culture with 
conditioned media from keloid tissue ex vivo cultures (K-CM) caused a decrease in BRD2 























Figure 3.11 - Expression of BRD2 in cultured fibroblasts after stimulation. (A) Western 
blot of cultured NDF lysates after 72 hour stimulation with 10ng/ml IL-6, 10ng/ml IL-17A, 
10ng/ml TGF-β1 and 20ng/ml PDGF-BB. (B) Western blot of cultured NDF lysates after 72 
hour stimulation with 0.05µg/ml LPS, 10ng/ml PMA, 5ng/ml IFNγ, 100ng/ml TNFα. (C) 
Western blot of cultured NDF and KDF lysates after 24 hour stimulation with 1:3 diluted ex 
vivo culture conditioned media from 3 different patients. All blots were probed for BRD2 and 






3.3.  Discussion 
 
In this study, we have confirmed literature reports that COLA1, COL3A1 and FN are increased 
in keloid tissue compared to normal skin, we have also confirmed a difference in collagen 
distribution in keloid tissue compared to both normal skin and normal scar. We have also 
contributed new knowledge in that Brd2 is expressed both in dermal fibroblasts and in whole 
skin tissue. We have novel data that suggests a possible overexpression of Brd2 in keloid scar 
dermis with a potential differential isoform of 60kDa that has not been reported in the literature 
and could have altered function. 
During the span of this project, information for 37 patients was collected when informed 
consent was given for sample collection. This information was analysed to better understand the 
patient demographics and characteristics of our clinical samples. Firstly, analysis of the patient 
information sheets showed that around two-thirds of patients had multiple keloid scars. A much 
bigger cohort of patients (211) in an Afro-Caribbean population analysed by Bayat et al in 2004 
found that 42% of their patients had keloids in multiple anatomical sites and also found that this 
did not vary between males and females (Bayat et al., 2004). However, it is unclear whether 
patients in our study who stated that they suffered from multiple keloid scars had multiple 
anatomical sites that were affected. Since many keloid scars are located on the earlobe as a 
result of piercing, it is likely that both ears are affected and could be classified as multiple scars 
and account for some over-reporting of multiple keloid prevalence. There is not yet information 
in the literature regarding the cause of multiple keloids, however the Bayat study did show that 
in their cohort of patients, there is a greater incidence of multiple keloids in younger patients, 
females and those with a family history of keloids (Bayat et al., 2004).  
The Bayat study also found that between 41 and 54% of patients reported a family history 
which is comparable to our results where 15 of 33 patients had confirmed family history. 
Despite a definite familial link for keloid risk, there has been a number of studies to elucidate 
the genetic basis of keloid formation with no consistent genes or pathways proven to be 
causative across the multiple populations studied.  
Additionally, the Bayat study reported that 35% of their patients were male and 65% were 
female, which again was similar to our findings that 24 out of 37 patients were female (64.8%). 
It is possible that due to the cosmetic nature of many keloid scars, females are more likely to 
seek care especially as it is often reported that keloid scars have equal rates of occurrence in 
males and females, (Gauglitz et al., 2011). However, there is good evidence to suggest that there 
is a true biological bias towards keloid scars occurring in females, including the growth and 
recurrence of keloids during pregnancy and decrease or absence of keloid formation in 
menopause, which has been reported for many decades and indicates a role for female hormones 
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although is limited to clinical observations (Moustafa and Abdel-Fattah, 1975; Park and Chang, 
2012; Kim et al., 2013).  
Whilst 17 out of 37 patients in our study reported their scars were itchy and another 17 reported 
their scars as itchy and painful, there were no patients that reported pain in the absence of 
itching. Pruritus is a significant clinical issue in keloid scars and is therefore a focus for 
treatment strategies (Bock et al., 2006). Inflammation and itch may also be directly linked 
through the influence of inflammatory mediators such as histamine by mast cells, which have 
been reported to be present in keloid scar tissue (Bagabir et al. 2012a). Additionally, pruritus 
and temperature sensitivity in keloids was linked to abnormalities in small nerve fibre functions 
which were postulated to be caused by the dense collagenous matrix that may compress or 
damage nerves (Lee et al. 2004).  
The dense collagenous keloid matrix was observed both in histology and by qPCR of whole 
keloid tissue mRNA. The overexpression of fibronectin (FN), collagen I (COL1A1) and 
collagen III (COL3A1) in keloid tissue was statistically significant and confirmed previous 
findings in the literature (Abergel et al., 1985; Babu, Diegelmann and Oliver, 1989; Clark, 
1990). Notably, keloid expression of these factors was variable, and the two patients that 
showed the highest expression of fibronectin also showed the highest expression of the two 
collagen types. The overexpression of collagens as well as the unusual arrangement of collagen 
fibres in keloid tissue seen in histological staining could support the importance of 
biomechanics in keloid pathology. A hypothesis published in 2016 postulated that the ‘stiffness 
gap’ caused by excessive and abnormal ECM deposition in keloids may drive cellular behaviour 
such as migration and proliferation that can cause keloid growth (Huang et al., 2016). Certainly 
mechanosensing by cells in the skin is integral for successful wound healing and the abnormal 
ECM environment found in keloid scars could affect cell behaviour and contribute to the 
activation and differentiation of fibroblasts to a myofibroblast phenotype (Hinz, 2009; Huang et 
al., 2012; Kenny and Connelly, 2014).   
The lower level of ACTA2 (ɑ-SMA) mRNA seen in keloid tissue compared to normal skin is 
not surprising, given that firstly there are such varied reports of ɑ-SMA positivity in keloid scars 
and secondly that normal skin is highly vascularised and these vessels stain as ɑ-SMA positive 
(personal communications/unpublished data, Zoe Drymoussi).  
With an improved understanding of the fibrotic environment of keloid tissue, BET proteins 
were then analysed both at the mRNA and protein level in keloid tissue compared to normal 
controls. qPCR analysis of normal skin and keloid whole tissue mRNA did not indicate any 
difference in expression of BRD3 between normal and keloid scar and equally analysis of 
BRD3 protein in normal skin and keloid dermal tissue lysates by western blot showed similar 
levels of expression with a single keloid sample showing higher expression. Interestingly, the 
108 
 
keloid that showed the strongest BRD3 expression also showed the greatest expression of BRD2 
which may not be surprising as these two BET family members are thought to have overlapping 
functions (Leroy, Rickards and Flint, 2008). BRD3 has the least amount of literature available 
(Table 3.4) and therefore much less is known about its function in both health and disease. 
Some level of expression was detected in all samples suggesting it has some importance in 
normal skin biology.  
 




Data based on PubMed search (11/06/17) for ‘Brd2[title] OR RING3[title]’, ‘Brd3[title]’ or 
‘Brd4[title]’. 
 
Slightly higher levels of BRD4 mRNA expression was observed in normal skin compared to 
keloid scar and this also held true at the protein level where 4 out of 6 normal skin dermal 
lysates had higher BRD4 protein by western blot. BRD4 expression patterns were then 
examined by IHC of normal skin, normal scar and keloid tissue, which revealed positivity in 
almost all cells in the dermis of all three types of tissue, although staining appeared most intense 
in normal skin. As cells with fibroblast morphology were observed to be BRD4 positive, BRD4 
mRNA was also analysed in normal skin and keloid fibroblasts, both of which were positive 
although not different which may be attributable to the culturing method, which will be 
discussed later. 
The high levels of BRD4 in normal skin tissue again suggests that BRD4 is likely to have a 
physiological role in the skin. Indeed sustained Brd4 silencing in mice causes a substantial skin 
defect through an unknown mechanism, with epidermal hyperplasia, increased sebaceous gland 
size and increased numbers of (and abnormal formation of) hair follicles (Bolden et al., 2014). 
A possible mechanism for the hair phenotype is that Brd4 is thought to be important for stem 
cell differentiation (Micco et al., 2014). Our IHC showed lots of BRD4 positivity surrounding 
the bulge region of the hair follicle where such stem cells would reside (data not shown), and 
the lack of appendages including hair follicles in keloid scar may explain the lower amount of 
Brd4 compared to normal skin. 
The most striking difference in BET expression was seen for BRD2. qPCR analysis of whole 
tissue mRNA indicated substantial overexpression of BRD2 (up to 100 fold higher than normal 
Keyword # of publications with keyword in the title 





skin) in 3 out of 5 keloid samples, although this was not statistically significant. Normal skin 
mRNA showed less variation, even the normal skin sample from a keloid patient, isolated 
adjacent to keloid scar, had expression levels in line with other normal skin samples. Similarly, 
when normal skin and keloid scar tissue were lysed and analysed for BRD2 protein by western 
blot, there was higher BRD2 expression in a number of keloid samples. Notably, in instances 
where two keloids from the same patient were assessed for expression, both keloids had some 
level of overexpression which could suggest there is a common mechanism in the formation of 
multiple keloids. There was no obvious clinical explanation for keloid dermis that showed 
strong BRD2 expression, such as anatomical site or level of inflammation (assessed by 
examining H&E histology) as BRD2 was expressed by immune cell clusters in our IHC and it is 
important in immune cell function (Belkina, Nikolajczyk and Denis, 2013; Belkina et al., 2014). 
The relatively low BRD2 protein expression in normal skin by western blot was not unexpected 
given that BRD2 has been linked to progression of the cell cycle (Sinha, Faller and Denis, 2005) 
and in normal skin there is very little turnover of fibroblasts in the dermis (McGrath, Eady and 
Pope, 2004). 
Analysis of BET proteins was somewhat complicated by the appearance of multiple bands of 
unexpected sizes, in particular a 60kDa BRD2 band that was strongly expressed in a subset of 
keloid samples. This was further explored in a western blot with a range of cell lysates which 
indicated further differential expression of BRD2 bands with sizes ranging between less than 
30kDa and more than 250kDa. Consistent with this, a number of commercial antibodies report 
band sizes that are not predicted but are thought to be the consequence of post-translational 
modification. For example, a BRD2 antibody retailed by Sigma (cat no. 07-1526) reports an 
observed band at ~110kDa with an uncharacterised band in some lysates at ~90kDa described to 
be due to phosphorylation at different sites on the protein. This demonstrates the difficulty 
presented by using BET antibodies and interpreting resulting banding patterns. Attempts to 
immunoprecipitate with the rabbit polyclonal BRD2 antibody, to identify the multiple BRD2 
bands with mass spectrometry (as well as other potential interacting proteins) were unsuccessful 
(Appendix, Figure 7.2). 
The rabbit polyclonal BRD2 antibody has been validated as detecting recombinant full length 
BRD2 (GSK) but is raised against an epitope between the two bromodomain regions of the 
protein and so it is possible that the bands represent different isoforms and/or post translational 
modifications of the proteins. Indeed, when focussing on BRD2 in particular, there are at least 8 
possible protein coding isoforms (Figure 3.12). Protein sequences from each isoform reported 
on Vega/Havana were entered into a publicly available online tool for protein domain prediction 
(ScanProSite). BRD2-023 could account for the 60kDa band observed in the tissue lysates, 
which notably lacks the nuclear localisation signal domain (NLS) and the N Extra Terminal 




Figure 3.12 - Schematic of possible protein-coding BRD2 isoforms. Protein sequence 
information for each BRD2 isoform reported on Ensembl.org was entered into the ExPASy tool 
ScanProSite to generate a structure of predicted motifs. 
 
This could explain some cytoplasmic presence of BRD2 which was observed in IF staining of 
fibroblasts, which was also seen in staining of rheumatoid arthritis (RA) fibroblast-like 
synoviocytes (Xiao et al., 2015). The consequence of BRD2 in the cytoplasm is currently 
unknown; however, given that BETs can interact with non-histone proteins through acetylated 
lysine, there may be relevant protein interactions occurring in the cytoplasm. Also, similarly to 
the BRD4 short isoform (Alsarraj et al., 2013), this truncated version of BRD2 may have a more 
promiscuous binding pattern to histones, which in turn may drive different patterns of gene 
expression.  
Efforts to investigate the expression profiles of different isoforms were unsuccessful within the 
span of this project, first through RACE-PCR and then through extensive qPCR attempts using 
primer sets to amplify various combinations of isoforms (in Appendix, below). 
Two internal reverse primers were designed within the second exon of BRD2 whilst a RACE 
forward primer specific for the sequence that was ligated onto the 5’ end of transcripts during 
cDNA preparation was used. This method theoretically should have allowed the amplification 
of multiple BRD2 isoform transcripts (including full length BRD2 and the 60kDa isoform of 
particular interest) which could be separated by electrophoresis and identified by size and/or 
sequencing.  
qPCR primers were also designed with the help of Catriona Sharp (GSK) to amplify the 
different transcripts. Unique primers sets could be designed for BRD2-001 and BRD2-002 only 
(Figure 3.12), whilst other primer sets were designed to amplify different combinations of 
transcripts (detailed in Appendix, below). Due to technical challenges in controlling for primer 
efficiency across the different transcripts, it was not possible to make the detailed analysis of 
BRD2 isoforms that was planned. If differential isoforms, such as the 60kDa BRD2 isoform, are 
indeed present in disease, then cloning and overexpression of specific constructs in dermal 
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fibroblasts could help to understand their functions and in turn importance in disease, as well as 
gaining a better understanding of the function of BET protein domains.  
A commercial BRD2 IHC antibody from Bethyl Lab was used for the IHC analysis as pilot 
experiments showed the GSK BRD2 antibody did not work (data not shown). This antibody was 
raised against an epitope at the C terminal end and therefore should only detect the full length 
protein. The BRD2 positive cells within the dermis were interpreted to be fibroblasts based on 
their location and morphology, although this could not be confirmed by co-staining due to the 
lack of specific human fibroblast marker. Interestingly, there was variable expression of BRD2 
in dermal fibroblasts in some normal skin samples, indicating the possibility of fibroblast 
subsets that are BRD2 negative and positive. Our understanding of fibroblast heterogeneity is 
expanding with the discovery of a number of progenitor fibroblast populations in mice that are 
likely to have different contributions to wound repair in particular (Driskell and Watt, 2014; 
Rinkevich et al., 2014). However, similar work is still ongoing in human skin (Phillippeos & 
Watt, personal communication). The comparatively more homogenous expression of BRD2 
seen in the keloid dermal fibroblasts by IHC may reflect an expansion of the BRD2 positive 
fibroblasts. In future work, it would be helpful to work up a Ventana staining method with a 
different coloured substrate to allow co-staining (e.g. for CD45) to better understand the cell 
populations that are contributing to dermal expression. 
As it appeared to be mainly dermal fibroblasts that were responsible for BRD2 expression in the 
dermis, western blotting was carried out on cultured NDFs and KDFs isolated from human 
samples. This showed no difference in the expression of BRD2 protein and indeed no difference 
in the mRNA level of BRD2, BRD3 or BRD4, including the ratio between the short and long 
BRD4 isoforms. The lack of difference seen could be due to the artificial environment of cell 
culturing whereby conditions are formulated to promote growth and expansion of cells rather 
than retaining in vivo characteristics. We believe this environment, on a tense plastic substrate in 
the presence of serum may cause NDFs to become less ‘normal’ and more scar like. Foetal calf 
serum is often added as a supplement of culture media and is a key driver of cell proliferation 
(Ryan, 1979) however some reports describe that cells in contact with serum are demonstrating 
a damage-like response, as in vivo serum is involved in the clotting response after wounding and 
contains many growth factors and hormones that may induce proliferative behaviour (Chang et 
al., 2004).  
To better understand what factors may regulate BRD2 expression in vivo, which may be missing 
in our culturing conditions, cells were treated for 72 hours with a panel of keloid associated 
factors (IL-6, IL-17A, TGF-β1 and PDGF-BB) or inflammatory type factors (LPS, PMA, IFNγ 
and TNFɑ). All of these keloid associated factors caused a small increase in BRD2 protein in 
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the NDF line, however the inflammatory factors LPS and TNFɑ induced higher levels of BRD2, 
which included another band at ~60kDa.  
LPS stimulation in some way models a bacterial infection of cells by stimulation through TLR4, 
which has been shown to activate inflammatory gene expression in hypertrophic scar dermal 
fibroblasts through NF-κB activation (Wang et al. 2010). In vivo, TNFɑ may be produced by a 
range of immune cells, activated macrophages in particular (Olszewski et al., 2007), which have 
been reported to be present in keloids (Bagabir et al., 2012a). Keratinocytes can also produce 
TNFɑ (Bashir, Sharma and Werth, 2008), and this may be aberrant in keloids where the cells are 
abnormally differentiated (Limandjaja et al., 2017). It would be interesting to repeat the LPS 
and TNFɑ stimulation in KDFs to see whether similar induction of BRD2 expression occurs or 
whether the expression may be regulated differently in these cells. It is unclear why conditioned 
media from keloid ex vivo cultures is able to reduce BRD2 protein levels in a KDF line after 24 
hours of culture; it may be due to a range of factors in the supernatant that we have not tested 
that may be able to negatively regulate expression. Better characterisation of the secretome of 
keloid tissue in the future may aid with further studies of BRD2 regulation. 
It would be informative to examine the direct transcriptional consequences of Brd2 in keloid vs 
normal skin. One strategy to do this would be to analyse chromatin binding patterns of BRD2 
by ChIP-Seq, including association with super-enhancer regions. Inflammation has been shown 
to cause BRD4 recruitment to chromatin in the form of super-enhancers, which could drive 
pathological gene expression as has previously been reported in other cell types (Brown et al., 
2014; Xu and Vakoc, 2014). Super enhancers have been shown to regulate a range of processes 
from cell fate to disease progression (Hnisz et al., 2014; Micco et al., 2014) although limited 
information can be gleaned from existing datasets as BET protein activity is thought to be very 
cell and stimuli specific (personal communications with GSK). It would also be interesting to 
undertake proteomics on BRD2 immunoprecipitation on whole keloid tissue or cells to identify 
non-histone targets which may be different in health vs disease. The following chapters explore 
BET protein activity in keloid fibroblasts by examining the cellular consequences of BET 
protein inhibition, which may also shed light on whether these proteins could be targets of 




Chapter 4:  Evaluating the effect of BET protein 
inhibition on disease associated cell behaviours 
4.1. Introduction 
 
Keloid derived cells, in particular fibroblasts (KDFs) appear to have altered characteristics and 
behaviour that contribute to the disease; KDFs have been shown to be more proliferative (Satish 
et al., 2004; Blažić and Brajac, 2006; Ghazizadeh et al., 2007), more resistant to apoptotsis 
(Chipev et al., 2000; Ishihara et al., 2000), more inflammatory (Messadi et al., 2004; Fujiwara, 
Muragaki and Ooshima, 2005; Uitto, 2007), more contractile (Chipev et al., 2000) and more 
matrix producing (Babu, Diegelmann and Oliver, 1989; Syed et al., 2011).Targeting epigenetics 
may offer a novel strategy to influence multiple cell behaviours and “normalise” the phenotype 
of disease cells to a healthy state.  
There is strong evidence for epigenetic changes in disease particularly in inflammatory 
conditions (Tough et al., 2016) with increasing interest in targeting this therapeutically. Keloid 
scars specifically have been reported to be epigenetically changed compared to normal controls, 
with one particular study focussing on keloid fibroblasts which showed differential DNA 
methylation and histone acetylation compared to normal controls (Russell et al., 2010). 
Although there has been no analysis of the wide-scale acetylome in keloid fibroblasts the 
Russell et al study did show a decrease in specific keloid-gene transcription, such as IGFBP5 
and JAG1, after treatment with the histone deacetylase (HDAC) inhibitor TSA. Interestingly 
overexpression of p300, an enzyme with the opposite activity (histone acetyl transferase, HAT) 
also had an anti-fibrotic effect in scleroderma patient fibroblasts cultured with TGF-β1, 
suggesting that differential acetylation at specific genomic loci, be it increased or decreased, can 
modulate the expression of fibrosis relevant target genes, such as collagen genes. Given the 
association of BET proteins with acetylated lysine residues on proteins including histones, this 
may indicate that BET proteins could have differential activity in diseases including keloid 
scarring. 
Indeed, small molecule BET inhibitors, which bind to and block BET bromodomain activity, 
have shown efficacy in a wide range of disease models, many of which have relevant features to 
keloid scarring. These studies have also importantly indicated that the efficacy of BET 
inhibition does not exclusively dependent on the overexpression of BET proteins in disease. 
Instead BET proteins may influence disease through different patterns of gene expression which 
can be altered or even reverted to a ‘normal’ phenotype by BET protein inhibition.  
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BET inhibition has shown positive effects in a range of cancer models, namely through the 
inhibition of proliferation and induction of apoptosis (Dawson et al., 2011; Chaidos et al., 2014; 
Gallagher et al., 2014). This could offer an advantage in the treatment of keloid scars where 
cells are thought to be persistently proliferative and/or resistant to apoptosis, which is a process 
that is essential to normal wound healing resolution (Sayah et al., 1999; Ishihara et al., 2000). 
In addition to this, BET inhibition has been shown to be anti-inflammatory, in part by causing a 
decrease in proinflammatory cytokines, and it is via this mechanism that the drug is thought to 
improve outcomes in models of retinal degenerative disease (Li et al., 2017), sepsis (Belkina, 
Nikolajczyk and Denis, 2013) and rheumatoid arthritis (RA) (Klein et al., 2014). More recently, 
there has been increasing evidence that BET inhibition showing beneficial effects in several 
organ fibrosis models including in the kidney (Zhou et al., 2017), liver (Ding et al., 2015) and 
lung (Tang et al. 2013a), by downregulating fibrosis related genes, including those related to the 
deposition of matrix such as collagen and fibronectin. 
This section of work utilised one such inhibitor called I-BET151 (GlaxoSmithKline) as a pre-
clinical tool to interrogate the effect of BET protein inhibition in both NDFs and KDFs on both 
protein/gene read-outs and corresponding phenotypic behaviours. 
I-BET151, also named GSK1210151A, was created by GlaxoSmithKline to target BET family 
proteins, and was first published in a paper showing efficacy in models of an aggressive and 
difficult to treated form of leukaemia called mixed lineage leukaemia (MLL) (Dawson et al., 
2011). The inhibitor caused cell cycle arrest and apoptosis in human and mouse MLL cell lines 
and provided a significant survival benefit in two different mouse models of MLL.  
Given the plethora of effects of BET inhibitors reported on different cell types, the main 
objective of this chapter was to explore the effects of BET inhibition in a dermal fibroblast 
context. We used I-BET151 as a pre-clinical tool, treating NDF and KDF monolayers and 
evaluating the effect on four key cell behaviours: 
1. Proliferation 
2. Collagen gene expression 
3. Contraction 
4. Protease activity 
In addition, a whole tissue biopsy ex vivo model (Bagabir et al. 2012b) was utilised to evaluate 






4.2.1.  Proliferation is decreased in both normal and keloid 
dermal fibroblasts after pharmacological BET inhibition 
 
Cell counting experiments were used to assess the effect of bromodomain inhibition by I-
BET151 on the proliferation of primary dermal fibroblasts. Due to the relatively slow doubling 
time of dermal fibroblasts, counts were performed at 72 hours. In both cell lines a statistically 
significant decrease in cell number was seen after treatment with 1µM I-BET151 with around 
50% less cells than the vehicle control on average (Figure 4.1A). To explore variations in 
sensitivity to BET inhibition between NDFs and KDFs, a titration of I-BET151 concentration 
was used for a number of biological replicates and this showed a concentration-dependent 
decrease in cell number of both NDFs and KDFs, with an effect even seen at a low dose of 1nM 
with around 75% of the cell number of the vehicle control (Figure 4.1B). Additionally I-
BET151 treatment seemed to have a greater effect on KDFs, although this was not statistically 
significant (Figure 4.1B). 
Curiously, a higher throughput method of measuring cell number by WST-1 assay was trialled 
but unsuccessful. WST stands for water soluble tetrazolium salt and is a colormetric assay 
which relies on the conversion of a dye from a colourless to a coloured substrate through 
cleavage by mitochondrial enzymes (Peskin and Winterbourn, 2000). This assay should in 
theory reflect cell number, however despite visual and cell count confirmation that there were 
less cells present after I-BET151 treatment, the WST-1 results remained equal across vehicle 
and drug treated conditions (data not shown).  
No visible signs of cell death, such as floating cells or blebbing nuclei, were observed in 
response to I-BET151, but to confirm that this decrease in cell number indeed due to a decrease 
in proliferation, rather than cell death, cells were analysed for Ki67 staining which is a 
proliferation marker expressed in late G1, S, G2 and M phase of the cell cycle (Bologna-Molina 
et al., 2013). Ki67 immunofluorescent staining of fibroblasts treated for 24 hours with 1µM I-
BET151 or a vehicle control (0.01% DMSO) was performed and images were analysed in 
ImageJ to determine the percentage of Ki67 positive cells relative to the total number of cells as 
marked by DAPI (Figure 4.2A). A decrease in the percentage of Ki67/DAPI double positive 
cells after 1µM I-BET151 treatment was observed with further reduction at 10µM, with only 
~35% of NDFs and ~20% of KDFs double positive at this dose, which showed statistical 
significance compared to the vehicle control (Figure 4.2B) although this was deemed to be 
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approaching a concentration that could give rise to off-target and potentially toxic effects 
(personal communications with GSK). 
A wash-off experiment was also carried out to investigate the persistence of the anti-
proliferative effect induced by I-BET151, (Figure 4.3). Both NDFs and KDFs showed a 
decrease in Ki67 expression after 24 hours of 1µM I-BET151 treatment, denoted as ‘0h’. 
Following removal of drug and thorough washing with PBS, the reduction in Ki67 persisted for 
less than 6 hours, indicating this is a reversible effect. Although this experiment was conducted 
on limited biological replicates, it seems that the decrease in KDF proliferation may persist 
longer after wash off compared to NDFs. Intriguingly in early KDF time points there appears to 
be an increase of GAPDH with I-BET151 treatment (Figure 4.3B) showing further evidence for 























Figure 4.1 - Dermal fibroblast proliferation is reduced after I-BET151 treatment. (A): Cell 
counts were taken at 72 hours after treatment with 0.01% DMSO vehicle or 1µM I-BET151 
treatment, where dots linked with lines are paired samples, n=5, * = p<0.05 by Wilcoxon t-test. 
(B) Concentration dependent decrease in NDFs and KDF cell number after 72 hours of I-
























Figure 4.2 - Decreased Ki67 positivity with I-BET151 treatment. (A) Representative images 
of Ki67 (red) and DAPI (blue) immunofluorescent staining on NDF and KDF cell line after 24 
hours of 1µM I-BET151 treatment. Scale bar = 20µm. (B) Quantification of Ki67 staining (% of 
Ki67+ nuclei / total nuclei (DAPI) after 24 hours of 1µM I-BET151 treatment in both NDF 
(n=4) and KDFs (n=3), error bars represent SEM. * = p<0.05, ** = p<0.005 by 2-way ANOVA 






















Figure 4.3 - Recovery of dermal fibroblast proliferation after I-BET151 wash-off. 
Representative western blots showing Ki67 expression after 24 hours 1µM I-BET151 treatment 




4.2.2.  BET inhibition does not affect collagen expression  
 
The production of collagen was also analysed, following previous observations that keloids are 
characterised by excessive collagen (Figure 3.3). Firstly, mRNA levels of two stereotypical scar 
associated fibrillar collagens were analysed using primers for COL1A1 and COL3A1 in NDF 
and KDF cultures treated for 48 hours with 1µM I-BET151 or vehicle control. This analysis 
showed that cells had a very heterogeneous response to drug treatment. 60% of NDFs and KDFs 
showed a decrease in COL1A1 (3 out of 5 biological replicates after I-BET151 treatment 
(Figure 4.4A). However, KDFs had a slightly more consistent decrease in COL3A1 after I-
BET151 treatment with decreased expression in 5 out of 6 biological replicates, compared to 4 
out of 6 NDFs (Figure 4.4B). 
When secreted collagen I protein was measured by western blot in the supernatants of NDFs 
and KDFs (n=3) treated for 48 hours with I-BET151 or vehicle control, no difference was seen 






















Figure 4.4 - Effect of I-BET151 on collagen expression. Collagen was analysed after 48 hours 
of treatment with 1µM I-BET151 or vehicle control. qPCR was used to analyse mRNA levels of 
two scar associated collagen transcripts, COL1A1 (A) and COL3A1 (B) using the standard 
curve reference and normalising to the reference gene B2M.  Secreted collagen 1 was then 
measured in supernatants of cultures by western blot with Ponceau staining of total protein as a 




4.2.2.  Contraction is decreased in both normal and keloid dermal 
fibroblasts after BET inhibition  
 
Contractility is another important scar associated cellular parameter that was measured in 
response to BET inhibition. Although contractility isn’t explicitly reported to be increased in 
keloid dermal fibroblasts, there have been reports in other fibroses such as scleroderma that 
contractility is enhanced (Chen et al., 2005). To assess dermal fibroblast contractility, a collagen 
gel contraction assay was used with low passage fibroblasts (less than 3 passages) in an effort to 
retain the in vivo phenotype of the cells as pilot studies showed these cells tended to be more 
contractile. Fibroblast-seeded collagen gels (n=7 biological replicates) were free-floated in 
media containing either DMSO (vehicle) or 1µM I-BET151. At 72 hours, a significant reduction 
in gel size was seen in vehicle treated replicates as opposed to I-BET151 treated replicates that 
retained much of their original size (Figure 4.5). A subset of KDF lines showed increased 
contractility compared to NDFs but this was not consistent across all patient samples tested. 
Cell contractility in scar associated fibroblasts can be mediated by ɑ-SMA, which is often 
referred to as a myofibroblast marker (Hinz et al., 2007). Therefore fibroblast monolayer 
cultures treated with 1µM I-BET151 or DMSO vehicle control for 48 hours were harvested for 
RNA extraction. After reverse transcription, levels of ACTA2 (ɑ-SMA transcript) and the 
reference gene B2M were measured by qPCR. This analysis showed a dramatic decrease in 
ACTA2 mRNA in both NDFs and KDFs after 48 hours of treatment with 1µM I-BET151 

























Figure 4.5 - I-BET151 decreases collagen gel contraction with an associated reduction in 
ɑ-SMA expression. (A) A representative gel contraction assay +/- I-BET151 with a keloid 
fibroblast cell line pictured after 72 hours of contraction. (B) Summary of experiments carried 
out for n=7 NDFs and KDFs with gel size measured at 72 hours (* =p<0.05 by Wilcoxon’s t-
test). (C) qPCR for ɑ-SMA in n=5 NDFs and KDFs after 48 hours of I-BET151 treatment, 
relative to the reference gene B2M, normalised to the untreated control where lines represent 
different patient isolations.  
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4.2.3.  Decrease in protease expression after BET inhibition 
 
In order to further probe the effects of BET inhibition on keloid fibroblasts and more widely on 
keloid tissue, an ex vivo culturing technique was used (Bagabir et al. 2012b). The model is a 
4mm ø biopsy of tissue maintained in a media-collagen gel, with the epidermal surface at the 
air-liquid interface with a small volume of media on the surface of the gel which is replenished 
every 2-3 days. In this case, both the media-collagen gel and the media were supplemented with 
1µM I-BET151 or DMSO as a vehicle control. 
The original paper concluded that this culturing technique was capable of maintaining tissue 
health and integrity for up to 6 weeks (Bagabir et al. 2012b). The group then used this model to 
evaluate the effect of pharmacological compounds and siRNAs, showing effects such as tissue 
shrinkage, increased apoptosis, decreased proliferation, reduced inflammation and reduced 
collagen production (Syed et al., 2013).  
When the model was used in our lab, the first and most remarkable observation was a sporadic 
degradation of the collagen-media gel surrounding some tissue biopsies after 1-2 weeks of 
culture (Figure 4.6). Anecdotally, this observation occurred in both tissue types but with more 






















Figure 4.6 - Illustrative examples of the degradative nature of keloid ex vivos, which was 
prevented with I-BET151 treatment. (A) Example image of degradation after the keloid tissue 
biopsy was removed from the collagen ‘bed’, conditions were performed in technical duplicate 
with vehicle control 0.01% DMSO (top row) or 1µM I-BET151 (bottom row). (B) Image 
captured on light microscope showing keloid tissue biopsy edge (*) and surrounding 






To investigate the mechanism behind this striking observation of tissue being released from the 
collagen bed, and I-BET151’s ability to block this, supernatants were taken from these cultures 
after 24 hours of treatment with 1µM I-BET151 or vehicle control. 24 hour supernatants were 
also taken from fibroblast monolayer cultures with vehicle vs 1µM I-BET151 treatment. 
These supernatants were used to probe the hypothesis that the degradation seen in the ex vivo 
cultures may be as a result of proteolytic activity, and that BET inhibition may be able to skew 
the protease balance to prevent this degradation. Therefore, MMPs and TIMPs were measured 
by a Luminex assay, a magnetic bead, antibody based multiplex assay with a similar protocol to 
an ELISA but allowing for the detection of a range of target analytes. Specifically, MMP1, 3, 7, 
8, 9, 10, 12, and 13, and TIMPs 1, 2, 3, and 4 were measured. This technology detected pro and 
active forms of assayed MMPs, as well as TIMP complexed MMPs so was a measure of overall 
levels. When examining levels of MMPs and TIMPs, it was apparent that keloid tissue showed a 
trend for higher amounts of almost all MMPs, except MMP7, and similar amounts of TIMPs, 
compared to normal skin (Figure 4.7A). In contrast, monolayers of KDFs generally had lower 



















Figure 4.7 - Baseline MMP and TIMP production in tissue ex vivo models. Summary of 
Luminex data of all assayed analytes in 24 hour supernatant from 4mm tissue ex vivo model 
embedded in collagen with 200µl of media, n= 6 (A) and fibroblast cultures, seeded at 4 x 104 
cells per well in a 12 well plate with 500µl media, n = 3 (B). Bars represent mean +/- SEM 
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In addition to highlighting potentially greater proteolytic activity in keloid ex vivo cultures 
compared to normal skin ex vivo cultures, the results of the ex vivo experiment also suggested 
that this could be limited by I-BET151 treatment. Consistent with this, Luminex analysis on 
both ex vivo and fibroblast cultures treated with I-BET151 or vehicle control indicated a general 
decrease in a number of MMPs and an increase in a number of TIMPs after I-BET151 treatment 
(Figure 4.8 and Figure 4.9). There were high levels of heterogeneity in both normal skin and 
keloid scar, in terms of starting level of analyte and in response to I-BET151. To visualised this 
information as fold change, the data was normalised by dividing each I-BET151 result by the 
paired vehicle control (Figure 4.8B). 
MMP-9 showed the most consistent decrease after I-BET151 with almost all samples (10 out of 
12, across both normal skin and keloid ex vivo cultures) (Figure 4.8A). In fact the two keloid 
samples that produced a particularly high level of MMP-9 were the most drastically affected 
with around a 10 fold decrease. TIMP-1 showed the most consistent increase after I-BET151 
with 11 out of 12 samples showing a higher concentration with treatment. However, upon 
thorough statistical analysis, there were only a few analytes that showed a significant change 
after I-BET151 treatment and these were not consistent between tissue types. Significant 
decrease by parametric testing was seen in MMP3, MMP9 and MMP12 in normal skin, whereas 
no significant changes were seen by parametric testing in keloid, although MMP8 and TIMP1 
were significantly changed by non-parametric testing in keloid (Table 4.1). 
When the same analysis was repeated for supernatants from the fibroblast cultures, there was 
less heterogeneity, and a clearer effect of I-BET151 treatment. Specifically, I-BET151 treatment 
decreased MMPs with a more dramatic response in KDFs (Figure 4.9B). Statistics are not 

























Figure 4.8 - MMPs and TIMP production in normal skin and keloid tissue ex vivo cultures. 
(A) Summary of Luminex data of all assayed analytes in normal skin and keloid tissue with 
0.01% DMSO or 1µM I-BET151 treatment for 24 hours and (B) and change in expression after 
24 hours of I-BET151 treatment (I-BET151 normalised to vehicle control), mean +/-SEM, n=5.  
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Table 4.1 - P values for effect of I-BET151 on ex vivo cultures. 
 Normal Skin Keloid 
Para Non Para Para Non Para 
MMP1 0.26 0.44 0.35 1.00 
MMP3 0.03 0.06 0.40 0.69 
MMP7 0.11 0.15 0.39 0.53 
MMP8 0.06 0.09 0.12 0.03 
MMP9 0.02 0.06 0.11 0.06 
MMP10 0.33 0.31 0.35 0.44 
MMP12 0.01 0.03 0.37 0.44 
MMP13 0.08 0.09 0.30 0.31 
TIMP1 0.31 0.31 0.12 0.03 
TIMP2 0.75 0.69 0.12 0.22 
TIMP3 0.54 0.69 0.09 0.16 
TIMP4 0.85 1.00 0.12 0.06 
Parametric and non-parametric (Wilcoxon’s) t-tests were conducted on the Luminex data for 























Figure 4.9 - MMP and TIMP production in NDF and KDFs. (A) Summary of Luminex data 
of all assayed analytes in NDFs and KDFs with 0.01% DMSO or 1µM I-BET151 treatment for 
24 hours and (B) and change in expression after 24 hours of I-BET151 treatment (I-BET151 
normalised to vehicle control), mean +/-SEM, n=3.  
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When comparing the Luminex results of the I-BET151 response of ex vivo cultures vs fibroblast 
cultures, an interesting pattern was seen in keloid vs normal skin. MMP3, MMP7, MMP10 and 
MMP13 showed a consistent downregulation in both normal skin ex vivo cultures and NDF 
cultures (Figure 4.10A). However, in the keloid comparison, these proteases were strongly 
decreased in KDFs, as above, but there was very little change in keloid ex vivo cultures (Figure 
4.10B), suggesting another cell type within keloid scar tissue could be important for releasing 
these proteases that is non-responsive to I-BET151 inhibition. In addition, these four analytes 
showed much stronger correlation, by Spearman’s correlation analysis, within keloid tissue and 
not normal skin (Figure 4.10C & D).  
Given the dogma in the literature that MMP and TIMP interactions occur in a non-biased 1:1 
ratio (Tuuttila et al., 1998), a crude measure of protease balance was also calculated by dividing 
the total quantity of MMPs by the total quantity of TIMPs. This analysis revealed an overall 
decrease after I-BET151 treatment in 5 out 6 normal skin biopsies and 5 out of 6 keloid biopsies 
(Figure 4.11). Fibroblast cultures also showed a consistent decrease in ‘protease activity’ with 

























Figure 4.10 - Comparison of ex vivo vs fibroblast monoculture production of MMP3, 
MMP7, MMP10 and MMP13 after I-BET151 treatment. Luminex data for I-BET151 treated 
cultures normalised to vehicle control to show mean change in expression after 24 hours I-
BET151 or vehicle treatment, in tissue ex vivo cultures vs fibroblast cultures in normal skin (A) 
and keloid (B), mean +/-SEM, n=3/5. (C) Spearman’s correlation co-efficient (R) for the level 
of MMP3, MMP7, MMP10 and MMP13 in control normal skin and keloid supernatants, where 






















Figure 4.11 - ‘Protease ratio’ of cultures. Protease ratio was calculated by dividing total MMP 
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4.2.4.  Decrease in proteolytic activity after BET inhibition 
 
After establishing that the ratio of MMP to TIMPs was decreased with BET inhibition, it was 
important to identify whether this did indeed cause a reduced proteolytic phenotype in 
fibroblasts, especially as the Luminex method, in addition to measuring active MMPs, also 
detected pro-form and TIMP-complexed forms of MMP.  In order to answer this question, a 
zymography technique was used to examine 24 hour serum-free supernatants from 3 NDF and 3 
KDF cultures treated with 1µM I-BET151 or 0.01% DMSO. A pan-MMP substrate that 
produced a colorimetric reaction after cleavage, in order to get an overall picture of MMP 
activity change, rather than examining particular MMPs in detail. 
Absorbance at 412nm was read on a plate reader after the addition of all components to the plate 
to give a 0 hour baseline reading. The plate was incubated at 37°C for the zymography reaction 
to take place and absorbance was measured at 6, 24, and 48 hours.  
Almost no difference was observed in the water only control throughout the experiment, 
whereas some increase was seen in the media only control, suggesting there may be some 
component in the media that has the potential to cause the DTNB to reduce and change colour. 
Nonetheless, both the NDF and KDF cultures showed protease activity above the media control 
that increased over time (Figure 4.12A/B). NDFs had higher protease activity over the time 
course compared to KDFs, with an average of twice as much protease activity at the 24 hour 
timepoint (0.10 vs 0.04 respectively at 24 hours) (Figure 4.12B) which closely matched the 
protease ratio from the Luminex data, (Figure 4.11A). BET inhibited fibroblast cultures tended 
to have a decrease on protease activity, especially in NDF cultures that showed a higher level of 



























Figure 4.12 - Proteolytic activity of fibroblasts after I-BET151 treatment Absorbance at 
412nm over time for n=3 NDF (A) or KDF (B) supernatants treated with 1µM I-BET151 or 
0.01% DMSO minus the media control. (C) Protease activity at 48 hours minus the media 
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Keloid cells have a number of features thought to contribute to the pathology; here the ability of 
I-BET151 to mediate some of these, including proliferation, collagen gene expression, 
contraction and protease activity, were investigated.  
Firstly, the impact of BET inhibition on fibroblast proliferation was assessed by counting cells 
after 72 hours of I-BET151 treatment. This experiment showed a significant decrease in 
proliferation in both NDF and KDFs, although I-BET151 treated wells still had around half the 
cells of the vehicle control at this timepoint. This was further confirmed with the presence of 
around 35-45% Ki67 positive cells after 24 hours of I-BET151 treatment, with a percentage 
decrease compared to the vehicle control of around 35-40%. Remarkably, even at a 10µM dose 
of I-BET151, approximately 20-30% of fibroblasts were Ki67 positive, indicating that a subset 
of fibroblasts could be resistance to BET inhibition. 
An anti-proliferative effect of BET inhibition has been reported in a range of cell types 
including cancer cells from prostate cancer (Asangani et al., 2014), myeloma (Chaidos et al., 
2014), colon cancer (Hu et al., 2015) and glioblastoma (Ishida et al., 2017), as well as cells 
from fibrotic conditions such as liver fibrosis (Ding et al., 2015) and lung fibrosis (Tang et al., 
2013a). In general, the anti-proliferative effect of BET inhibition is reported to be due to a 
downregulation of MYC (Delmore et al., 2011). However the role of MYC is not entirely clear 
in fibroblasts due to its diverse downstream targets (Soucek and Evan, 2011). Although it has 
been shown that MYC can promote proliferation (Hanson et al., 1994), it has also been shown 
to increase resistance to apoptosis in low serum conditions (Evan et al., 1992). MYC is reported 
to be both increased (Hu, Lou and Luo, 2002; Jiao et al., 2016) and decreased in keloid cultures 
(Cohly et al., 2002) and we have not investigated whether the anti-proliferative effects of BET 
inhibition in this study are due to an effect on MYC expression.  
Resistance to BET inhibition has now been reported in some cancers, where a subset of a 
heterogeneous tumour cell population subverts the BET-mediated c-Myc transcription that is 
responsible for driving cell cycling (Settleman, 2016). In triple negative breast cancer this 
occurs through the non-bromodomain binding of BRD4 to another transcriptional regulator 
MED1 which can then act to bind and drive transcription of MYC (Shu et al., 2016). 
Alternatively, in acute myeloid leukaemia, cells can overcome the need for BRD4 interaction 
completely, instead activating MYC through β-catenin via Wnt signalling (Rathert et al., 2015). 
The finding that some fibroblasts in our model are still cycling could also indicate that there is 
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similar heterogeneity in this cell population that is retained in culture, with differing abilities to 
overcome BET inhibition and continue proliferating.  
To understand the reversibility of the BET mediated decrease in proliferation, wash-out 
experiments were conducted where cells were first treated with I-BET151 or vehicle control for 
24 hours followed by washing and removal of the inhibitor and continued culture for up to 48 
hours. This experiment illustrated the recovery of active proliferation marked by Ki67 protein 
levels. The prolonged Ki67 reduction in KDFs, along with the slightly reduced number of KDFs 
compared to NDFs after 72 hours of I-BET151 treatment, suggests that KDFs may have a 
slightly higher sensitivity to I-BET151 in terms of the proliferative response. We do not have 
information regarding binding stability of this drug to the bromodomain of BET proteins, but 
GSK describe this inhibitor as fully reversible on a timescale measured in minutes. If the 
increased sensitivity of KDF proliferation in response to I-BET151 holds true, it could reflect 
possible differences in the factors driving cellular proliferation and potentially varying 
mechanism of action of this drug which could offer a useful therapeutic advantage in vivo.  
Interestingly, despite some reports that keloid fibroblasts may be more proliferative (Calderon, 
Lawrence and Banes, 1996; Satish et al., 2004; Blažić and Brajac, 2006) and especially given 
the sheer size of keloid scars, there was no observable difference in proliferation between NDFs 
and KDFs in this project. If anything, there may be a slightly lower proliferation rate in KDFs as 
evidenced by lower cell counts and Ki-67 percentage in vehicle controls. NDFs may have 
increased proliferation due to the unnatural environment of in vitro culture. In particular, the 
cells were grown in 10% serum which contains a range of proteins including growth factors that 
are well established to promote proliferation (Iyer et al., 1999; Pohlers et al., 2009). This 
promotes the unnaturally proliferative behaviour of fibroblasts in culture. The slightly slower 
growth rate of KDFs may also be due to missing co-stimulatory factors that promote 
pathological proliferation in vivo. For example, fibroblast proliferation may be driven by other 
cell types are important in keloid pathology and direct interactions with these cells or their 
secretions such as basal keratinocytes (Werner, Krieg and Smola, 2007) or immune cells 
(Wynn, Yugandhar and Clark, 2013). Numerous factors are well recognised to stimulate keloid 
proliferation, such as IL-6 (Lim et al., 2006), PDGF-BB (Bonner et al., 1990) and TGF-β1 
(Clark et al., 1997) which can be produced in an autocrine or paracrine manner.  
Conditioned medium from KDFs was not able to promote the proliferation of NDF cultures 
(Russell et al., 1988). This suggests that what promotes fibroblast proliferation in vivo is 
produced by alternative cellular source, or there is differences in NDFs and KDFs in their 
ability to sense and trigger signalling after cytokine or growth factor stimulation (Satish et al., 
2004). This paper also postulates that KDFs may be more similar to foetal cells and express 
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growth promoting genes (Russell et al., 1988) although the identity of these genes was not 
described.  
It is also hypothesised that KDF proliferation in vivo is exacerbated by a lack of apoptosis; there 
is less apoptosis in keloid tissue by in situ hybridisation (Sayah et al., 1999) and cultured KDFs 
are more resistant to ceramide triggered apoptosis than NDFs (Ishihara et al., 2000). Although 
apoptosis was not directly assessed after BET inhibition in this work, it has been shown in 
multiple cells types that BET inhibition can induce apoptosis, which again may be mediated 
through c-myc (Baker et al., 2015; Jostes et al., 2016). Although BET inhibition did not appear 
to cause notable apoptosis in our homeostatic cultures (no nuclei blebbing or floating cells 
seen), it would be interesting to measure apoptosis in our cultures after BET inhibition by 
examination of markers such as caspases following an insult that would promote cell death, with 
the hypothesis that BET inhibition may abrogate KDF resistance to apoptosis. 
We saw some evidence that BET inhibition can reduce collagen transcripts in some donors, in 
particular in KDFs, especially COL3A1. However, at the protein level there was no change in 
collagen I secretion in supernatants and unexpectedly KDFs showed decreased collagen I 
compared to NDFs. This may be because most collagen that is secreted is not soluble and is 
instead deposited onto the cell culture plate, or that the length of treatment is not long enough to 
see a substantial difference at the protein level. Further analysis could be done to look at cell 
lysates that are scraped directly from plates to capture this deposited collagen. Reduced collagen 
has been observed by others at the RNA and protein level in renal interstitial fibroblasts after I-
BET151 treatment although the concentration was increased to 5µM to see a strong effect 
(Xiong et al., 2016). Decreased COL1A1 transcript has also been reported after BET inhibition 
in TGF-β1 treated lung fibroblasts (Tang et al. 2013b). Interestingly, a study in pancreatic 
stellate cells saw a decrease in collagen RNA and protein after treatment with I-BET151 or 
siRNA against BRD4, however siRNAs against BRD2 or BRD3 increased expression of matrix 
proteins (Kumar et al., 2017).  
We next examined the effect of I-BET151 on cellular contractility using a collagen gel 
contraction model. We observed a statistically significant decrease in contraction after 72 hours 
of I-BET151 treatment. Increased contractility contributes to other fibrotic conditions such as 
scleroderma (Chen et al., 2005) and scarring trachoma (Kechagia et al., 2016) and could have 
relevance in keloids although the evidence for this is scant. Undoubtedly, contractile forces are 
important during wound repair (Hinz, 2007) and persistence of this tension can exacerbate 
‘normal’ scarring (Hinz et al., 2012). Keloid scars are often characteristically taut and stretched 
across areas of skin tension and are more likely to form at sites of high tension such as the 
sternum or shoulders (Gauglitz et al., 2011). Reducing tension in this context may give benefit 
in reducing mechanosensitive pathways, such as Rho and Erk signalling (Kenny and Connelly, 
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2014), and reducing clinical pain (Bordoni and Zanier, 2013). Stretching tension at wound 
edges has also been associated with the outgrowth of keloid tissue and therefore have seeded the 
use of compression dressings to prevent keloid growth (Ogawa, 2017). Clinical reports of the 
advantageous effects of Botox treatment of keloid scars may be attributable to a reduction in 
tension (Robinson, Khadim and Khan, 2013) 
A plethora of cell behaviour and expression profiles have been linked with changes in tension. 
In particular, tension has been shown to increase fibroblast proliferation (Webb et al., 2006), 
decrease apoptosis (Aarabi et al., 2007) and increase myofibroblast differentiation (Hinz et al., 
2001). One particularly elegant study seeded NDFs and KDFs into a 3D model of in vivo 
tension, and showed increased proliferation, especially in KDFs, and increased expression of 
Hsp27, PAI-2 and ɑ2β1 integrin which appeared to mediate the proliferative response as 
knockdown of these factors prevented the tension mediated increase in proliferation (Suarez et 
al., 2014). Integrins are extremely important for mechano-sensing, allowing cells to bind to a 
range of matrix proteins and trigger downstream signalling leading to changes in cell behaviour 
(Kenny and Connelly, 2014); therefore it is likely relevant that keloid cells have been shown to 
express increased ɑ2β1 integrin compared to cells from both hypertrophic scar and normal skin 
(Szulgit et al., 2002). It would therefore be insightful to examine the expression of machinery 
for the adhesion to the collagen matrix which could affect the contractile ability of fibroblasts in 
both NDFs and KDFs with and without I-BET151 treatment. It is possible that BET inhibition 
could reduce the expression of this machinery (e.g. ɑ2β1 integrin) causing less adhesion to 
matrix and therefore less contraction. Indeed, scratch closure migration assays showed a trend 
for increased fibroblast migration after BET inhibition (data not shown) which may suggest a 
loss of adhesion molecules (Tamariz and Grinnell, 2002). 
The non-cellular environment could also impact on contractility. In vivo contractility can induce 
a positive feedback loop through the activation of latent, matrix-bound TGF-β1, which can go 
on to cause further myofibroblast differentiation and contraction (Wipff et al., 2007). Therefore 
contractility is a relevant and important cell behaviour to target, and it may be worth exploring 
the ability of I-BET151 to reduce contraction mediated by relevant growth factors (e.g. TGF-β1) 
or co-cultured with macrophages, which have been shown to accelerate scarring trachoma 
fibroblast contraction (Kechagia et al., 2016). 
Some KDFs had a higher contractile ability compared to NDFs with a reduced gel size in the 
vehicle controls. Although this was not statistically significant, this in vitro culture is anticipated 
to under represent the in vivo contractility of the cells which can be influenced by immune cell 
signals that are likely to be more abundant in the keloid environment compared to normal skin 
and scar (Bagabir et al., 2012a). It has been shown that platelets (Zagai et al. 2003) and 
eosinophils (Zagai et al., 2004) can induce collagen gel contraction by lung fibroblasts. 
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Macrophages may also contribute to the contractile phenotype, although depending on the 
model used it has been shown that macrophages can both exacerbate (Zhu et al., 2001; 
Kechagia et al., 2016) or inhibit fibroblast contraction in the resolving stages of wound healing 
(Newton et al., 2004). 
We found that both NDFs and KDFs expressed the myofibroblast, contractile marker ɑ-SMA at 
the mRNA level and this was decreased after 48 hours of I-BET151 treatment, suggesting a 
decrease in the myofibroblast phenotype of these cells. However, cells extracted from the 
collagen gels did not show any consistent change in ɑ-SMA protein levels following I-BET151 
treatment (data not shown). A recent study in the field of liver fibrosis found a reduction in ɑ-
SMA protein in hepatic stellate cells after JQ1 treatment (Ding et al., 2015). In further in vivo 
work they demonstrated a therapeutic benefit of BET inhibition in a model of liver fibrosis and 
attributed this to a decrease in the myofibroblast phenotype, although speculatively link this 
specifically to Brd4 despite using the BET family inhibitor JQ1 (Ding et al., 2015). Even more 
recently, I-BET151 has been shown to reduce both basal and TGF-β1 induced α-SMA in 
cultured renal interstitial fibroblasts (Xiong et al., 2016). They also showed more convincingly 
that this may be as a result of BRD4 in particular, since the same effect was seen with BRD4 
siRNA (Xiong et al., 2016). 
One IHC study suggested that only 45% of 40 keloid samples showed α-SMA expression, 
compared to 70% of the 40 hypertrophic scars examined (Lee et al., 2004) and this may simply 
reflect the mature stage of keloid development when histology was carried out. It is likely that 
keloid tissue has been growing for many months, if not years, at the point it is surgically excised 
and available for this analysis. In our sample collection, the mean age of scar was 6 years and 
the median was 5 years. Potentially, ɑ-SMA expression was expressed early in keloid formation 
but lost in a more mature scar. 
Another study indicated increased ɑ-SMA in hypertrophic scars compared to keloid scars, 
although this difference was lost upon in vitro culturing (Ehrlich et al., 1994). This is evidence 
that in vitro culturing in a monolayer on plastic affects ɑ-SMA expression in NDFs and KDFs, 
as has been seen in our western blot analysis that shows no difference in expression between the 
two cell types (data not shown) which is not unexpected. We postulate that this may be due to 
both a possible decrease in ɑ-SMA expression in KDFs and a possible increase in expression in 
NDFs due to the artificial culturing environment.  
In addition to the debatable absence or presence of ɑ-SMA in keloid pathology, the expression 
of this protein has also been reported to be dispensable for contraction in vitro in other disease 
contexts such as scarring trachoma (Kechagia et al., 2016). Therefore the mechanism of 
collagen gel contraction by these dermal fibroblasts, as well as the mechanism by which I-
BET151 reduces contraction may not be entirely dependent on ɑ-SMA. Instead, other actin-
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myosin networks could be important in fibroblast contraction (Hinz, 2007) and influenced by 
BET inhibition, the examination of which was outside of the scope of this project. 
It is possible that the inhibitory effect of I-BET151 treatment on collagen gel contraction was as 
a result of reduced proliferation; proliferation of cells within the gels was not directly measured, 
although the reduction of ɑ-SMA suggests a true anti-contractile effect of BET inhibition. 
Experiments to address this question further could include: seeding increasing amounts of 
fibroblasts in collagen gels to see if there is a linear correlation between cell number and 
contraction of the gel; running the contraction assay with the addition of the anti-proliferative 
agent such as mitomycin C to identify if I-BET151 can still decrease contraction independent of 
proliferation; and a collagen contraction assay seeded with a higher number of fibroblasts but 
measured over a shorter time span to eliminate proliferation as a variable. However, it has been 
previously shown that scarring trachoma fibroblasts have an intrinsically higher level of 
contractility than control fibroblasts in a collagen gel model, which was explicitly shown not to 
be dependent on cell proliferation or survival, although the mechanism for this increased 
contraction is unknown (Kechagia et al., 2016). 
Importantly, there is no evidence that the collagen gels were being degraded rather than 
contracted in our model, as a small number of gels were weighed on a fine balance and did not 
showed any difference in mass between vehicle control treated (i.e. contracted) and I-BET151 
treated (i.e. larger) gels (data not shown). Despite no evidence for degradation, MMPs have 
been shown to be important for collagen gel contraction by fibroblasts (Daniels et al., 2003) and 
we have also seen decreases in MMP production after I-BET151 treatment which could provide 
a mechanism for the reduced contractility we have observed and will be discussed next. 
When keloid tissue ex vivo models appeared to degrade the surrounding collagen gel, it was 
postulated that the cells within the tissue were producing proteases to cause this effect. 
Anecdotally, this response was more common in keloid scar than normal skin. We have two 
main hypotheses; firstly that it is due to an exacerbated response to the wounding inflicted by 
the biopsy punch or that it is be due to the proteolytic nature of keloid edge tissue. Upon 
biopsying, keloid cells may be inappropriately activated and upregulate the production of 
proteases causing the excessive degradation of the collagen gels we have observed. The 
abnormal ECM environment of pure collagen I itself, with different physical properties, may 
also induce specific protease production from cells. Unpublished non-cellular proteome data 
from the lab give strong evidence for an altered and unusual ECM content in keloids that may 
induce a differential protease production from resident cells even after removal from the 
environment. The variation in the basal level of protease production and activity in our models 
could also be reflective of different biopsy locations within the keloid. There has been almost no 
literature attention on spatial location of MMP expression as most approaches have studied 
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MMPs at mRNA or protein level in whole tissue without specifics of the location of biopsying 
such as the fibrotic core vs the actively growing margin. However, unpublished IHC work has 
shown spatial variation with increased expression of a number of MMPs at the edge region of 
keloid tissue, compared to very little expression within the core of the lesion (personal 
communications, Dr Zoe Drymoussi, QMUL). One study also showed increased MMP2 
expression in keloid scar at the edge of collagen bundles which could also facilitate this 
invasive, growing phenotype of the keloid edge region (Imaizumi et al., 2009). The edge region 
of the keloid is actively growing and has been described as locally ‘invasive’ (Muir, 1990; 
Ogawa, 2017) with the clinical definition of keloid scarring being that the scar expands outside 
the origin wound margin. Increased proteolytic activity, through increased proteases such as 
MMPs and/or decreased endogenous inhibitors such as TIMPs at this growing wound edge may 
serve as invasive and therefore pathological in terms of keloid outgrowth.  
Based on the hypothesis that the collagen was being degraded, additional experiments were 
undertaken to substantiate this interpretation. 24 hour supernatants from these ex vivo models, as 
well as from fibroblast monolayers, treated with I-BET151 or vehicle control were analysed by 
Luminex for levels of MMPs and TIMPs.  
The Luminex analysis confirmed heterogeneity in patient samples, both in whole tissue and in 
isolated fibroblasts cultures. Nonetheless, in terms of the basal level of expression, vehicle 
control KDFs showed lower levels of most MMPs and increased levels of TIMP-1, the most 
highly expressed inhibitor of MMP in these fibroblasts, compared to NDFs which at face value 
could contribute to excess matrix accumulation. Indeed when the proteolytic ratio was 
calculated from this data, by dividing total MMP by total TIMP, this confirmed slightly 
increased proteolytic capacity in NDFs versus KDFs, whilst conversely keloid tissue generally 
showed an increased proteolytic capacity compared to normal skin. 
The levels of MMPs measured in fibroblast monolayers may not be fully representative of their 
in vivo phenotype due to the absence of a secretory signals such as PDGF-BB (Bauer et al., 
1985), TGF-β1 (Edwards et al., 1987) and IL-6 (Dasu et al., 2003),  or direct interaction to other 
cell types that could be present in vivo that may induce protease expression in fibroblasts. For 
example it is also thought that mast cells can interact directly with fibroblasts to induce MMP-9 
production through Erk signalling (Abel and Vliagoftis, 2008) which have also been reported as 
present in keloid scars (Bagabir et al. 2012a). 
It would therefore be interesting to treat cells with such wound-associated signals to explore 
NDF and KDF capability to produce MMPs upon stimulation and the capability of I-BET151 to 
mediate this. Incubation of fibroblasts with pro-inflammatory macrophages is reported to 
increase production of MMP-1, MMP-2, MMP-3, MMP-14 and TIMP-1 with an overall 3 fold 
increase in proteolytic activity (Ploeger et al., 2013). Notably this effect was mitigated by the 
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addition of conditioned media from M2 macrophages (Ploeger et al., 2013) suggesting that the 
balance of inflammation in the keloid environment may affect MMP production in fibroblasts to 
cause the potentially elevated levels of protease activity we have seen in whole keloid tissue.  
Indeed within the ex vivo culture models there are a range of cell types that can contribute to 
MMP production such as immune cells which are known to produce MMP8, MMP9 and 
MMP14 for example (Rohani and Parks, 2015). It is true that the comparison of normal skin and 
keloid tissue biopsies is problematic as keloid tissue is likely to be more cellular including a 
strong immune cell presence and have a greater depth with a thicker epidermis. However, this 
does make the equal or even slightly lower level of TIMP in keloid tissue vs normal skin tissue 
particularly striking.  
Despite heterogeneity amongst the patient tissue and cells, I-BET151 generally decreased the 
production of MMPs with no clear effect of TIMPs in all cultures. The most striking effect was 
the substantial decrease in proteolytic ratio after I-BET151 treatment, in both normal skin and 
keloid scar, and in NDFs and KDFs. In addition, the zymography experiment, despite showing 
heterogeneity between patient samples, also showed a decrease in proteolytic activity of NDFs 
and KDFs after I-BET151 treatment. 
There have been some limited observations of MMP changes after BET inhibition in the 
literature including one publication that showed a reduction in TNFα and IL-1β induced 
production of MMP1 and MMP3 in synovial fibroblasts (Klein et al., 2014).  In this case, MMP 
activity is pathological as it contributes to the matrix destruction characteristic of RA. This 
paper eludes to these MMP differences being as a secondary result of the anti-inflammatory 
nature of BET inhibition. However, another study has shown a reduction in MMP2 and MMP9 
after BRD4 knock down, which was a result of reduced signalling through the Sonic hedgehog 
pathway (Wang et al., 2015). Furthermore, a phosphorylation dependent activity of Brd4 has 
been shown to directly induce MMP9 expression through chromatin recruitment of AP-1 and 
NF-κB (Wu et al., 2016). It is possible that the downregulation of MMP we have seen is due to 
a decrease in AP-1 activity, as RA synoviocytes treated with JQ1 show a strong downregulation 
of the AP-1 subunit c-Jun (Zhang et al. 2015) and AP-1 is a well-established, common regulator 
for almost MMPs (Benbow and Brinckerhoff, 1997).  
The decrease in proteolytic activity seen after I-BET151 in our models may also have relevance 
in other diseases, as although an increase in MMP:TIMP ratio has been associated with scar free 
healing in studies in mammalian foetuses (Dang et al., 2003), it has also been associated with 
oncogenic tumour growth and metastasis (Deryugina and Quigley, 2006; Shay, Lynch and 




Differential responses to I-BET151 were seen in whole tissue versus fibroblast cultures, with an 
interesting difference between normal skin and keloid scar. MMP3, MMP7, MMP10 and 
MMP13 were regulated by I-BET151 in a similar manner in both normal skin tissue and NDFs, 
whereas these MMPs were all downregulated in KDFs whilst being relatively unaffected in 
keloid tissue. As has been previously discussed, keloid tissue may have a different cellular 
composition, especially in terms of immune cells and keratinocytes, which are capable of 
producing a range of MMPs (Kähäri and Saarialho-Kere, 1997). It is known that the effects of 
BET inhibition are highly cell specific (personal communications, GSK) and so the variety of 
cellular sources for MMP may explain this differential response to BET inhibition. 
Interestingly, these four MMPs had a very strong positive correlation in keloid tissue unlike in 
normal skin suggesting they may be produced by a common cell type abundant in keloids. 
There is a large volume of conflicting literature surrounding the presence or absence of MMPs 
and their subsequent role in keloid aetiology. This leaves a confusing picture of MMP 
contribution to keloid scar initiation and growth. However, given the hypothesis that MMP 
activity may be increased at the actively growing edge of the keloid lesion, whilst decreased in 
the fibrotic core, the ultimate goal of an epigenetic approach in this context would be to raise 
proteolytic activity in the fibrotic core of the keloid whilst decreasing proteolytic activity at the 
growing edge. This ‘tailored’ approach would be superior to the widely studied MMP inhibitors, 
many of which have failed clinical trials in cancer, due to off-target effects of pan-MMP 
reduction which may due to the impact on the ‘good’ and ‘bad’ effects of MMP activity 
(Fingleton, 2008). 
A key limitation of this project was the lack of stratification of samples between the keloid core 
and keloid edge regions which are likely to have distinct characteristics, such as increased 
proteolytic activity, cellular metabolism, or proliferation at the invasive, actively growing edge, 
compared to the hypoxic, matrix dense keloid core. In future work, it would be pertinent to 
increase sample stratification to address this, and to further understand the effect of BET 






Chapter 5: Investigating the effect of BET protein 
inhibition on differential IL-6 signalling in keloid scars 
 
5.1. Introduction   
 
In resting human skin, IL-6 is generally restricted to the epidermal layer (Romero and Pincus, 
1992). Upon stimulation or wounding, IL-6 can be produced as part of the acute phase response 
(Gruys et al., 2005; Murphy, Travers and Walport, 2008). It is thought that keratinocytes 
produce much of this IL-6, but other key players include fibroblasts and immune cells such as 
macrophages and mast cells (Paquet and Pierard, 1996). Additionally, it has more recently been 
found that melanocytes, which were previously thought to be immunologically ‘inert’, are also 
capable of producing IL-6 in vitro when stimulated with IL-1β (Tam and Stępień, 2011).  
The importance of IL-6 in wound repair is shown by the substantial delay of wound healing in 
IL-6 deficient mice, which show slower re-epithelisation, less granulation tissue formation and 
less inflammatory influx (Luster, 2000). This effect was reversed with the addition of 
recombinant IL-6. The same group later showed that the addition of recombinant IL-6 could 
also rescue delayed healing in immunosuppressed mice (Gallucci et al., 2001). 
Despite its importance in normal wound healing, high levels of IL-6 has been associated with 
fibrosis by propagating a chronic inflammatory state (Fielding et al., 2014). This suggests the 
precise temporal regulation of IL-6 in healing wounds is important for successful wound repair 
without the development of fibrosis or scarring. 
In the early 1990s it was shown that IL-6 stimulation of human dermal fibroblast cultures could 
induce the production of collagen (Duncan and Berman, 1991). Although the authors postulated 
that this could be driving pathology in some skin diseases, they stated there was currently no 
evidence for overzealous IL-6 production in diseased fibroblasts and these cells are responding 
in a paracrine manner to IL-6 produced by another cellular source. 
Evidence for increased IL-6 in keloids compared to normal skin and normal scars has 
accumulated in the past two decades (Xue, McCauley and Zhang, 2000; Ghazizadeh et al., 
2007; Zhang et al., 2009). There is only a single paper suggesting a chronic presence of system 
IL-6 in keloid patients, with elevated IL-6 in patient PBMCs compared to healthy controls 
(McCauley et al. 1992). This is not surprising given that keloid scarring tends to be an 
anatomically isolated clinical issue, with no general inflammatory phenotype. It is likely that IL-
6 is locally dysregulated, as has been proposed in conditions including systemic sclerosis 
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(Paquet and Pierard, 1996). There are no reports for wounding experiments in IL-6 
overexpression mice, however at rest these mice are not thought to have substantial skin 
phenotypes, with the exception of a thickened stratum corneum layer (Turksen et al. 1992). It is 
therefore difficult to predict the effect of elevated IL-6 in the scenario of keloid scarring, 
although it has been shown that inhibition of IL6r in KDFs could reduce ECM production and 
proliferation (Ghazizadeh et al., 2007).  
The current literature in the keloid field, plus evidence from other disease fields including 
systemic sclerosis (Khan et al., 2012), suggests that IL-6 may have importance in keloid 
biology, specifically driving fibroblast behaviour including collagen production and 
proliferation (Zhang et al., 2005; Ghazizadeh et al., 2007; Yu et al., 2014). Although typically 
thought to exert its effects through Stat3, other downstream pathways including those driven by 
Erk and Akt could also have a part to play in cellular responses to IL-6 (Wegiel et al., 2008; 
Rodriguez-Berriguete et al., 2010). Given that IL-6 is a cytokine that appears to be consistently 
upregulated in keloids in several studies, it has become an increasingly attractive therapeutic 
target, in spite of limited evidence about its effects. 
BET protein inhibition has been demonstrated to decrease NF-κB mediated transcription, 
including IL-6, which is thought to be mediated mainly through BRD2 in melanoma cells 
(Gallagher et al., 2014) and BRD4 in lung epithelial cancer cells though direct interaction with 
RelA  . Additionally, it has been found that BET proteins can drive transcription of IL-6 by 
specifically regulating the binding of CBP to the IL-6 promoter region and this can be blocked 
with BET inhibition (Belkina, Nikolajczyk and Denis, 2013; Barrett et al., 2014).  
This chapter therefore investigates IL-6 expression and activity in keloids and the effect of BET 
inhibition on this with the following key objectives: 
1. Confirm elevated IL-6 production in keloid tissue and keloid dermal fibroblasts as 
reported in the literature 
2. Investigate the ability of NDFs and KDFs to respond to IL-6 
3. Explore the effect of BET inhibition on IL-6 production and downstream signalling in 
dermal fibroblasts 
Experiments were conducted in both 10% serum, as per usual tissue culturing conditions and 






5.2.1.  IL-6 production is increased in both keloid tissue and 
keloid dermal fibroblasts 
 
The first part of this study aimed to confirm whether keloids have elevated IL-6 production, as 
has been previously described in the literature (Xue, McCauley and Zhang, 2000; Uitto, 2007; 
Zhang et al., 2009). Supernatants were taken after 24 hours of culture of fibroblast monolayers. 
Supernatants were also taken after 24 hours of culture of tissue ex vivo models as used for the 
previous Luminex analysis. An IL-6 DuoSet ELISA kit from R&D Biosystems was used to 
measure levels of IL-6 in these supernatants plated neat and at 1:10 dilution in reagent diluent 
(1% BSA in PBS). Absorbance results at 420nm for each sample were compared to the standard 
curve. 
This analysis did confirm elevated levels of IL-6 production in keloid tissue ex vivo cultures 
compared to normal skin (Figure 5.1A), as well as significantly increased IL-6 production in 
KDF cultures compared to NDF cultures (Figure 5.1B).  
As culturing cells with serum may induce the production of cytokines including IL-6 (Chang et 
al., 2004), IL-6 production by fibroblast monolayers in serum free conditions was also analysed 
in a single NDF and KDF line at 24 hours (Figure 5.1C). 72 hour supernatants were also 
analysed as these cultures were expected to produce much lower levels of cytokines. Indeed, it 
was found that fibroblasts in serum free conditions around 10 fold less IL-6 than in 10% serum, 
but cytokine production was still markedly higher in the KDF line. IL-6 was below the level of 
detection in the NDF line until 72 hours of culture, whereas 3.2ng/ml of IL-6 was detected in 





Figure 5.1 - Elevated IL-6 in keloid tissue and fibroblast cultures. IL-6 ELISA of 24 hour 
supernatants from n=7-9 normal skin and keloid scar ex vivo cultures (A) and n=8 NDF and 
KDF cultures in 10% serum (B) ** = p<0.005, Mann-Whitney test, mean +/- SEM) and of 24 
hour and 72 hour supernatants from a NDF and a KDF culture in both 10% serum and serum 
free conditions (C), where IL-6 production in serum free NDF culture was undetectable at 24 





5.2.2.  In serum free conditions, KDFs have elevated basal pStat3, 
reduced by IL-6r blockade, and elevated pStat3 induction after IL-6 
stimulation 
 
To examine the level of signalling downstream of IL-6 in three possible downstream pathways 
that may mediate the cytokine response (Stat3, Erk and Akt), cells were cultured in both 10% 
serum and serum free conditions before ligand-stimulated activation of each pathway was 
analysed by western blot. Briefly, three NDF and KDF lines were cultured in 10% serum and 
serum free conditions for at 24 hours before treating with 10ng/ml human recombinant IL-6 for 
30 minutes and protein lysis. Blots were probed for the phosphorylated form of each signalling 
molecule as readouts of the three potential downstream pathways as well as GAPDH as a 
loading control. Blots were then stripped with a mild stripping buffer for 20 minutes before 
washing and re-probing for the total form of each signalling molecule. 
Then, to explore whether IL-6 was responsible for driving elevated basal signalling of these 
three pathways in KDFs, Tocilizumab was used to block IL-6 signalling in fibroblast cultures. 
Tocilizumab is a blocking antibody which can target and block IL-6r in both membrane bound 
and soluble form and is used in the clinic for inflammatory arthritis including Rheumatoid 
Arthritis (Jones and Ding, 2010). NDFs and KDFs in 10% serum and serum free conditions 
were treated for 72 hours with increasing concentrations of 1, 10 and 100µg/ml of Tocilizumab, 
based on literature review (Suzuki et al., 2010; Oguro et al., 2013; Sakkas, 2016) and personal 
communications with colleagues who frequently use this antibody. 
Firstly, Stat3 signalling was examined. In 10% serum conditions, it was observed that IL-6 
stimulation was able to increase pStat3 levels in all NDFs and 2 out of 3 KDFs tested. However, 
there was no observable difference between NDFs and KDFs in 10% serum conditions, in terms 
of basal or IL-6 stimulated levels of pStat3 (Figure 5.2). The removal of serum from the system 
revealed more discrete differences between the NDFs and KDFs tested; all 3 KDFs showed 
heightened basal pStat3 with no observable pStat3 band in NDFs in this condition even with a 
20 minute blot exposure. In serum free conditions, IL-6 stimulation caused a modest induction 
of pStat3 but generally showed a greater induction in KDFs.  Blockade of IL-6r by 72 hours of 
Tocilizumab treatment caused some reduction in basal pStat3 levels at increasing doses (Figure 
5.3) although this was most striking in KDFs in serum free culture (Figure 5.3B). However, 
detectable levels of pStat3 were still observed even with Tocilizumab treatment at a 





Figure 5.2 -  Western blot showing basal Stat3 signalling and after acute IL-6 simulation 
in dermal fibroblasts. n=3 NDF and KDF cultured in 10% serum and serum free conditions 
were lysed after a 30 minute stimulation with 10ng/ml IL-6. Blots were probed for pStat3, Stat3 











Figure 5.3 - IL-6r blockade reduces basal pStat3 in NDFs and KDFs. Western blot of NDF 
and KDF cultures in 10% serum (A) and serum free conditions (B) treated for 72 hours with 
increasing concentrations of the IL-6r blocking antibody Tociluzumab. Blots were probed for 
pStat3, Stat3 and GAPDH in order to identify the contribution of IL-6 in these cultures for 
driving basal pStat3 activity. 
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5.2.3.  Only KDFs in serum free conditions activate pErk 
following IL-6 stimulation and decrease pErk after IL-6r blockade 
 
Next, Erk signalling was examined, stripping of the pErk1/2 was deemed unsatisfactory, so 
GAPDH alone was used as a control for these blots (Figure 5.4). In 10% serum conditions, 
although there were higher basal levels of pErk in 2 out of 3 KDFs compared to NDFs, 
phosphorylation was not affected by IL-6 stimulation in either cell type (Figure 5.4). Whereas 
in serum free conditions, there was no difference in basal pErk in KDFs compared to NDFs, but 
KDFs had some induction after IL-6 stimulation which wasn’t seen in NDFs (Figure 5.4).  
Again, the effect of blocking IL-6 driven Erk signalling was examined in Tocilizumab treated 
cells. In 10% serum conditions, there was no effect of Tocilizumab in NDF or KDF, although 
basal levels were fairly low in these cultures (Figure 5.5A). However, in serum free conditions, 
Tocilizumab did reduce pErk in the KDF line at the lowest dose with no concentration response 




Figure 5.4 - Western blot showing pErk signalling at the basal level and after acute IL-6 
stimulation in dermal fibroblasts. n=3 NDF and KDF cultured in 10% serum and serum free 
conditions were lysed after a 30 minute stimulation with 10ng/ml IL-6. Blots were probed for 











Figure 5.5 - Consequence of IL-6r blockade on basal pErk in NDFs and KDFs. Western 
blot of NDF and KDF cultures in 10% serum (A) and serum free conditions (B) treated for 72 
hours with increasing concentrations of the IL-6r blocking antibody Tociluzumab. Blots were 
probed for pErk1/2 and GAPDH in order to identify the contribution of IL-6 in these cultures 
for driving basal Erk1/2 activity. 
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 5.2.4.  KDFs in serum free conditions have higher basal and IL-6 
stimulated pAkt, which is absent in NDFs, but no effect of IL-6r 
blockade on basal pAkt levels is observed 
 
Lastly, analysis of Akt stimulation was assessed (Figure 5.6). In 10% serum conditions, there 
was elevated basal pAkt levels in 2 out of 3 KDFs compared to NDFs and a small induction of 
pAkt after IL-6 stimulation across all cultures.  
However, in serum free conditions, strikingly there was an absence of pAkt in NDFs basally and 
after IL-6 stimulation, whereas KDFs showed some basal pAkt and a marked increase after IL-6 
stimulation (Figure 5.6). This IL-6 induced pAkt was highest in the same KDF that also had a 
strong induction of pStat3 in these conditions (Figure 5.2). 
Tocilizumab treatment had no effect on pAkt, in NDFs and KDFs in 10% serum or serum free 





Figure 5.6 - Western blot showing basal and IL-6 stimulated pAkt signalling in dermal 
fibroblasts. n=3 NDF and KDF cultured in 10% serum and serum free conditions were lysed 
after a 30 minute stimulation with 10ng/ml IL-6. Blots were probed for pAkt, Akt and GAPDH 











Figure 5.7 - Consequence of IL-6r blockade on basal pAkt in NDFs and KDFs. Western 
blot of NDF and KDF cultures in 10% serum (A) and serum free conditions (B) treated for 72 
hours with increasing concentrations of the IL-6r blocking antibody Tociluzumab. Blots were 
probed for pAkt, Akt and GAPDH in order to identify the contribution of IL-6 in these cultures 
for driving basal Akt activity.  
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5.2.5.  KDFs show elevated levels of IL-6r in serum free 
conditions compared to NDFs 
 
Due to the dramatic differences seen in the signalling response to IL-6, especially in serum free 
conditions, the abundance of IL-6r was analysed in NDFs and KDFs. Cells were cultured for 24 
hours prior to RNA extraction and RT-PCR. Primers published in (Vermes et al., 2002) were 
used to distinguish both the full-length IL-6r (219bp) as well as the shorter length IL-6r (125bp) 
spliced isoform that gives rise to soluble IL-6r. Primers for ESP8 were also used as a reference 
gene. THP-1s were used as a positive control as they are known to express both forms of the 
receptor (Jones et al., 1998). A 35 cycle PCR was conducted on 50ng of cDNA (further 
described above). PCR products were then run on a 2% agarose, Diamond-Dye containing gel 
alongside one well of Low Molecular Weight ladder to approximate product size. Gels were run 
for ~2 hours at 100V before visualisation. 
In 10% serum conditions, it was apparent that NDFs and KDFs both expressed similar amounts 
of IL-6r transcript, with a low level of spliced isoform expression (Figure 5.8A). Band intensity 
was quantified and no difference between NDF and KDF IL-6r expression was identified 
(Figure 5.8B).  
The PCR was then repeated in serum free conditions. In both cases, serum removal induced IL-
6r expression (Figure 5.8C), however this was much more notable in KDFs which mirrored the 
increased signalling in response to IL-6 stimulation in serum free conditions (Figure 5.8D). 
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Figure 5.8 - IL-6r mRNA expression in NDFs and KDFs. (A) Full length IL-6r and the 
spliced isoform of IL-6r (which would generate the soluble form) were analysed by semi 
quantitative RT-PCR in n=4 NDFs and KDFs as well as THP-1 as a positive control. This result 
was then quantified (B) using ImageLab software, normalising band intensity of the sum of the 
two IL-6r bands to the intensity of the ESP8 band in n=4 NDFs and KDFs. (C) IL-6r was 
analysed by semi quantitative RT-PCR in n=2 NDFs and KDFs which were cultured in 10% 
serum or serum free conditions for 24 hours, as well as THP-1 as a positive control. Separation 
of full length IL-6r and the spliced isoform was not successful in this PCR. This was also 
quantified using ImageLab software (D).  
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Flow cytometry was then used to examine IL-6r protein expression in an NDF and a KDF line 
cultured in 10% serum or serum free conditions. To capture both surface bound and internalised 
receptor, cells were split into two groups for extracellular and intracellular staining. It was 
postulated that due to the high level of IL-6r recycling (Zohlnhöfer et al., 1992), intracellular 
staining would increase our ability to detect small differences in expression between NDFs and 
KDFs that may have biological significance. Intracellular staining was conducted by 
permeabilising cells with saponin to allow antibody internalisation. A REAfinity™ 
phycoerthyhin (PE) conjugated IL-6r antibody from Miltenyi Bio was used (clone REA291) and 
cells were also stained for viability using Fixable Viability Dye eFluor™ 506.  
Compensation and sample acquisition were undertaken with assistance from Celine Trouillet 
using the FACSCanto (BD Biosciences). The resulting .fcs files were analysed using FlowJo, 
whereby events were gated on live singlet cells by forward/side scatter and Live/Dead dye 
negativity (above). During preliminary analyses, it became obvious that whilst KDFs appeared 
somewhat different by forward and side scatter then NDFs, appearing larger and more auto-
fluorescent, the permeabilisation protocol also affected cell shape and fluorescence. Therefore, 
unstained and live-dead only controls were needed for each condition. 
IL-6r expression was relatively low, with high levels of autofluorescence and no clear positive 
or negative population. However, when expression was represented as a histogram, there was a 
shift in fluorescence intensity, and therefore expression, in permeabilised, serum free KDFs, 
above the level of the fluorescent-minus negative control (cells from the same condition, stained 
only with live/dead dye) (Figure 5.9A). To quantify this further, geometric mean of the MFI 
was calculated in Flowjo for each acquired sample. These values were tabulated for both the 
fluorescent minus negative control and the fully stained sample in each condition (Figure 5.9B).  
The level of expression above the fluorescent minus negative control was calculated by 
subtracting the geometric mean MFI of the negative control from the geometric mean MFI of 
the stained sample (Figure 5.9C). This showed that in non-permeablised cells only KDFs in 
serum free conditions showed detectable IL-6r expression. After saponin permeablisation the 
NDF and KDF lines in 10% serum and serum free conditions all had some detectable IL-6r. In 
these permeablised cells, serum removal approximately doubled the level of IL-6r expression in 
the KDF line tested, whilst having no clear effect in the NDF line.  
An ELISA was also used to measure sIL-6r levels in the supernatant of fibroblasts cultures. 
Despite using concentrated supernatants which were collected after 72 hours of culturing, sIL-6r 
was undetectable in fibroblast cultures, suggesting sIL-6r levels in this system must be below 
15.6pg/ml (data not shown). However, supernatants from the whole tissue ex vivo models were 
above this detection limit and did show increased production in keloid scar tissue compared to 

























Figure 5.9 - IL-6r expression in NDF and KDF. (A) Flow cytometry analysis of IL-6r 
expression in NDF and KDF grown in serum free conditions where fluorescent minus controls 
are cells stained with live/dead dye only. Cells were permeabilised prior to staining, events were 
gated on live, singlet cells and expression was plotted as histograms to visualise expression 
shift.  Mean fluorescence intensity (MFI) was tabulated as geometric mean for all samples 
including –ve controls (B). MFI was then plotted for NDF and KDF in 10% serum and serum 
free conditions in non-permeablised and permeabilised cells by subtracting the MFI value for 
















Figure 5.10 - sIL-6r protein expression in tissue ex vivo models. ELISA of 24 hour 
supernatants from n=4 normal skin and keloid tissue ex vivo cultures measuring sIL-6r levels 




5.2.6.  KDFs may have altered levels of GP130 and SOCS3 in 
serum free conditions compared to NDFs 
 
qPCR was then used to investigate whether there may be a change in expression of other 
important IL-6 signalling machinery. mRNA levels of the main negative regulator of IL-6 
signalling, SOCS3 (Croker et al., 2003), and the co-receptor for IL-6 and other cytokine 
signalling, GP130 (Silver and Hunter, 2010), were examined. In 10% serum conditions, 
statistically significant differences in expression were not confirmed although there was an 
indication that there was slight increased GP130 and a trend for a decreased level of SOCS3 
mRNA in a subset of KDFs compared to NDFs (Figure 5.11A & B). 
After serum starvation, different responses were seen in NDFs vs KDFs. Upon serum removal, 
all 3 NDFs decreased gp130 expression, whilst 2 out of 3 KDFs increased GP130 expression 
(Figure 5.11C). The effect of serum removal on SOCS3 was less clear, however there appeared 






Figure 5.11 - GP130 and SOCS3 mRNA levels in NDFs and KDFs. GP130 (A), the co-
receptor needed for IL-6 signalling , and SOCS3 (B), a key negative regulator of IL-6 
signalling, were analysed by qPCR and relative expression was calculated using a standard 
curve and normalised to the reference gene B2M, n=7, mean +/- SEM. GP130 (C) and SOCS3 
(D) were analysed by qPCR in n=3 NDFs and KDFs which were cultured in 10% serum or 
serum free conditions for 24 hours, relative expression was calculated using a standard curve 




5.2.7. I-BET151 can reduce IL-6 secretion by NDFs and KDFs 
 
Since BET inhibition had previously been reported to be anti-inflammatory (Belkina, 
Nikolajczyk and Denis, 2013), and BET proteins have been documented to interact with NF-κB 
signalling (Belkina, Nikolajczyk and Denis, 2013) and specifically the IL-6 promoter region via 
CBP (Barrett et al., 2014), the effect of BET inhibition on fibroblast IL-6 production was 
examined.  
NDFs and KDFs were treated with 1µM I-BET151 or 0.01% DMSO (vehicle control), for 24 
hours before analysing the level of IL-6 in the supernatants by ELISA. This analysis showed a 
statistically significant decrease in IL-6 in both NDF and KDF supernatants, with a particularly 
striking decrease seen in KDFs that had the most elevated IL-6 levels in the paired controls 
(Figure 5.12A). 
To briefly examine how the temporal dynamics of this inhibition, supernatants were taken from 
I-BET151 and vehicle treated wells of a single NDF line over a number of timepoints: 1, 2, 4, 8, 
24 and 72 hours (Figure 5.12B). The I-BET151 mediated decrease in IL-6 secretion was not 






















Figure 5.12 - Effect of BET inhibition on IL-6 secretion in NDFs and KDFs. IL-6 ELISA of 
(A) 24 hour supernatants from n=8 NDF and KDF cultures in 10% serum, treated with 0.01% 
DMSO or 1µM I-BET151, *, p<0.05 Mann-Whitney test. (B) Time course of NDF in 10% 





5.2.8.  I-BET151 can reduce IL-6 induced signalling in KDFs in a 
transcription-dependent manner 
 
Given the strong effect that I-BET151 appeared to have on IL-6 production, we next explored 
the effect of I-BET151 on downstream signalling. Cells were pre-treated with 1µM I-BET151 












Figure 5.13 - Schematic representing experimental setup to investigate BET inhibition 
effect on signalling.Diagram showing treatment regime for experiment to investigate the effect 
of BET inhibition on basal and IL-6 signalling through Stat3, Erk1/2 and Akt, cells were pre-
treated for 2 hours with I-BET151 or vehicle control, followed by 30 minute stimulation with 
IL-6 or vehicle control, still in the presence of absence of I-BET151. Protein was then lysed and 




A complete experiment with all four conditions in one NDF and one KDF line was run on a 
single western blot to directly compare the basal and IL-6 induced signalling activity in the two 
cell types. This experiment was repeated in both 10% serum and serum free conditions in n=3 
NDF and KDF lines. A representative blot is shown (Figure 5.14) and quantification was 
conducted for the pStat3 and pAkt response, normalised to GAPDH, in all three biological NDF 
and KDF replicates (Figure 5.15). Quantification was not possible for pErk due to blot quality 
and normalisation to GAPDH rather than the total form of each signalling molecule was chosen 
due to possible inefficient stripping before reprobing of blots. 
When examining IL-6 induced signalling pathways that were decreased after I-BET151 in 10% 
serum conditions, two KDFs showed decreased levels of two signalling pathways whilst only 
one NDF showed slight decreased levels of just one signalling pathway (Stat3) which is the blot 
shown (Figure 5.14). In 10% serum conditions there was a variable response to I-BET151 
(Figure 5.15). However, responses were variable and in some cases (one NDF and one KDF 
line), I-BET151 appeared to cause slight increased levels of IL-6 induced signalling (Figure 
5.15) 
In serum free conditions, the ability of I-BET151 to inhibit IL-6 signalling was much more 
striking in KDFs, with all three KDF showing decreases in multiple signalling pathways 
(Figure 5.14, Figure 5.15), whereas only one NDF showed any I-BET151 mediated decrease in 






















Figure 5.14 - Effect of BET inhibition on basal and IL-6 induced signalling. Representative 
western blot of NDF and KDF cultures treated with 1µM I-BET151 or 0.01% DMSO vehicle (2 
hour pre-treatment) before IL-6 treatment for 30 minutes. Blots were probed to examine the 





















Figure 5.15 - Summary of effect of BET inhibition on basal and IL-6 induced signalling. 
Summary of the effect of 1µM I-BET151 on IL-6 induced Stat3 and Akt activation in 10% 






As BET has known interactions with histone and non-histone proteins (Xu and Vakoc, 2014; 
Xiao et al., 2015), it was unclear whether the I-BET151 mediated decrease in signalling was 
dependent on transcriptional changes. To explore this, Actinomycin D was used as a 
transcriptional inhibitor. Actinomycin D is a bacterial compound that intercalates into DNA and 
prevents the progression of RNA polymerase (Koba and Konopa, 2005). Historically it has been 
used as a chemotherapy drug, however it has been used in laboratory experiments as a 
transcriptional inhibitor since the 1970s (Koba and Konopa, 2005).  
To determine an appropriate dose of Actinomycin D in our model, an NDF line was treated with 
increasing concentrations of Actinomycin D based on previous literature for 2.5 hours. RNA 
was isolated, cDNA generated and qPCR was conducted. SOCS3 was chosen as a readout of 
inhibition because literature suggested rapid degradation of this transcript within the time span 
of this experiment (Siewert et al., 1999). B2M was also analysed as a reference gene. This pilot 
analysis suggested that the two highest concentrations were the most effective at reducing 
transcription (Figure 5.16A). 
Then, a KDF line in 10% serum conditions was treated as Figure 5.13, but in the absence or 
presence of 1µg/ml or 2µg/ml Actinomycin D throughout the experiment (added at the same 
time as I-BET151). Again, protein was lysed and analysed by Western blot. It was found in the 
absence of Actinomycin D as expected there was an increase in pStat3 upon IL-6 stimulation 
and a decrease when treated with I-BET151 (Figure 5.16B). However, in the presence of 
Actinomycin D, the effect of I-BET151 was lost. Also, there was some indication that in the 
presence of 1µg/ml Actinomycin D the resting level of pStat3 was decreased and the induction 
of pStat3 after IL-6 treatment was slightly increased, which could be linked to a decrease in 






Figure 5.16 - Effect of transcription inhibition on I-BET151 mediated signalling decrease. 
(A) qPCR was conducted on NDFs treated with increasing doses of the transcriptional inhibitor 
Actinomycin D for 2.5 hours to find an appropriate dose to prevent transcription in these cells. 
SOCS3 was chosen due to its short stability (~15 minutes). Relative expression was calculated 
using a standard curve and normalised to the reference gene B2M. (B) Western blot of KDF 
treated as described in Figure 1-13, +/- treatment with 1µM I-BET151 or 0.01% DMSO vehicle 
(2-hour pre-treatment) +/- 10ng/ml IL-6 stimulation, but in the absence and presence of the 
transcriptional inhibitor Actinomycin D (added at the same time as I-BET151) to examine 
whether the I-BET151 mediated decrease in signalling was reliant on transcription. Blots were 




 5.2.9.  I-BET151 causes a small reduction in IL-6r expression 
 
Having determined that the I-BET151 mediated reduction of signalling was likely due to a 
transcriptional change, we examined the effect of I-BET151 on IL-6r expression which we saw 
as a potential regulation point for signalling. RT-PCR was used to measure IL6r transcript 
following the 2.5-hour experiment depicted in Figure 5.13 in serum free conditions in a NDF 
and KDF line. 
As found previously (Figure 5.8C), the KDF showed higher IL-6r mRNA abundance than the 
NDF in serum free conditions. The 30 minute IL-6 stimulation did not affect expression of IL6r, 
however I-BET151 treatment did appear to reduce expression slightly in both the NDF and 
KDF (Figure 5.17). However, this reduction was relatively mild in comparison to the marked 
reduction in signalling and was similar in the NDF and KDF, suggesting that this is not a KDF 





Figure 5.17 - IL-6r expression after IL-6 stimulation and BET inhibition. Full length IL-6r 
and the spliced isoform of IL-6r (which would generate the soluble form) was analysed by semi 
quantitative RT-PCR in a NDF and KDF line in four conditions, treated as described in Figure 
1-13, +/- treatment with 1µM I-BET151 or 0.01% DMSO vehicle ( 2 hour pre-treatment) +/- 
10ng/ml IL-6 stimulation as well as THP-1 as a positive control (A). This result was then 
quantified (B) using ImageLab software, normalising band intensity of the sum of the two IL-6r 







 5.3.1.  IL-6 ligand production 
 
The increase in IL-6 production seen in both keloid tissue ex vivo cultures and in fibroblast 
monolayer cultures confirms what has previously been reported in multiple studies (Xue, 
McCauley and Zhang, 2000; Ghazizadeh et al., 2007; Zhang et al., 2009). Interestingly, there 
appears to be some stratification of patients with some IL-6 over-producers and some within the 
range of normal tissue. This was also mirrored in other Luminex data from the lab. Heightened 
IL-6 has been shown to be an indicator of poorer prognosis in cancer (Egler et al., 2008; Khan 
et al., 2012; Chen et al., 2013) and in systemic sclerosis (Khan et al., 2012), and therefore could 
be used as a factor to stratify patients. It would be valuable to better characterise the tissue from 
each keloid patient and correlate this to IL-6 production, for example by investigating whether 
IL-6 overproducing cells derived from keloids that are actively growing or particularly 
inflamed, to better understand what may drive, or be a consequence of, high IL-6 in keloids.  
Fibroblast cultures up to passage 7 were used in the analysis of IL-6 production suggesting that 
the ability of KDFs to produce increased levels of IL-6 is retained in their cellular ‘memory’. 
This may be due to priming in vivo by the keloid environment, including contact with other cell 
types. The current literature educates us on the strong memory of fibroblasts related to their 
anatomical origin (Ivanov et al., 2016) and previous mechano-stress (Yang et al., 2014), 
thought to be driven at least in part by exposure to environmental cues that cause epigenetic 
changes. Therefore, it is likely that the chronic inflammatory environment of a keloid scar also 
imparts some level of epigenetic ‘memory’ onto KDFs that results in behavioural changes that 
are retained in vitro. A pro-inflammatory memory has been described in synovial fibroblasts, 
from both healthy and diseased (RA) joints, whereby repeated proinflammatory cytokine 
stimulation (TNFɑ or IL-1ɑ) caused an increased inflammatory response with higher levels of 
IL-6 production (Crowley et al., 2017).  
Whilst KDFs produced around double the amount of IL-6 compared to NDF, keloid tissue 
produced around 10 times the amount of IL-6 compared to normal skin. The high level of IL-6 
produced in keloid tissue ex vivos may be reflected by the increased cellularity and/or increased 
depth of tissue biopsy, however it may also suggest that there are other cells present within the 
keloid tissue that are responsible for IL-6 production such as inflammatory macrophages 
(Bagabir et al., 2012a). The definite identity of IL-6 producing cells in keloids is difficult to 
ascertain given that we do not yet fully understand the cellular composition of these scars. 
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However, it does show that there are high levels of IL-6 in the keloid environment, which we 
have demonstrated that fibroblasts are capable of sensing. 
IL-6 production by the single NDF and KDF line in serum free conditions was much reduced 
(around 10 to 50 fold less) compared to 10% serum conditions, however it was still clear that 
the KDF culture could produce around double the amount of IL-6 compared to the NDF culture. 
Cellular cytokine production in serum free condition is much less characterised than in standard 
culturing conditions, especially in the keloid field. One studied found that in serum free 
conditions NDFs produced almost no TGF-β1 whereas KDFs produce moderate levels over a 72 
hour period (Hanasono et al., 2003). As TGF-β1 is known to drive IL-6 production in 
fibroblasts (Eickelberg et al., 1999), this may explain some of the disparity seen in IL-6 
production between NDF and KDF in serum free conditions. Serum may also stimulate 
fibroblasts in culture to become more inflammatory, and therefore produce more IL-6, as a part 
of a wound response to serum that has been previously described (Iyer et al., 1999). The 
possible activation of downstream signalling in both NDFs and KDFs was examined, at the 
basal level and after IL-6 stimulation, for three main signalling pathways: Stat3, Erk and Akt 
(Figure 1.6).  
 
 5.3.2.  Basal and IL-6 induced signalling  
 
Serum also appeared to activate fibroblasts, inducing higher basal pStat3 and pAkt in both 
NDFs and KDFs, although had little effect on basal pErk levels. The content of serum is 
somewhat uncharacterised, but is known to include a range of growth factors that may be 
capable of inducing both Stat3 and Akt signalling (Adi et al. 2001; Zhang et al. 2005). Many 
suggest that serum is very unnatural, cells are not bathed in serum in vivo, therefore the removal 
of serum enables us to look at a more simplified picture of signalling in the absence of any 
exogenous growth factors that may be present in serum. The removal of serum in our cultures 
has unravelled marked signalling differences that were not seen in 10% serum conditions. 
Additionally, the presence of 10% serum in culture dampened the effect of IL-6 stimulation on 
cell signalling, with only a small induction of pStat3, inconsistent induction of pAkt and no 
induction of pErk across the fibroblast cultures tested. The mean IL-6 production in the keloid 
ex vivo cultures was 4.6ng/ml, suggesting that the concentration of human recombinant IL-6 
used in stimulation experiments (10ng/ml) is appropriate. Upon serum removal, basal pErk was 
not affected in either cell type. Disparity in the serum starvation response has been observed in a 
study focussing on cancer that saw upregulation of phosphorylated protein and total protein 
(including Akt, Erk and Stat3 pathway proteins) in a range of glioma cell lines but not 
adenocarcinoma cell lines after serum starvation (Levin et al., 2010). The authors postulate that 
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this response is a molecular adaption to stress as the glioma cells also show resistance to 
apoptosis (Levin et al., 2010), which may be mirrored in keloids as resistance to apoptosis has 
also been reported.  
It is possible that IL-6 contributes to KDF basal pStat3 in serum free conditions as the IL-6r 
blocking antibody Tocilizumab reduced pStat3 levels in these cultures. However, there was no 
clear effect of Tocilizumab on pAkt levels, suggesting there is another intrinsic factor being 
released by fibroblasts, in the absence of serum, that is driving basal Akt signalling. There are a 
variety of other candidates that may be able to drive signalling including a range of cytokines 
(IL-9, IL-10, IL-11, IL-12, IL-17A, IL-27, TNFɑ, OSM, LIF, MCP-1) and growth factors 
(GCSF, GMCSF, HGF, EGF, FGF or PDGF). However, no IL-17A or IL-10 was detected in 
our fibroblast cultures by ELISA (data not shown), making their involvement unlikely. Similar 
experiments to the Tocilizumab investigation, using the tyrosine kinase inhibitor Imatinib 
showed some decrease in basal pAkt in both 10% serum and serum free conditions (data not 
shown), suggesting that PDGF-BB may be responsible for some of this signalling, although 
there was no effect on pStat3. 
In serum free conditions, NDFs had no detectable levels of pAkt or pStat3, whilst KDFs still 
showed low levels. Additionally, KDFs tended to induce higher levels of pStat3 than NDFs 
after IL-6 stimulation in serum free conditions. KDFs also responded to IL-6 stimulation in 
serum free conditions with an increase in pErk and a striking increase in pAkt that was 
completely absent in NDFs. It is possible that there is a component within serum that is 
blocking signalling triggered by IL-6 stimulation, however it is also possible that a component 
within serum drives basal signalling prior to IL-6 stimulation, which would in turn promote 
constitutive expression of a negative regulator of signalling. In this project, we have observed a 
possible decrease in SOCS3 expression after serum removal, although this was not consistent 
and was in limited replicates. The finding that NDFs and KDFs have disparity in their intrinsic 
signalling response to an external inflammatory stimuli may present important implications for 
keloid surgery, as ‘wounding’ of a keloid scar may not elicit the same inflammatory response 
seen in normal skin. 
 
 5.3.3.  Stat3 signalling  
 
All three signalling pathways were activated, to some extent, in KDFs in serum free culture in a 
way that wasn’t seen in NDFs. This indicates that these pathways could have some importance 
in keloid fibroblast behaviour and pathology. Stat3 is the most well characterised signalling 
molecule downstream of IL-6 and also the most studied in its role in keloid pathology. pStat3 
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has been reported to be upregulated in severe scars but appears to be inconsistent in some 
experiments, which in some cases may be due to serum in culture media as we have observed. 
pStat3 has been shown to be elevated in hypertrophic scar IHC however the interpretation of 
this data is difficult given the damage to tissue sections seen in this paper (Ray et al., 2013). 
More convincing evidence that pStat3 is elevated in keloid scars has been shown by IHC and 
western blot (Lim et al., 2006). This study also showed increased total Stat3 which may indicate 
a higher capability of these cells to induce Stat3 signalling after stimulation (Lim et al., 2006) 
although this is not something we observed in our western blot experiments. In a later study, the 
Lim group showed that in low serum conditions (0.5% serum) IL-6 as well as OSM caused 
induction of pStat3, although they saw no difference between NDFs and KDFs (Lim et al., 
2009). Increased pStat3 has been observed in a hypertrophic scar fibroblast line (HSDF) 
compared to an NDF line, and the authors also state that there was an increase in pStat3 in the 
HSDF after a co-stimulation with IL-6 and sIL-6r but the data for this experiment is not shown 
(Ray et al., 2013).  
Interestingly, a more complex co-culture system with patient-matched fibroblasts and 
keratinocytes has shown a decrease in pStat3 which indicates some level of negative regulation 
in this cell system, although they do not see the baseline differences between NDF and KDFs 
that we have observed (Lim et al., 2009). Additionally, although this is a more complex model, 
it may not be much more relevant to the in vivo scenario, given the other cells resident in 
keloids that may be contributing towards the production of IL-6 (and other activating analytes 
including sIL-6r) such as inflammatory macrophages, which could further drive Stat3 
signalling.  
Mechanistically, pStat3 is thought to be very important in a fibrotic context (Knight, Mutsaers 
and Prêle, 2011) and could indeed be relevant in keloid scars. It has been shown that Stat3 
activation can lead indirectly to Smad3/TGF-β signalling through the induction of the 
transcription factor Gremlin in systemic sclerosis skin fibroblasts (O’Reilly et al., 2014). Given 
the reports of overexpression of TGF-β1 in keloids (Jagadeesan and Bayat, 2007), this could be 
a shared mechanism in the two diseases. A small number of studies have demonstrated 
inhibition of Stat3 signalling that may be clinically beneficial, with a decrease in a range of 
ECM proteins, proliferation and migratory behaviour after treatment with Stat inhibitor or Stat3 
siRNA (Lim et al., 2006; Ray et al., 2013). One paper suggests the reduction in phenotype is to 
the level of the typical NDF (Lim et al., 2006), although no clear data have been shown to 
support this. 
In our investigations we used a Stat3 antibody against the phosphorylated single tyrosine 
residue (Tyr705) which is thought to be the main point of regulation of Stat3 activity, as this 
allows dimerization and consequent downstream activation (Schindler and Darnell, 1995). It has 
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been shown that maximal Stat3 activation can be caused by a secondary phosphorylation at a 
single serine residue (Ser727) (Schuringa et al., 2000). There is some evidence that pStat3 
Ser727 is also increased in keloids (Lim et al., 2006) and it would be insightful to investigate 
this in our cultures as this may explain the heightened response to IL-6 stimulation seen in 
KDFs in serum free conditions. 
 
 5.3.4.  Erk signalling  
 
When Erk signalling was examined after IL-6 stimulation, only KDFs in serum free conditions 
appeared to be able to increase pErk levels, with KDFs in 10% serum and NDFs in all 
conditions having no pErk response. Interestingly, it has been suggested that Erk signalling can 
function to inhibit Stat3 signalling (Sengupta et al., 1998), which may be an antagonistic 
‘damage control’ mechanism that kicks in KDFs which are highly phosphorylating Stat3. 
Supporting this theory, the KDF in serum free conditions that had the highest induction of 
pStat3 after IL-6 stimulation also had the highest induction of pErk (1st KDF). Intriguingly, the 
inhibitory action of Erk signalling is thought to be caused by post-translational modification of 
IL-6 signalling machinery (Sengupta et al., 1998), although the identify of these is not 
described.  
pErk, as well as pAkt has been shown to be increased in NDFs and KDFs that are co-cultured 
with keratinocytes and are thought to be important for proliferation (Phan et al., 2003) and for 
the production and modification of ECM proteins (Lim et al., 2003). Pharmacological inhibition 
of both Erk and Akt pathways in these systems showed decreased levels of collagens, laminin 
and fibronectin and changed molecular mass in the case of fibronectin (Lim et al., 2003). 
Mechanistically, Erk signalling has also been linked to the nuclear translocation of NF-κB in 
prostate cancer (Rodriguez-Berriguete et al., 2010), which could further propagate 
inflammatory transcription that has been documented in keloids (Messadi et al., 2004). Erk is 
also thought to mediate the exaggerated transcriptional responses by KDFs compared to NDFs 
when under mechanical strain, as the upregulation of TGF-β1 and collagen Iɑ genes were 
inhibited with an Erk inhibitor U0126 (Wang et al. 2006). 
 
 5.3.5.  Akt signalling  
 
The most striking difference in signalling after serum starvation was the dramatic induction of 
Akt signalling in KDFs that is completely absent in NDFs. This signalling could be interpreted 
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as a stress response that is lacking in NDFs. Akt signalling is often described as pro-
proliferative or a pro-survival mechanism and is often constitutively active in cancer (Nicholson 
and Anderson, 2002). It is clear from the literature that as well as a plethora of possible 
downstream substrates of Akt there are many interacting proteins that can modulate its activity 
including its impact on other signalling pathways (Table 5.1) (Brazil, Park and Hemmings, 
2002). Hence the literature in this area is highly conflicting and makes it extremely difficult to 
postulate what biological effect Akt may be mediating in a keloid context although it has been 
linked to proliferation (Wegiel et al., 2008), survival (Horowitz et al., 2004), metabolism 
(Robey and Hay, 2009), and migration (Franke et al., 2003). Similarly to Stat3, we only 
examined phosphorylation of a single residue (Ser473), however phosphorylation at Thr308 
also appears to be important to fully activate Akt activity (Gao, Moten and Lin, 2014) so again 
it would be useful to probe our blots with an antibody against this residue also. 
The relevance of Akt signalling in collaboration with Stat3 signalling is unclear. It has been 
proposed that in scar fibroblasts, IL-10 stimulation can stimulate cross talk between Stat3 and 
Akt which drives an anti-fibrotic response (Shi et al., 2014). However, another paper shows that 
co-operation of Stat3 and Akt signalling can lead to faster tumour progression in a mouse model 
of prostate cancer (Blando et al., 2011).  
 
Work in our laboratory by MSc student Yvonne Abrokwah suggests that despite differences in 
IL-6 induced signalling in pathways that may be classically associated with proliferation, there 
is no difference in the proliferative response between NDF and KDFs treated with IL-6 and/or 
Akt inhibitor for 72 hours (data not shown). However, Akt signalling is also known for its role 
in apoptosis and with clues in the literature that KDFs may be more resistant than NDFs to 
apoptosis (Ladin et al. 1998; Sayah et al. 1999; Ishihara et al. 2000). Resistance to apoptosis is 
a relevant clinical issue and may be due to mechanical load as modelling scar contractures in 
mouse wounds similar to human hypertrophic scars does induce pro-survival Akt signalling 
(Aarabi et al., 2007). It has been shown in lung fibroblasts that TGF-β1 induced resistance to 
apoptosis appears to be mediated through Akt signalling and the release of a soluble factor, as 
conditioned media from TGF-β1 treated cells can activate Akt signalling in unstimulated cells 
(Horowitz et al., 2004). It would be interesting to conduct a similar experiment, transferring 
conditioned media from serum free, IL-6 stimulated KDFs to NDFs and comparing the Akt 
signalling response compared to a direct serum free IL-6 stimulation. This would enable us to 












 5.3.6.  IL-6 signalling machinery 
 
To rationalise what is facilitating the differences seen in signalling between NDFs and KDFs, 
especially in serum free conditions which has not been reported, the expression of key 
machinery needed for the transduction of IL-6 signalling was measured; the IL-6r, co-receptor 
GP130 and negative regulator SOCS3. 
There has been debate in the literature as to whether fibroblasts express IL-6r, with some groups 
suggesting that they instead rely on sIL-6r made by other cells in the environment to respond to 
IL-6 ligand (Spörri et al., 1999; Barnes, Anderson and Moots, 2011; O’Reilly et al., 2014). As 
we saw a signalling response in our fibroblast cultures in response to IL-6, even in the absence 
of serum, this suggested that fibroblasts do possess some level of functional IL-6r. Further 
confirming this, we saw mRNA of both full length and cleaved IL-6r in all our fibroblast 
cultures. Initially it was thought that the differential migration of the two IL-6r bands between 
fibroblasts and the THP-1 positive control during electrophoretic analysis may be due to an 
altered isoform. However, it is more likely to be a technical issue with the DNA dye affecting 
gel migration.  
In 10% serum conditions there was no clear difference in mRNA levels of IL-6r, despite another 
study showing an increase (although not statistically significant) in IL-6r mRNA in KDFs 
compared to NDFs in these conditions (Ghazizadeh et al., 2007). However, after serum 
starvation we saw a substantial increase in IL-6r after serum starvation in KDFs that was much 
less pronounced in NDFs which could account for the increased signalling we have observed. It 
was difficult to detect IL-6r at the protein level, due to the low level of expression and high 
auto-fluorescence of fibroblasts but we were able to see an increase in IL-6r expression in KDF 
in serum free conditions, which was more easily detected after permeabilising of cells, most 
likely due to high level of receptor recycling (Zohlnhöfer et al., 1992). Reflecting the PCR 
results, no difference in IL-6r protein expression was seen between NDFs and KDFs in 10% 
serum conditions.  
Despite observing the presence of cleaved IL-6r transcript that should give rise to sIL-6r, no 
sIL-6r was detected in 72 hour supernatants from fibroblast cultures. This is likely due to a 
detection limit issue, since it was possible to detect the transcript of ADAM17, which is an 
enzyme that is known to cleave membrane bound IL-6r from the surface to also form sIL-6r 
(data not shown). However, the detection of higher levels of sIL-6r in keloid tissue also suggests 
there may be an even greater potential for IL-6 signalling in vivo.  
The induction of IL-6r in KDFs in serum free conditions may be physiologically relevant, given 
that it has been observed that IL-6r is also increased in keloid tissue (Zhang et al., 2009). It 
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would be pertinent to investigate signalling phosphorylation with a titration of IL-6 
concentrations to investigate whether this translates to a heightened capacity of KDFs to 
respond. Although IL-6r protein expression appeared to be very low, this may be due to the 
technical limitations of FACS may still be functionally significant even at low levels due to a 
potent effect of ligand-receptor engagement.  
Intriguingly, it is also a possibility that IL-6 may be causing signalling events independent of 
IL-6r. This is based on observations by a group that compared the IL-6 knockout and IL-6r 
knockout mice and saw differences in the cutaneous wound healing process in these two 
different groups (McFarland-Mancini et al., 2010). Both mice had delayed re-epithelisation 
however, IL-6 knockout mice had a much more severe wound healing deficit with delayed 
macrophage influx, decreased contraction and decreased fibrin clearance resulting in slow 
closing wounds and higher incidence of ulcers (McFarland-Mancini et al., 2010). Intriguingly, 
another study has also found differences in these mice in a colitis model, with IL-6 deficient 
mice showing attenuated disease whereas IL-6r deficient mice showed no difference to the wild 
type mice (Sommer et al. 2014). This has led both authors to conclude that there may be an 
additional, presently unidentified receptor for IL-6. Despite the fact that the authors do not show 
if they have also knocked out the soluble, spliced isoform of IL-6r, an alternative receptor could 
be valid given the stark difference in phenotypes observed. To examine whether there is a level 
of signalling after IL-6 stimulation that cannot be blocked solely with Tocilizumab treatment 
may be a better model to answer this question.  
As well as IL-6r, conventional signalling by IL-6 also requires the co-receptor GP130 which is 
expressed by most cell types (Heinrich et al., 1998). There does not appear to be any consistent 
difference in GP130 expression between NDFs and KDFs in 10% serum conditions, despite an 
increase being reported in the literature, although again this is not statistically significant and 
was only examined in four biological replicates (Ghazizadeh et al., 2007) . Increased GP130 
expression has been seen in HSDF after trans-signalling (co-incubation with IL-6 and sIL-6r), 
which was not seen in NDFs (Ray et al., 2013). However, this conclusion is based on limited 
biological replicates and is not a phenomenon that is broadly acknowledged in the field. Our 
qPCR analysis also showed that GP130 was upregulated in 2 out of 3 KDFs after serum 
starvation whilst all three NDFs downregulated gp130. Increased GP130 may facilitate 
increased IL-6 signalling, in collaboration with increased IL-6r,  as well as having an impact on 
signalling pathways driven by other IL-6 family members including IL-11, IL-27, LIF, OSM 
and CNTF (White and Stephens, 2011). GP130 can also be present in a soluble form (sgp130) 
and unlike sIL-6r, it acts antagonistically on IL-6 signalling (Jostock et al., 2001) and has 
therefore been developed as a therapeutic (gp130fc fusion protein) to prevent excessive IL-6 
signalling (Barkhausen et al., 2011). Sgp130 was not explored in the scope of this project but 
could be another level of regulation in the IL-6 driven keloid pathology and there are 
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commercially available ELISA kits to measure this in cell culture supernatant, as with sIL-
6r.SOCS3 is another important mediator of signalling, being the main “off-switch” to IL-6 
signalling (Carow and Rottenberg, 2014), and in 10% serum conditions there was no clear 
difference in the expression of SOCS3, an important regulator of IL-6 signalling in KDFs. 
However, after serum starvation there was some evidence that there was less expression in 
KDFs which may also be related to the reduced IL-6 production we have seen in these cultures, 
given that IL-6 drives the transcription of SOCS3 to negative regulate its own signalling 
(Croker et al., 2003). It would be informative to examine levels of the other main regulator of 
IL-6 signalling SHP2 to see if its expression is altered (Fischer et al., 2004). 
 
 5.3.7.  Effect of I-BET151 on IL-6 and downstream 
signalling 
   
Given the differences we have seen in IL-6 and downstream signalling, including higher IL-6r 
expression, and the literature evidence for IL-6 and its signalling in pathology, the effect of BET 
inhibition was examined. Firstly, it was seen that BET inhibition reduced IL-6 production as has 
been previously reported in range of other contexts (Klein et al. 2014; Deeney et al. 2016; 
Garcia-Faroldi et al. 2017). We also have evidence that I-BET151 treatment can reduce the 
level of TGF-β1 induced IL-6 production (data not shown). This is likely to be regulated 
through well recognised mechanisms, either through inhibition of NF-κB (Belkina, Nikolajczyk 
and Denis, 2013) or interruption of direct interaction of BET proteins with the IL-6 promoter 
region through CBP (Barrett et al., 2014). It would be useful in this cell system to examine the 
effect of I-BET151 treatment on other NF-κB regulated cytokines such as TNFɑ or IL-1β to 
determine whether this is an IL-6 specific effect as has been reported in a murine macrophage 
cell line (Barrett et al., 2014). The effect of I-BET151 on the production of IL-17A and IL-10 in 
fibroblast monolayers were examined by ELISA but even the basal level of production was not 
detectable (data not shown). 
BET inhibition also reduced signalling in a relatively short period (2 hours pre-treatment plus 
30 minutes during IL-6 stimulation), especially in serum free KDFs. The ability of I-BET151 to 
reduce pAkt, pStat3 and pErk in KDFs suggests that BET inhibition could offer a multi-pronged 
approach to tackle downstream signalling pathways, which has recently been noted in ovarian 
cancer cells where reduction in pAkt, pErk, and pFOSL1 was observed after JQ1 treatment 
(Kurimchak et al., 2016). There also appears to be some selectivity in its effect, with KDFs 
being affected more than NDFs, which could also offer a therapeutic advantage. Advantages 
over therapies such as IL-6r blockade with Tocilizumab that has shown success in inflammatory 
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arthritis (Jones and Ding, 2010), is that I-BET151 may be able to mediate downstream 
signalling from other ligands that may be present in disease such as MCP-1, which has been 
reported to be secreted by keloid CD14+ cells and cause Akt activation and proliferation in 
dermal fibroblasts (Liao et al., 2010). Further insight could be gleaned by repeating the 
stimulation +/- I-BET151 experiments with other keloid associated cytokines or growth factors, 
such as PDGF-BB, to see whether BET inhibition is indeed capable of reducing other ligand 
induced signalling, especially given that JQ1 and I-BET treatment had no effect on Smad 
signalling in lung fibroblasts after TGF-β1 stimulation (Tang et al., 2013b). 
 
 5.3.8.  Possible mechanisms of I-BET151 effect on 
downstream IL-6 signalling 
 
We have confirmed the I-BET151 mediated decrease in signalling is somehow reliant on 
transcription through the experiment with Actinomycin D, however the mechanism is still 
unknown. Given the relatively short (2.5h) total time of the experiment, it is likely that the 
transcript/s that caused this effect has a half-life that is shorter than this time. From LPS-
induced transcript half-life information on TTP-Atlas (ttp-atlas.univie.ac.at), IL6ra seems to be 
a very stable mRNA and is unlikely to be affected over the time course of the experiment, 
although the atlas data is based on macrophage experiments and there may be cell specific RNA 
degrading enzymes that differ in fibroblasts. Previous literature also stated, although the data is 
not shown, that BET inhibition using JQ1 had no effect on the expression of IL-6r in murine T 
cells (Mele et al., 2013).  We found that 2.5 hours of BET inhibition caused a small decrease in 
the mRNA expression of IL6r that isn’t thought to be sufficient to account for the decrease seen 
in signalling (although it is not clear whether this translates into a change at the protein level).  
The effect of BET inhibition on expression of GP130 and SOCS3 has not yet been tested. 
However, given the expression of GP130 on many cell types, it is unlikely to be the limiting 
factor in a signalling response to IL-6.  Previous studies have suggested that BET inhibition 
either reduces SOCS3 (Ray et al., 2014; Toniolo et al., 2015) or has no effect on SOCS3 (Chan 
et al., 2015) which would not provide an explanation for the reduction in signalling we have 
observed. An I-BET151 mediated reduction in SOCS3 would not be surprising given that IL-6 
signalling drives its transcription. To further understand the mechanism behind I-BET151 
mediated signalling decreases, ChIP PCR could be conducted on a range of candidate genes to 




Despite the Actinomycin D experiment results indicating that the signalling inhibition is at least 
partially transcriptionally mediated, there is recent evidence of a direct interaction between 
BRD2 and acetylated regions of STAT3, facilitating its recruitment to enhancer regions 
(Cheung et al., 2017). However, it is not clear how binding of BRD2 to STAT3 directly relates 
with the level of phosphorylation it is possible that at least in part, BET inhibition may affect 
signalling because of the interruption of a direct Brd2-Stat3 interaction. These types of non-
histone BET interactions are important and often overlooked, especially when considering the 
mechanistic basis of the effects seen after BET inhibition in a range of cells and disease models. 
The preferential effect of BET inhibition on KDFs over NDFs is intriguing and highlights a 
number of possible hypotheses. Firstly, the difference in response may be due to an altered 
transcriptional response in these cells. It has been shown that when BRD4 is bound to super-
enhancers, which may be formed during disease, it is preferentially removed from these regions 
following BET inhibition (Lovén et al., 2014). There is strong evidence to show that chronic 
inflammation can drive the formation of super-enhancers (Brown et al., 2014). In this way, BET 
inhibition therefore may ‘normalise’ KDF responses and downstream behaviours by targeting 
KDF-unique enhancer regions. Alternatively, BET proteins may be post-translationally 
modified in some way in KDFs that alters their function; it is known that many such 
modifications can occur (Wang et al., 2017) but their functional consequences are not 
understood. Recent literature has highlighted the role of phosphorylation in the control of BRD4 
function through binding to chromatin as well as other transcriptional regulators (Chiang, 2016). 
Lastly, there may be an altered acetylation pattern in KDFs compared to NDFs that may 
facilitate differential BET protein binding as this could be explored further through acetylome 
analysis. 
 
 5.3.9.  Possible functional relevance of increased IL-6 
signalling in KDFs 
 
As well as understanding the mechanism of reduced signalling by I-BET151 it is highly 
important to understand the functional relevance of this and whether this may indeed be linked 
to other cell changes that have been seen in this project such as decreased proliferation, ɑ-SMA 
expression, contraction and protease activity. However, gauging the link between a signalling 
response and a cell behaviour is not clear cut, for example it has been shown that KDFs have a 
robust activation of Erk signalling, comparable to that of NDFs, after EGF stimulation, however 
they show limited downstream activity in the form of a migratory response (Satish et al., 2004). 
To understand this better, future experiments should first focus on characterising the response of 
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NDFs and KDFs to IL-6 stimulation, especially in a serum free context, with a functional read-
out and then identifying the importance of the individual pathways (Stat3, Erk and Akt) in this 
response with pharmacological inhibitors. 
It is not yet clear from current literature whether IL-6 is causing disease relevant cell behaviour 
in keloids, or whether it is simply a side effect of the chronic environment and simply serves as 
a biomarker.  However, Ponceau Red staining of serum free IL-6 stimulation experiment 
western blots indicated a unique protein response in KDFs, with induction of an unidentified 
protein at ~70kDa (data not shown) suggesting these cells are responding differently at a protein 
level. It would also be highly informative to characterise the effect of IL-6 stimulation on NDFs 
vs KDFs with a transcriptomic and proteomic approach. RNA-seq and discovery mass-
spectrometry on NDFs and KDFs +/- IL-6 stimulation in serum free conditions would be hugely 
useful tools to unravel a potentially abnormal response of KDFs, that may also be shared with 
other inflammatory or fibrotic diseases. 
A publication in 2009 isolated colony forming ‘precursor’ cells from keloid scar and normal 
skin tissue, which could be interpreted as fibroblasts, and found that in low 1% serum 
conditions both cell types proliferated to the same extent in response to IL-6 stimulation shown 
by BrdU staining (Zhang et al., 2009). However, when these cells were incorporated into a 
hydrogel with IL-6 before transplantation into immunocompromised mice, the keloid derived 
cell gel grew faster than the normal skin derived equivalent. They also found that the keloid 
cells produced stereotypically thick collagen fibrils when examined histologically (Zhang et al., 
2009) although the data in the supplementary materials supporting this statement was difficult to 
interpret. When naïve T cells were added to this system, the growth of the gels was further 
increased (Zhang et al., 2009). This demonstrates the advantages of increasing complexity in 
culture models to better understand the importance of IL-6 in the in vivo environment, which 
may provide even more insight into the relevance of the intrinsic differences we have seen in 




Chapter 6: Overall conclusions and future direction 
6.1. Principal findings 
 
In order to best represent the contribution of this thesis to the technical field, a summary of the 
main findings of this project, including those of particularly novelty are represented in Table 
6.1. Those findings that were novel, rather than reaffirming previous literature reports, such as 
simply the anti-proliferative effect of BET inhibition, are boldened in the table. Those findings 
that are deemed as of particular importance or significance to the field, whether that be to the 
keloid or the BET protein field, are further highlighted by underlining. 
 
Table 6.1 - Summary of thesis contributions.  
Chapter Key findings 
3 – 
Characterisation 
of BET protein 
expression in 
keloid scars 
• Brd2 appears to be increased at the mRNA and protein level in a 
subset of keloid tissue samples. 
• Possible expression of a differential 60kDa isoform of Brd2 that 
may have alternate functions. 
• Brd2, Brd3 and Brd4 are all expressed in dermal fibroblasts with no 
difference between NDF and KDF in standard culturing conditions. 
• Inflammatory factors including TNFɑ and LPS appears to induce 
Brd2 expression in NDF. 
4 – Evaluating the 





I-BET151 treatment  
• Decreases dermal fibroblast proliferation with possible increased 
sensitivity in KDFs compared to NDFs.  
• Does not affect collagen expression or have any clear effect on 
contraction despite decreasing ACTA2 expression. 
• Appears to decrease overall MMP levels and protease activity in 
fibroblasts and in whole tissue. 
5 – Investigating 
the effect of BET 
protein inhibition 
on differential IL-6 
signalling in keloid 
scars 
• Confirmed increased IL-6 secretion in KDFs and keloid tissue reported 
in the literature. 
• Confirmed increased pStat3 in KDFs but also showed increased pAkt 
and pErk1/2 compared to NDFs. 
• Striking induction of pAkt in KDFs in serum free conditions after 
IL-6 conditions not seen in NDFs. 
• Confirmed presence of IL-6r at mRNA and protein level in dermal 
fibroblasts 
Novel findings not previously reported are boldened, and those also underlined are deemed as 
particularly important to the field. 
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Keloid scars are currently an unmet clinical need, growing invasively outside the original 
wound margin, often becoming very itchy and painful for the patient and frequently 
unresponsive to current lines of treatment (Gauglitz et al., 2011). In this work, we have 
confirmed what has been previously reported in keloids, including increased levels of the matrix 
transcripts COL1A1, COL3A1 and FN compared to normal skin, which are typical scar 
components (Xue and Jackson, 2015). However, we have also seen evidence in this project and 
through other work in the lab, that keloid scarring is a distinct form of scarring. We have shown 
that transcript levels of ɑ-SMA are much lower in keloid scar than in normal skin, which is 
contrary to what has been reported in many other fibroses, where increased ɑ-SMA levels are 
indicative of myofibroblasts (Hinz et al., 2007). Interestingly, unpublished data from the lab 
suggests there is a unique and abnormal ECM production in keloid scars rather than just over-
deposition of typical fibrillar collagens. 
We have also seen substantial heterogeneity between patients, both in their tissue characteristics 
and in isolated fibroblasts, such as the variable levels of IL-6 production and basal signalling. 
Clinically, patients differ greatly; for example, in our patient collections, one female patient had 
a single non-itchy, non-painful keloid with no family history, whereas one male patient had 
multiple, itchy and painful scars and had a family history of keloids. The lack of stratification of 
these samples is not only something that is absent from scientific research in this area but also 
within the clinic; many patients respond well to hydrocortisone steroid injections whereas others 
do not (Ud-Din et al., 2013), and the basis for this is not fully confirmed. In the future, better 
patient stratification may help inform treatment strategies.  
Unexpectedly, we saw many common cell characteristics between NDFs and KDFs, such as 
proliferation; however, reports of KDF hyper-proliferation in the literature are also variable. 
However striking differences were seen in IL-6 secretion and downstream signalling and 
importantly demonstrates that there are some intrinsic characteristics in keloid dermal 
fibroblasts that are still retained despite in vitro culturing. These differences that we have found 
to date emerged when the culture conditions were simplified with removal of serum. Colleagues 
have also found through transcriptional profiling experiments that in order to see differences 
between healthy and disease cells, serum levels in culture need to be reduced to at least 0.1% 
(personal communications, Dr Christina Phillippeos). 
For the first time, serum starvation revealed striking differences in downstream IL-6 signalling 
in KDFs; particularly, IL-6 strongly induced pAkt, which was not seen in NDFs. Although the 
functional consequences of this are not yet understood, it does demonstrate a distinct phenotype 
that is retained in these cells in culture that may be due to an epigenetic ‘memory’. High levels 
of IL-6 and differential downstream signalling are anticipated to be of relevance in keloid scars, 
although direct experimental investigation of this was outside the scope of this project but still 
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highly relevant given its proinflammatory reputation and marked reduction after I-BET151 
treatment. From ongoing experiments in the lab, it appears it is unlikely that the differential 
signalling is responsible for driving a proliferative response, as there is no keloid specific 
proliferative response to IL-6 stimulation in serum free conditions. We are currently exploring 
whether this signalling could be driving other cell behaviours including survival, migration and 
fibrotic gene expression. 
In vivo it has been postulated that IL-6 signalling could be linked to endothelial dysfunction as 
described in (Ogawa & Akaishi, 2016; Wassmann et al., 2004) which may drive inflammation 
through vessel permeability. IL-6 could also be a mediator of cellular contraction in this model; 
although it is thought that IL-6 does not directly drive fibroblast contractility, as shown in a 
scarring trachoma study, it is thought to cause the activation of macrophages which could in 
turn cause increased contractility (Kechagia et al., 2016). 
A large part of this project was investigating BET proteins and the potential therapeutic value of 
BET inhibition by modifying keloid associated cell behaviours including IL-6 and downstream 
signalling. Patient heterogeneity was also seen in the expression of BET proteins in tissue, 
however higher expression of BRD2 in keloid tissue was observed convincingly at the mRNA 
level and in a subset of patients at the protein level. IHC analysis suggested that fibroblasts were 
strongly positive for BRD2 and so further analysis focussed on the role of BET proteins in 
fibroblasts. In further investigations, NDFs and KDFs did not show any obvious differences in 
BET mRNA or protein expression, which may be due to a limitation of our culturing system, 
although it was found that some inflammatory stimuli, such as TNFɑ could increase BRD2 
expression. 
Analysis of BRD2 protein by western blot indicated a band at 60kDa, which may coincide with 
a predicted isoform that lacks the NLS and NET domains with a likely impact on protein 
function. Although we could not confirm the identity and sequence of this band by alternative 
methods in the scope of this project, it does give some possible explanation for differential BET 
protein function in normal skin vs keloid tissue. The possible existence of this shorter isoform is 
especially interesting given that a short BRD4 isoform has reported to be pro-metastatic due to 
more promiscuous histone binding (Alsarraj et al., 2013) and this warrants further investigation. 
BET inhibitors have been progressing in a range of clinical trials and there is growing interest in 
the application of these treatments to organ fibrosis (Stratton, Haldar and McKinsey, 2017). The 
first evidence within the skin has now shown BRD4 knockdown decreases myofibroblast 
differentiation (Ijaz et al., 2017) and much of the data in this project would add to the body of 
evidence that BET inhibition could be beneficial in fibrotic scarring in the skin, including for 
keloids.  We have confirmed previously reported effects of BET inhibition that were observed 
in other cell systems, including decreases in proliferation and a decrease in the pro-
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inflammatory cytokine IL-6. However, we have added knowledge to the field with the 
observation of additional novel effects of BET inhibition, including a reduction in contraction in 
a collagen gel model, and a reduction in protease activity. These findings may be applicable to 
other diseases including cancers; for example, I-BET151 could offer a solution to the increase in 
MMP activity in the cancer microenvironment, which drives the invasive migratory behaviour 
of cells and subsequent metastasis (Sternlicht and Werb, 2009). 
The mechanisms of the observed effects of I-BET151 on cell behaviour, especially the KDF-
specific inhibition of downstream IL-6 signalling, are difficult to determine without large scale 
analyses such as ChIP-Seq to identify important BET protein binding patterns. Transcriptional 
and epigenetic datasets are available from associated BET inhibition and BET siRNA studies, 
especially for Brd4, which is known to be associated with super enhancers that have particular 
importance in cancer (Lovén et al., 2014). The indication of heightened sensitivity of KDFs to 
I-BET151, in terms of proliferation and IL-6 signalling, may not be related to levels of BET 
proteins but instead due to differential binding patterns and activity. Very little is known about 
the regulation of BET protein activity, with some new literature emerging suggesting that 
phosphorylation of BRD4 can affect its activity (Wu et al 2013) with hyper-phosphorylated 
BRD4, modulated by casein kinase II (CK2), recently being associated with NUT midline 
carcinoma (Wang et al., 2017). 
Interestingly, cell specific I-BET151 effects were unravelled in the signalling experiments, 
where I-BET151 specifically decreased signalling only in KDFs in serum free conditions, 
without effect on signalling in NDFs in the same conditions. This echoes findings from GSK 
(personal communications), whereby BET inhibitor treatment appears to have specific effects 




6.2. Project limitations 
 
One limitation of the work is our ‘normal’ control tissue. Due to ethical reasons, it is not 
possible for us to isolate normal, unaffected skin from keloid patients due to the risk of new 
keloid formation. Occasionally samples were received with a small normal skin border, but it is 
also debatable about how ‘normal’ this tissue really is. Our normal skin samples tended to be 
derived from Caucasian patients aged 40-50+ whereas our keloid scar samples tended to be 
from younger patients with darker skin, which is relevant given that both age and ethnicity are 
known to influence skin biology (Rawling, 2006; McGrath, Robinson and Binder, 2012). An 
appropriate normal scar was difficult to come by; for the IHC analysis we used scars from 
melanoma re-excision patients at ~6 weeks which may be slightly less normal due to their 
association with cancerous tissue and are also small and clinically precious. Older scars may be 
accessible from scar revision surgeries, but these are likely to be relatively resolved with a low 
cellular content and cleared inflammation (Desmoulière et al., 1995) unlike keloid scars that are 
often still in active inflammation and growth. In addition, this project did not discriminate 
keloids according to location of sampling, with recent literature making clear that keloids are 
spatially diverse and may have different cellular activity in the actively growing edge vs the 
hypoxic fibrotic core (Jumper et al., 2017).  
In addition, in this project, and in the field in general, there is a limitation in the lack of 
stratification of keloid tissue. There is increasing awareness of spatial variability within keloids 
at the actively growing edge region for example, compared to the hypoxic core. Fibroblasts may 
retain some epigenetic memory of their environment and therefore cells from the edge region 
could potentially be more metabolically active, more proliferative, more contractile and more 
proteolytically active than those found at the core. This limitation came to light in particular 
during the analysis of ACTA2 expression in keloid tissue, where although the expression was 
somewhat anticipated to be higher than normal skin, it was found to be lower compared to 
normal skin. This is likely due to these tissue samples originating from the core region of keloid 
where tension and myofibroblast activation is likely to be lower. As such, it is important to 
evaluate potential effects of BET inhibition at a spatial, as well as whole keloid, level to ensure 
that the drug does not cause a decrease in MMPs at the core for example, when an increase in 
MMP, in order to clear the fibrotic matrix deposition, is desired. 
A factor that is limiting work in the entire human dermal fibroblast field is the lack of a unique 
cell surface marker. Part of this problem is that isolated fibroblast populations are often treated 
as a single population as we have done in this project. However, growing evidence is showing 
that fibroblasts are heterogeneous, with subpopulations that may have different functions in 
wound repair. It has been noted for several decades that site-matched fibroblasts from the 
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papillary and reticular dermis have different characteristics. Papillary fibroblasts appear to have 
higher levels of proliferation, collagen deposition, growth factor production and a distinct gene 
expression signature in comparison to reticular fibroblasts (Harper and Grove, 1979; Tajima and 
Pinnell, 1981; Sorrell, Baber and Caplan, 2004; Janson et al., 2012). More recently, it has been 
shown in mice that these two types of fibroblasts respond differently in wounding. A lineage of 
fibroblasts which make up the lower dermis, including the reticular layer and hypodermis, are 
responsible for the first wave of dermal repair and are not able to support formation of new hair 
follicles. The upper lineage of fibroblasts are only recruited later in wound repair, during re-
epithelisation (Driskell et al., 2013). Currently, most of the understanding of fibroblast 
heterogeneity is restricted to mouse models but work is ongoing to characterise such functional 
subpopulations in humans and their contribution in homeostasis and in wound response. Given 
that we do not yet know the origin of keloid fibroblasts, increasing understanding of these 
subpopulations and availability of markers to define them will allow us to investigate whether 
keloid fibroblasts may be an expansion of a specific subpopulation. 
Another limitation of our model is that fibroblast behaviour is somewhat abnormal in vitro. It is 
increasingly appreciated that the artificial 2D plastic in vitro environment may cause drastic 
changes in cell morphology and behaviour, including gene expression (David, Sayer and 
Sarkar-Tyson, 2014; Yeung et al., 2015).  The rigid plastic surface on which cells are cultured 
in plates or tissue culture flasks generates unnatural tension which would not be experienced in 
vivo (Wells, 2008). In fact, a transcriptomic study demonstrated that exposure of fibroblasts to 
serum induced a wound-like and cancer-like response (Chang et al., 2004). There are also many 
factors that are still absent from the system, including ECM and the presence of other important 
cell players such as immune cells or keratinocytes (Werner, Krieg and Smola, 2007). Given the 
plasticity of dermal fibroblasts, which is utilised as an advantage in regenerative medicine and 
stem cell research, it is likely that paracrine factors from other cells can induce significant 
expression changes (Slany et al., 2014).  
A comprehensive characterisation of keloid tissue would be hugely beneficial in understanding 
the cellular composition of keloids. A single paper has taken an IHC approach to identify these 
cells, but have found that almost all immune cell subsets are increased in keloid scars (Bagabir 
et al., 2012a). This project attempted to isolate cells directly from tissue for ex vivo analysis by 
FACS however this was technically challenging with high auto-fluorescence, low digestion 
efficacy and lack of fibroblast marker. A better understanding of the cellular composition would 
also aid in creating better models of keloids, which are currently very limited, both through 
tissue engineering techniques and animal models, which is hampering all research into the early 
stage of keloid development. The transplantation of human keloid tissue to immune 
compromised mice is currently the best used in vivo model of keloids, but are not wholly 
suitable, as it is likely that immune cells have a strong influence on the disease, and it does not 
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give information on the initiating events of keloid formation (van den Broek et al., 2014). There 
has been a number of reviews in recent years which have summarised the current research status 
of appropriate scar models including for keloids (Williams, Herndon and Branski, 2014; Suttho 
et al., 2017). The consensus is that the modelling of fibrotic scars is extremely complicated, 
given their complex biology and immune cell influence. Keloid-like tumours can form on the 
lower leg of some horses although they are not epithelialised in the same way as keloids 
(Theoret et al., 2013). Duroc pigs also produce a hypertrophic version of scarring, but this is 
still likely to be a distinct pathology in comparison to keloid scars (Zhu et al., 2003). 
The ex vivo biopsy tissue culture model was initially anticipated to be a useful tool to evaluate 
the effect of I-BET151 on all the important cell types in keloid tissue, using qPCR, western blot 
or IHC to analyse markers of disease such as Collagen I, markers of proliferation such as Ki67 
and markers of inflammation such as IL-6. An extensive collection of these models was formed, 
however upon IHC staining there was a complete absence of Ki67 unlike freshly isolated tissue 
which showed strong positivity in the basal keratinocyte layer and scattered fibroblast positivity 
in the upper dermis (data not shown). This indicated that the tissue health was not optimal so the 
decision was made not to pursue further analysis of these samples. In revisiting the original 
publication of this model, minimal evidence was given for tissue health, as data for the week 2 
time point indicated over 25% of cells were Ki67 positivity which is surprisingly high 
depending on the location within the tissue, whereas over 15% of cells were TUNEL positive 
indicating apoptosis (Bagabir et al. 2012b) which would have not allowed for the extraction of 
good quality RNA.  
RNA extraction from fibrous tissue is notoriously difficult and despite efforts to optimise 
homogenisation and extraction protocols for keloid tissue, RINs (a measure of RNA integrity) 
were still somewhat variable. A small pilot study indicated that a 1 hour incubation in dispase 
solution at 37°C to remove the epidermal layer of the tissue caused a substantial decrease in 
RIN so whole tissue was used for this work. The variable RINs of keloid tissue may be due to 
fibrous matrix not allowing for the penetration of RNAlater preservation solution, despite only 
being a 4mm diameter biopsy. In future, it may be beneficial to finely dice tissue before 
preservation in RNAlater solution to improve preservation and this may also assist in achieving 
better homogenisation and RNA yield. An investigation of RNA quality in a tissue bank 
reported that fatty, fibrous or necrotic samples had relatively low RINs (Kap et al., 2014). The 
average RIN for most tissue types was between 7 and 8, whilst skin tissue had an average of 
4.95 (Kap et al., 2014) demonstrating the technical challenge of isolating high integrity RNA 
from fibrous skin samples. Despite this, there are varying reports on the importance of RNA 
integrity in qPCR analysis and indeed the accuracy of Bioanalyser-calculated RIN numbers as a 
measure of integrity. A review published in 2006 stated “there are no statistically confirmed 
studies at which threshold RNA integrity is useless for quantitative downstream applications” 
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(Fleige and Pfaffl, 2006). This study found that RNA integrity did impact cycle threshold 
values, but this was counteracted by normalisation to a reference gene.  
 
6.3. Future directions 
 
There is a variety of possible research avenues that have arisen from this project and those 
deemed of the highest importance are described below.  
Firstly, knockdown of specific BET family members would allow the investigation of the 
contribution of each BET protein to fibroblast biology. There is increasing awareness that BET 
proteins may have differing roles in health and disease. It has been shown that BRD2 and BRD4 
have differing binding patterns and roles in T cells to drive Th17 differentiation (Cheung et al., 
2017). Equally, in multiple disease models, different effects of BET inhibitors vs individual 
knockdowns have been observed. For example, BRD4 knockdown in TGF-β1 treated dermal 
fibroblasts could stop myofibroblast differentiation in the form of ɑ-SMA expression, whereas 
JQ1 treatment achieved this whilst also preventing the production of fibronectin and collagen 
1a1 (Ijaz et al., 2017), suggesting that another family member (possibly Brd2 based on our own 
observations) is responsible for the regulation of these genes. Due to technical challenges and 
the time constraints of this project, it was not possible to overexpress Brd2 in dermal fibroblasts 
to assess functional importance. However, there is an indication from the literature that 
increased expression of BRD2 may cause acceleration of cell cycling in fibroblasts (Sinha, 
Faller and Denis, 2005). 
Secondly, it is important to note that all effects seen in this project after I-BET151 treatment are 
due to changes to bromodomain activity and therefore acetylated lysine binding, but not overall 
BET protein function. Given that there are other functional domains that may have important 
biological roles, it would be informative to better understand the role of other functional 
domains. A recent publication by the Bradner group demonstrated a new tool wherein JQ1 was 
conjugated to a phthalimide compound in order to target BET proteins for proteasome 
degradation (Winter et al., 2015). This could, therefore, be compared to a conventional BET 
inhibitor to evaluate the importance of non-bromodomain regions of BET proteins. In this 
project, we found a specific overexpression of BRD2 and a possible expression of a differential 
60kDa isoform lacking the NLS and NET domains. Confirmation of the presence of this 
isoform by pull down and mass spectrometry was unsuccessful, but the use of an 
immunoprecipitation validated BRD2 antibody could allow this in the future. Transfection of 
cells with individual functional domains, or indeed the BRD2 short isoform, would also offer an 
approach to explore functionality in fibroblasts. 
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To better understand the mechanism of action of BET proteins in our system, ChIP-seq, or the 
recently described click-seq (Tyler et al., 2017), could also be conducted in our fibroblast 
cultures to analyse interactions between BET proteins and DNA. Existing datasets could be 
mined, however as these proteins are known to have very cell-specific and stimuli-specific 
binding this may only be slightly helpful. In addition, immunoprecipitation and mass 
spectrometry studies would also be helpful to investigate direct interactions between BETs and 
non-histone proteins, especially given the cytoplasmic presence we have seen in BRD2 staining 
of keloid tissue and fibroblasts. Gaining a better understanding of the mechanisms of action of 
I-BET151 is important for the progression of these compounds into the clinic. 
Lastly, another important avenue for future investigation is to better characterise the differential 
response to IL-6 in KDFs, especially in terms of the drastic induction of Akt signalling we have 
seen in serum free media. Firstly, we would like to examine the dynamics of the signalling 
response to IL-6 rather than the single timepoint of 30 minutes that has been examined in this 
project. Then we would like to understand the functional consequence of IL-6 stimulation in 
serum free media by looking at a range of read-outs, to explore whether there is a keloid-
specific cellular response to IL-6. Ongoing work suggests that there is no difference in the 
proliferative response to IL-6 in NDFs or KDFs, but we plan to also look at read-outs of other 
behaviours including apoptosis/survival, migration, and matrix production. Once a functional 
difference is identified, the contribution of Akt signalling could be explored using inhibitors of 
the Akt pathway, such as MK2206 (Hirai et al., 2010). 
In conclusion, the observations we have made in this project have added further evidence for an 
anti-proliferative and anti-inflammatory effect of BET inhibitors, but also offers new in vitro 
information that BET inhibition decreases contractile and proteolytic activity of dermal 
fibroblasts, and a disease specific effect on IL-6 downstream signalling, which may have 
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Chapter 7: Appendix 
7.1.  Example patient information sheet 
 




7.2.  BRD2 immunoprecipitation 
 
In an attempt to identify the 60kDa band that appeared in tissue lysate western blots when 
probed for BRD2, as well as any other keloid unique bands that may indicate a unique direct 
protein BRD2 interaction, an immunoprecipitation was undertaken using the same GSK 
polyclonal antibody. This was conducted on two normal skin and one keloid scar lysate samples 
before silver staining to visualise pulldown proteins which appeared to show unique bands 
(Figure 7.2). However, upon running the antibody alone and silver staining, it was clear that 
this was an antibody specific band (Figure 7.2). This suggested that the antibody was not 
suitable for immunoprecipitation and due to time constraints it was not possible to follow this 










Figure 7.2 - Silver staining of BRD2 immunoprecipitation. BioRad SureBead IP system was 
used to pull down three tissue lysates using the GSK BRD2 polyclonal antibody and an 
irrelevant GFP control antibody. Briefly the magnetised beads were coated with antibody, 
washed and incubated with 25µg of tissue lysate in 500µl total volume of RIPA buffer, 
following more washes beads were washed in elution buffer to elute the antibody bound to 
target protein. This elution buffer was run on an SDS gel as described in Materials & Methods 
and then Silver Stained. The gel appeared to show unique bands in the BRD2 specific lanes, 
however after running antibody alone and silver staining it was clear that these were antibody 




7.3.  5’ RACE-PCR for BRD2 isoform analysis 
 
In order to identify possible differential BRD2 isoforms that may have interesting cellular 
functions, two approaches were attempted.  
Firstly, 5’ RACE-PCR (also known as one sided or anchored PCR) was conducted using the 
FirstChoice™ RLM-RACE Kit (cat no. AM1700, ThermoFisher Scientific). Two internal 
primers were designed at the most 5’region which was common to all known transcripts as 
depicted in (Figure 7.3A). A forward primer was also designed as a positive control to check 
the success of the reverse primers during optimisation (Figure 7.3B). The primers were tested 
in a PCR using a BRD2 plasmid supplied by GlaxoSmithKline and showed two distinct bands of 
the correct size indicating effective primer design (Figure 7.3D). 
RNA was then prepared from a NDF as depicted (Figure 7.4A) firstly by treatment with calf 
intestinal alkaline phosphatase (CIP) to remove 5’PO4  to ensure no degraded mRNA or other 
types of RNA are amplified. Then the RNA is treated with tobacco acid pyrophosphatase (TAP) 
which de-caps full length mRNA to leave a mono-phosphate that a kit designed 5’ RACE 
adapter can be ligated onto. After ligation, reverse transcription was conducted as per usual 
protocols using random primers. 
The resulting cDNA was then used in two rounds of PCR, firstly using the outer primer set (one 
user designed outer reverse primer and one kit supplied outer forward primer). 5µl was kept for 
electrophoretic analysis and 2.5µl was used as the template cDNA for next round of PCR using 
the inner primer set. 
5µl of each round of PCR, including the NTC were run on a 2% agarose gel at 100V until good 
separation of the ladder.  A single band was visualised in the second round of PCR but upon 





Figure 7.3 - 5' RACE PCR primer design. (A) Primers were designed at the first shared exon 
(exon 2) for the majority of BRD2 transcripts as denoted by the dashed line. (B) A forward 
primer (F) was designed as a positive control and two nested reverse primers (R1 and R2) were 
designed 133bp and 184bp upstream of F with sequences shown. (C) RT-PCR was run using a 
Brd2 plasmid as template showing specific amplification of a 133bp and 184bp transcript from 
the two nested reverse primers (R1 and R2) with the forward primer (F) with the cycling 



























Figure 7.4 - 5'RACE PCR on fibroblast RNA. (A) RNA was prepared for 5’RACE RNA as 
shown. mRNA was decapped, ligated with the 5’ RACE adapter before reverse transcription as 
previously described in Methods & Materials. (B) Prepared cDNA was then used for two 
successive rounds of PCR, the first ‘outer’ round using the outer primer set (outer kit supplied 
primer specific for the ligated 5’ RACE adapter + R2) and the second ‘inner’ round using the 
inner primer set (inner kit supplied prime specific for the ligated 5’ RACE adapter + R1) under 
the cycling conditions as shown, with the addition of 5% DMSO into each PCR reaction to 
reduce secondary structures. No bands were seen following the first outer round of PCR 





7.4.  qPCR for BRD2 isoforms 
 
Another approach was then attempted to identify BRD2 isoform transcripts, using qPCR 
primers designed with the help of Catriona Sharp, GSK. Primers were designed to amplify 
specific Brd2 transcripts (Figure 3.12), however it was only possible to design unique primers 
for single transcripts for BRD2-001 and BRD2-002. The rest of the primer sets amplified 
different combinations of the transcript options (Table 7.1). 
The three primers were selected for each set (shown in blue in Table 7.2) and these were used 
for qPCR on n=4 normal skin and keloid scar tissue RNA isolations alongside the reference 
gene B2M. The best primer for each set out of the selected three, chosen on the basis of standard 
curve R2 and primer efficiency score (calculated by the slope of the standard curve) was selected 
and relative mRNA expression was calculated for each sample using the standard curve method 
and normalising expression to the reference gene B2M (Figure 7.5). 
Relative expression results were conflicting, as primers that amplified a single transcript e.g. Set 
1 showed higher relative expression than primers that amplified many different transcripts, 
including this single transcript e.g. Set 3. This was deemed to be a primer efficiency issue and 
therefore hindered our ability to make a comparative analysis of primer sets as planned. 
 




 BRD2 Isoform Transcripts 
001 002 005 006 009 201 023 026 
Set 1 ✓        
Set 2  ✓       
Set 3 ✓ ✓ ✓ ✓ ✓ ✓ ✓  
Set 4 ✓ ✓     ✓  
Set 5 ✓ ✓ ✓    ✓  
Set 6    ✓  ✓   
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Table 7.2 - List of BRD2 isoform primers. Designed by Catriona Sharp (GSK) with 5 primer 
pairs to amplify the same set of transcripts with some repetition of forward or reverse primers. 
Set Pair Forward Reverse 
1 1 GGGATAGGAAGCTGGGGATA CGAAACCCAGAGCGCTATAA 
1 2 AGGAAGCTGGGGATATGGAC CGAAACCCAGAGCGCTATAA 
1 3 GGGATAGGAAGCTGGGGATA CTATGTCCCGAAACCCAGAG 
1 4 TAGGAAGCTGGGGATATGGA CGAAACCCAGAGCGCTATAA 
1 5 TAGGAAGCTGGGGATATGGA CTATGTCCCGAAACCCAGAG 
2 1 GGGGAGGGTTTTTCCCTTA GGCTCAGAGCAGAAAAAGCA 
2 2 GGGGAGGGTTTTTCCCTTA GCTCAGAGCAGAAAAAGCAAG 
2 3 GGGGAGGGTTTTTCCCTTA GCTCAGAGCAGAAAAAGCAA 
2 4 ATACGGGTGTGCCTTTGG AGTCCTGGGAGGGATGACTT 
2 5 GGGGAGGGTTTTTCCCTTA CAGAGCAGAAAAAGCAAGTCC 
3 1 GAGGTGTCCAATCCCAAAAA AGGTATTGCAGCTGGTTGGT 
3 2 GAGGTGTCCAATCCCAAAAA TTTCCACAGAGCCTTCATCA 
3 3 AAAGCCAGGACGAGTTACCA TTTCCACAGAGCCTTCATCA 
3 4 AAGCCAGGACGAGTTACCAA TTTCCACAGAGCCTTCATCA 
3 5 GAGGTGTCCAATCCCAAAAA CATGCGAACTGATGTTTCCA 
4 1 GAACGAGCTGGAGGATTCTG CGGATGGAGGTGGATTGTAA 
4 2 GAATCCCTGCAGACCAACAG GATCTCAGACACCGTCGTCA 
4 3 AACAGCGGGCTATATTGACG GGCAACTAAGGAGGGACTGA 
4 4 CCCGACAAGAAGAGGGAATC CGTCAATATAGCCCGCTGTT 
4 5 AACAGCGGGCTATATTGACG GGGCAACTAAGGAGGGACTG 
5 1 ACTTAGCGGGTTATGCTGGA ATCTTGACCGCAAGGAACC 
5 2 CTTAGCGGGTTATGCTGGAC ATCTTGACCGCAAGGAACC 
5 3 CCAACTTAGCGGGTTATGCT ATCTTGACCGCAAGGAACC 
5 4 ACTTAGCGGGTTATGCTGGA CATCTTGACCGCAAGGAAC 
5 5 CTTAGCGGGTTATGCTGGAC CATCTTGACCGCAAGGAAC 
6 1 GAGGTGTCCAATCCCAAAAA AGGTATTGCAGCTGGTTGGT 
6 2 GAGGTGTCCAATCCCAAAAA TTTCCACAGAGCCTTCATCA 
6 3 AAAGCCAGGACGAGTTACCA TTTCCACAGAGCCTTCATCA 
6 4 AAGCCAGGACGAGTTACCAA TTTCCACAGAGCCTTCATCA 
6 5 GAGGTGTCCAATCCCAAAAA CATGCGAACTGATGTTTCCA 



























Figure 7.5 - Preliminary BRD2 isoform qPCR results on tissue RNA. qPCR was carried out 
on n=4 normal skin and keloid scar tissue mRNAs for the best 3 selected primers pairs for each 
set (denoted in bold in the previous table of primers), primers were selected on the basis of the 
highest R2 and consistent Ct value when run against a standard curve of pooled mRNA. qPCR 
was carried out in a 384 well plate format in a 10µl reaction as previously described in Materials 
& Methods, and the best primer pair out of the 3 was chosen for each set based on the highest 
R2 and reaction efficiency (calculated from the slope of the standard curve). As previously, 
qPCR relative values were calculated against a standard curve and normalised by dividing by 














































































































































































































































6 0 0 S e t 1
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
r
e
s
s
io
n
B
R
D
2
-0
0
1
/B
2
M
